<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1920_S09_C18_Idx_p361_384_8P</title>
		<link href="BCSC1920_S09_C18_Idx_p361_384_8P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1920_S09_C18_Idx_p361_384_8P" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="em-only_endmatter-title">Index</p>
			<p class="em-only_endmatter-idx1">(<span class="endmatter-idx1_italic">f</span> <span class="endmatter-idx1_symbol">=</span> figure; <span class="endmatter-idx1_italic">t</span> <span class="endmatter-idx1_symbol">=</span> &#173;table)</p>
			<p class="endmatter-idx-alpha">Abatacept, for uveitis, 112</p>
			<p class="em-only_endmatter-idx1">Accessory molecules, helper T cell expression of, 31</p>
			<p class="em-only_endmatter-idx1">Acquired immunodeficiency syndrome. <span class="endmatter-idx1_italic">See</span> AIDS</p>
			<p class="em-only_endmatter-idx1">Acrodermatitis chronica atrophicans, 228</p>
			<p class="em-only_endmatter-idx1">Actinomycetes, infectious scleritis caused by, 119<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Activated neutrophils, 10</p>
			<p class="em-only_endmatter-idx1">Acute anterior uveitis. <span class="endmatter-idx1_italic">See</span> Anterior uveitis, acute</p>
			<p class="em-only_endmatter-idx1">Acute macular neuroretinopathy, multiple evanescent white dot syndrome and, 189</p>
			<p class="em-only_endmatter-idx1">Acute posterior multifocal placoid pigment epitheliopathy (APMPPE)</p>
			<p class="em-only_endmatter-idx2">ce&#173;re&#173;bral vasculitis and, 170</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">definition of, 169</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 170–172, 171–172<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 170, <br />171<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence findings in, 163<span class="endmatter-idx2_italic">t,</span> 171, <br />172<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 170–171, 171<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 170, 170<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">medical management of, 93</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 164<span class="endmatter-idx2_italic">t,</span> <br />171, 172<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior uveitis in, 169–174, 170–173<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">prognosis for, 172–173</p>
			<p class="em-only_endmatter-idx2">relentless placoid chorioretinitis, 173<span class="endmatter-idx2_italic">f,</span> 173–174</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium involvement by, 171</p>
			<p class="em-only_endmatter-idx2">serpiginous choroiditis versus, 171</p>
			<p class="em-only_endmatter-idx2">systemic conditions associated with, 169–170</p>
			<p class="em-only_endmatter-idx2">vision loss risk &#173;factors in, 172–173</p>
			<p class="em-only_endmatter-idx1">Acute ret&#173;i&#173;nal necrosis, 252, 253–254<span class="endmatter-idx1_italic">f,</span> 326, 332</p>
			<p class="em-only_endmatter-idx1">Acute ret&#173;i&#173;nal pigment epitheliitis (ARPE), 162–164<span class="endmatter-idx1_italic">t,</span> 189<span class="endmatter-idx1_italic">f,</span> 189–190</p>
			<p class="em-only_endmatter-idx1">Acute syphilitic retinitis, 222, 224<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Acute zonal occult outer retinopathy (AZOOR)</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">course of, 191–192</p>
			<p class="em-only_endmatter-idx2">definition of, 190</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 191–192</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 191</p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence findings in, 163<span class="endmatter-idx2_italic">t,</span> 191, 192<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 164<span class="endmatter-idx2_italic">t,</span> <br />191, 191<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium findings in, 190, 190<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">visual acuity in, 191</p>
			<p class="em-only_endmatter-idx2">white dot syndromes versus, 192</p>
			<p class="em-only_endmatter-idx1">Acyclovir</p>
			<p class="em-only_endmatter-idx2">for herpes simplex virus, 251</p>
			<p class="em-only_endmatter-idx2">for varicella-&#173;zoster virus, 254</p>
			<p class="em-only_endmatter-idx1">Adalimumab</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 216, 218</p>
			<p class="em-only_endmatter-idx2">for uveitis</p>
			<p class="em-only_endmatter-idx3">description of, 110–111</p>
			<p class="em-only_endmatter-idx3">intermediate uveitis, 150</p>
			<p class="em-only_endmatter-idx3">sarcoidosis-&#173;associated uveitis, 199</p>
			<p class="em-only_endmatter-idx3">treatment studies of, 100–101<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Adaptive immune response/adaptive immunity</p>
			<p class="em-only_endmatter-idx2">conjunctiva and, 53</p>
			<p class="em-only_endmatter-idx2">definition of, 1</p>
			<p class="em-only_endmatter-idx2">effector responses of</p>
			<p class="em-only_endmatter-idx3">antibody-&#173;dependent cellular cytotoxicity, 47–48</p>
			<p class="em-only_endmatter-idx3">antibody-&#173;mediated, 39<span class="endmatter-idx3_italic">f,</span> 39–42, 40<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">lymphocyte-&#173;mediated, 42–46, 43<span class="endmatter-idx3_italic">f,</span> 44<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">natu&#173;ral killer cells in, 46</p>
			<p class="em-only_endmatter-idx3">types of, 38<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">innate immune response versus, 27</p>
			<p class="em-only_endmatter-idx2">mechanisms of, 36, 36<span class="endmatter-idx2_italic">f,</span> 38</p>
			<p class="em-only_endmatter-idx2">purpose of, 27–28</p>
			<p class="em-only_endmatter-idx2">subclinical presence of, 6</p>
			<p class="em-only_endmatter-idx1">Adaptive T regulatory cells, 34</p>
			<p class="em-only_endmatter-idx1">Adeno-&#173;associated virus, 58</p>
			<p class="em-only_endmatter-idx1">Adenovirus, 274</p>
			<p class="em-only_endmatter-idx1">Adult T-&#173;cell leukemia/lymphoma, 267, 268<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Aedes aegypti,</span> 269</p>
			<p class="em-only_endmatter-idx1">Afferent lymphatic channels. <span class="endmatter-idx1_italic">See</span> Lymphatics</p>
			<p class="em-only_endmatter-idx1">Afferent phase, of immune response arc, 29<span class="endmatter-idx1_italic">f,</span> 29–30</p>
			<p class="em-only_endmatter-idx1">AIDS. <span class="endmatter-idx1_italic">See also</span> HIV</p>
			<p class="em-only_endmatter-idx2">bacillary angiomatosis of, 240</p>
			<p class="em-only_endmatter-idx2">bacterial keratitis in, 336</p>
			<p class="em-only_endmatter-idx2">CD4<span class="endmatter-idx2_symbol">+</span> T cells in, 329</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Cryptococcus neoformans</span> choroiditis in, 335</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis in, 258, 330–331</p>
			<p class="em-only_endmatter-idx2">external eye manifestations of, 335–336</p>
			<p class="em-only_endmatter-idx2">herpes zoster and, 336</p>
			<p class="em-only_endmatter-idx2">immune recovery uveitis in, 331</p>
			<p class="em-only_endmatter-idx2">Kaposi sarcoma associated with, 335, 335<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">molluscum contagiosum associated with, 336</p>
			<p class="em-only_endmatter-idx2">necrotizing herpetic retinitis in, 332, 332<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular toxoplasmosis in, 283–284, 284<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ophthalmic manifestations of, 329–335, 330<span class="endmatter-idx2_italic">f,</span> <br />332<span class="endmatter-idx2_italic">f,</span> 334<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">opportunistic infections in, 330</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 329</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Pneumocystis jirovecii</span> choroiditis in, 334, 334<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">toxoplasmic retinochoroiditis in, 332<span class="endmatter-idx2_italic">f,</span> 332–333</p>
			<p class="em-only_endmatter-idx1">Albendazole</p>
			<p class="em-only_endmatter-idx2">for diffuse unilateral subacute neuroretinitis, 290</p>
			<p class="em-only_endmatter-idx2">for visceral toxocariasis, 286</p>
			<p class="em-only_endmatter-idx1">Alkylating agents</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 217–218</p>
			<p class="em-only_endmatter-idx2">for uveitis, 109–110</p>
			<p class="em-only_endmatter-idx1">Allelic diversity, in &#173;human leukocyte antigens, 63</p>
			<p class="em-only_endmatter-idx1">Allergic conjunctivitis, 2</p>
			<p class="em-only_endmatter-idx1">Allergic immune reactions, 2</p>
			<p class="em-only_endmatter-idx1">Alpha chemokines, 23<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Altered self, 30</p>
			<p class="em-only_endmatter-idx1">Alternative pathway activation, of complement, 17, 18<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Alveolar macrophages, 3</p>
			<p class="em-only_endmatter-idx1">American Uveitis Society, 252, 252t</p>
			<p class="em-only_endmatter-idx1">Amoxicillin, for Lyme disease, 231<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Amphotericin&#160;B, for <span class="endmatter-idx1_italic">Candida</span> fungal postoperative endophthalmitis, 300–301</p>
			<p class="em-only_endmatter-idx1">Anaphylatoxins, 18</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Ancylostoma caninum,</span> 289</p>
			<p class="em-only_endmatter-idx1">Angle-&#173;closure glaucoma, secondary, 320</p>
			<p class="em-only_endmatter-idx1">Ankylosing spondylitis (AS)</p>
			<p class="em-only_endmatter-idx2">acute anterior uveitis in, 130<span class="endmatter-idx2_italic">f,</span> 131–132</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen haplotype association <br />with, 64</p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">nonsteroidal anti-&#173;inflammatory drugs for, 132</p>
			<p class="em-only_endmatter-idx2">treatment of, 132</p>
			<p class="em-only_endmatter-idx1">Anterior chamber</p>
			<p class="em-only_endmatter-idx2">immunization in, 56</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t,</span> 55–56</p>
			<p class="em-only_endmatter-idx2">immunoregulatory systems of, 55–57</p>
			<p class="em-only_endmatter-idx2">shallowing of, 320</p>
			<p class="em-only_endmatter-idx1">Anterior chamber paracentesis</p>
			<p class="em-only_endmatter-idx2">in bacterial endogenous endophthalmitis, 297</p>
			<p class="em-only_endmatter-idx2">technique for, 92</p>
			<p class="em-only_endmatter-idx2">in uveitis, 90–92</p>
			<p class="em-only_endmatter-idx1">Anterior chamber-&#173;associated immune deviation (ACAID), 56–57, 59</p>
			<p class="em-only_endmatter-idx1">Anterior scleritis</p>
			<p class="em-only_endmatter-idx2">diffuse, 116, 118</p>
			<p class="em-only_endmatter-idx2">nodular, 116, 118–119, 119<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">subtype of, 116<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Anterior segment</p>
			<p class="em-only_endmatter-idx2">Lyme disease-&#173;related inflammation of, corticosteroids for, 230</p>
			<p class="em-only_endmatter-idx2">sympathetic ophthalmia findings in, 200</p>
			<p class="em-only_endmatter-idx2">syphilis findings in, 221–222</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 89</p>
			<p class="em-only_endmatter-idx1">Anterior synechiae, 320</p>
			<p class="em-only_endmatter-idx1">Anterior uvea</p>
			<p class="em-only_endmatter-idx2">B cells in, 56</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">metastasis to, 311</p>
			<p class="em-only_endmatter-idx2">T cells in, 56</p>
			<p class="em-only_endmatter-idx1">Anterior uveitis</p>
			<p class="em-only_endmatter-idx2">acute</p>
			<p class="em-only_endmatter-idx3">in ankylosing spondylitis, 130<span class="endmatter-idx3_italic">f,</span> 131–132</p>
			<p class="em-only_endmatter-idx3">antimetabolites for, 130</p>
			<p class="em-only_endmatter-idx3">characteristics of, 64, 65<span class="endmatter-idx3_italic">t,</span> 79<span class="endmatter-idx3_italic">f,</span> 130–131</p>
			<p class="em-only_endmatter-idx3">chorioret&#173;i&#173;nal scars with, 135<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">corticosteroids for, 130</p>
			<p class="em-only_endmatter-idx3">cycloplegics for, 131</p>
			<p class="em-only_endmatter-idx3">drug-&#173;induced, 139–140<span class="endmatter-idx3_italic">f,</span> 139–141</p>
			<p class="em-only_endmatter-idx3">fibrinous exudate in, 130, 130<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">in glaucomatocyclitic crisis, 135–136</p>
			<p class="em-only_endmatter-idx3">herpes simplex virus as cause of, 249–252</p>
			<p class="em-only_endmatter-idx3">HLA-&#173;B27 diseases associated with. <span class="endmatter-idx3_italic">See</span> Anterior uveitis, HLA-&#173;B27–&#173;associated</p>
			<p class="em-only_endmatter-idx3">hypopyon in, 130, 131<span class="endmatter-idx3_italic">f,</span> 214<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">in infectious endophthalmitis, 137</p>
			<p class="em-only_endmatter-idx3">in inflammatory bowel disease, 133</p>
			<p class="em-only_endmatter-idx3">intraocular lens-&#173;associated, 137–139, 138<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">lens-&#173;associated uveitis, 136<span class="endmatter-idx3_italic">f,</span> 136–137</p>
			<p class="em-only_endmatter-idx3">in psoriatic arthritis, 133, 134<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">in reactive arthritis syndrome, 132–133</p>
			<p class="em-only_endmatter-idx3">seronegative spondyloarthropathies associated with, 131–134, 133–134<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">in tubulointerstitial nephritis and uveitis syndrome, 134–135, 135<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">tumor necrosis factor-&#173;<span class="endmatter-idx3_greek">α</span> inhibitors for, 131</p>
			<p class="em-only_endmatter-idx2">aqueous flare in, 77, 79<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Beh<span class="endmatter-idx2_accent">ç</span>et disease, 214</p>
			<p class="em-only_endmatter-idx2">Busacca nodules in, 78, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 70</p>
			<p class="em-only_endmatter-idx2">chronic</p>
			<p class="em-only_endmatter-idx3">diagnostic criteria for, 141</p>
			<p class="em-only_endmatter-idx3">in juvenile idiopathic arthritis, 141–145</p>
			<p class="em-only_endmatter-idx3">in pseudophakic bullous keratopathy, 138<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cytomegalovirus-&#173;related, 250–251, 259</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 129</p>
			<p class="em-only_endmatter-idx2">epidemiology of, 129</p>
			<p class="em-only_endmatter-idx2">evaluation of, 71–72<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">fibrin in, 19</p>
			<p class="em-only_endmatter-idx2">granulomatous, 279</p>
			<p class="em-only_endmatter-idx2">HLA-&#173;B27–&#173;associated</p>
			<p class="em-only_endmatter-idx3">ankylosing spondylitis, 130<span class="endmatter-idx3_italic">f,</span> 131–132</p>
			<p class="em-only_endmatter-idx3">clinical pre&#173;sen&#173;ta&#173;tion of, 130, 130<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">description of, 64, 65<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">inflammatory bowel syndrome, 133</p>
			<p class="em-only_endmatter-idx3">pattern of, 130</p>
			<p class="em-only_endmatter-idx3">psoriatic arthritis, 133, 134<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">reactive arthritis syndrome, 132–133, 133<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">incidence of, 129</p>
			<p class="em-only_endmatter-idx2">inflammatory cells in, 77, 79<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">interstitial keratitis and, 220</p>
			<p class="em-only_endmatter-idx2">intraocular pressure in, 80–81, 319</p>
			<p class="em-only_endmatter-idx2">iris nodules in, 77–78, 80, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">keratic precipitates in, 77–78, 79<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior synechiae in, 77, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">prevalence of, 68</p>
			<p class="em-only_endmatter-idx2">in sarcoidosis, 195–196</p>
			<p class="em-only_endmatter-idx2">signs of, 77–81, 79–80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sudden-&#173;onset, 71<span class="endmatter-idx2_italic">t,</span> 76</p>
			<p class="em-only_endmatter-idx2">symptoms of, 76, 77<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">undifferentiated, 146–147</p>
			<p class="em-only_endmatter-idx1">Antibodies. <span class="endmatter-idx1_italic">See also</span> Immunoglobulin(s)</p>
			<p class="em-only_endmatter-idx2">anti-&#173;idiotypic, 41</p>
			<p class="em-only_endmatter-idx2">aqueous humor production of, 91</p>
			<p class="em-only_endmatter-idx2">in chronic inflammation, 42</p>
			<p class="em-only_endmatter-idx2">classes of, 39</p>
			<p class="em-only_endmatter-idx2">domains of, 39</p>
			<p class="em-only_endmatter-idx2">Fab region of, 39</p>
			<p class="em-only_endmatter-idx2">Fc portion of, 39</p>
			<p class="em-only_endmatter-idx2">hypervariable region of, 39</p>
			<p class="em-only_endmatter-idx2">idiotopes of, 41</p>
			<p class="em-only_endmatter-idx2">local production of, 41–42</p>
			<p class="em-only_endmatter-idx2">monoclonal</p>
			<p class="em-only_endmatter-idx3">description of, 41</p>
			<p class="em-only_endmatter-idx3">recombinant, 41</p>
			<p class="em-only_endmatter-idx2">plasma cell production of, 37</p>
			<p class="em-only_endmatter-idx2">structural features of, 39, 39<span class="endmatter-idx2_italic">f,</span> 40<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antibody Fc receptors, 12</p>
			<p class="em-only_endmatter-idx1">Antibody-&#173;dependent cellular cytotoxicity (ADCC), 47–48</p>
			<p class="em-only_endmatter-idx1">Antifungals</p>
			<p class="em-only_endmatter-idx2">for <span class="endmatter-idx2_italic">Candida</span> fungal postoperative endophthalmitis, 300</p>
			<p class="em-only_endmatter-idx2">for chronic fungal postoperative endophthalmitis, <br />295</p>
			<p class="em-only_endmatter-idx1">Antigen</p>
			<p class="em-only_endmatter-idx2">definition of, 27</p>
			<p class="em-only_endmatter-idx2">immune privilege with, 56</p>
			<p class="em-only_endmatter-idx2">immune pro&#173;cessing of, 30, 33<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Antigenic epitopes, 27, 41</p>
			<p class="em-only_endmatter-idx1">Antigenic epitopic fragments, 30</p>
			<p class="em-only_endmatter-idx1">Antigen-&#173;presenting cells (APCs)</p>
			<p class="em-only_endmatter-idx2">class I-&#173;dependent, 31<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">class II-&#173;dependent, 30, 32<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in conjunctiva, 53</p>
			<p class="em-only_endmatter-idx2">corneal lack of, 54</p>
			<p class="em-only_endmatter-idx2">definition of, 29–30</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen type and, 63</p>
			<p class="em-only_endmatter-idx2">in immune response arc, 29–30</p>
			<p class="em-only_endmatter-idx2">interleukin-12 production by, 35</p>
			<p class="em-only_endmatter-idx2">macrophages as, 14</p>
			<p class="em-only_endmatter-idx2">monocytes as, 3</p>
			<p class="em-only_endmatter-idx2">in phagocytosis, 30, 32<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Antiglaucoma medi&#173;cations, anterior uveitis caused <br />by, 141</p>
			<p class="em-only_endmatter-idx1">Anti-&#173;idiotypic antibodies, 41</p>
			<p class="em-only_endmatter-idx1">Antimetabolites</p>
			<p class="em-only_endmatter-idx2">for acute anterior uveitis, 130</p>
			<p class="em-only_endmatter-idx2">for uveitis, 106–108</p>
			<p class="em-only_endmatter-idx1">Antinuclear antibody testing</p>
			<p class="em-only_endmatter-idx2">in granulomatosis with polyangiitis, 159</p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus, 156</p>
			<p class="em-only_endmatter-idx1">Antiretroviral therapy, for cytomegalovirus retinitis, <br />258</p>
			<p class="em-only_endmatter-idx1">Anti-&#173;vascular endothelial growth &#173;factor, 276</p>
			<p class="em-only_endmatter-idx1">Apoptosis</p>
			<p class="em-only_endmatter-idx2">cytotoxic T cell inducement of, 46</p>
			<p class="em-only_endmatter-idx2">Fas ligand inducement of, 57</p>
			<p class="em-only_endmatter-idx1">Aqueous drainage, for uveitic glaucoma, 322</p>
			<p class="em-only_endmatter-idx1">Aqueous flare, in anterior uveitis, 77, 79<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Aqueous fluid polymerase chain reaction testing, in uveitis evaluations, 90–91</p>
			<p class="em-only_endmatter-idx1">Aqueous humor</p>
			<p class="em-only_endmatter-idx2">antibody production in, 91</p>
			<p class="em-only_endmatter-idx2">biological &#173;factors in, 55</p>
			<p class="em-only_endmatter-idx2">polymerase chain reaction testing of, in uveitis evaluations, 90–91</p>
			<p class="em-only_endmatter-idx1">Aqueous suppressants, for uveitic glaucoma, 321</p>
			<p class="em-only_endmatter-idx1">Arachidonic acid (AA), eicosanoids from, 19</p>
			<p class="em-only_endmatter-idx1">Argyll Robertson pupil, 223</p>
			<p class="em-only_endmatter-idx1">Arrestin, in experimental autoimmune uveoretinitis, 61</p>
			<p class="em-only_endmatter-idx1">Arthritis</p>
			<p class="em-only_endmatter-idx2">enthesitis-&#173;related, 142</p>
			<p class="em-only_endmatter-idx2">juvenile idiopathic. <span class="endmatter-idx2_italic">See</span> Juvenile idiopathic arthritis</p>
			<p class="em-only_endmatter-idx2">psoriatic</p>
			<p class="em-only_endmatter-idx3">acute anterior uveitis in, 133</p>
			<p class="em-only_endmatter-idx3">clinical pre&#173;sen&#173;ta&#173;tion of, 133, 134<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">laboratory tests for, 125<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">reactive</p>
			<p class="em-only_endmatter-idx3">acute anterior uveitis in, 132–133</p>
			<p class="em-only_endmatter-idx3">diagnostic criteria for, 132–133, 133<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx3_italic">t,</span> <br />132</p>
			<p class="em-only_endmatter-idx3">laboratory tests for, 125<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Aspergillosis, 303</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Aspergillus</span> endophthalmitis, endogenous, 302–303</p>
			<p class="em-only_endmatter-idx1">Autoantibodies, in systemic lupus erythematosus, 154</p>
			<p class="em-only_endmatter-idx1">Autocrine signaling, of cytokines, 21</p>
			<p class="em-only_endmatter-idx1">Autofluorescence, fundus</p>
			<p class="em-only_endmatter-idx2">in acute posterior multifocal placoid pigment epitheliopathy, 163<span class="endmatter-idx2_italic">t,</span> 171, 172<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in acute ret&#173;i&#173;nal pigment epitheliitis, 189</p>
			<p class="em-only_endmatter-idx2">in acute zonal occult outer retinopathy, 163<span class="endmatter-idx2_italic">t,</span> 191, 192<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 163<span class="endmatter-idx2_italic">t,</span> 166, 167<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 163<span class="endmatter-idx2_italic">t,</span> 179, 180<span class="endmatter-idx2_italic">f</span> 186–187<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in multiple evanescent white dot syndrome, 163<span class="endmatter-idx2_italic">t,</span> 186<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in punctate inner choroiditis, 163<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in serpiginous choroiditis, 163<span class="endmatter-idx2_italic">t,</span> 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in subret&#173;i&#173;nal fibrosis and uveitis syndrome, 163<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in uveitis evaluations, 89</p>
			<p class="em-only_endmatter-idx1">Autoimmune regulator–&#173;deficient mice, 62</p>
			<p class="em-only_endmatter-idx1">Autoimmune retinopathy, 192–193</p>
			<p class="em-only_endmatter-idx1">Azathioprine</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 217</p>
			<p class="em-only_endmatter-idx2">for uveitis, 106–107</p>
			<p class="em-only_endmatter-idx1">AZOOR complex of diseases, 192</p>
			<p class="endmatter-idx-alpha">B cells</p>
			<p class="em-only_endmatter-idx2">activation of, 35</p>
			<p class="em-only_endmatter-idx2">in anterior uvea, 56</p>
			<p class="em-only_endmatter-idx2">antigen receptors of, 35</p>
			<p class="em-only_endmatter-idx2">clonal expansion of, 37</p>
			<p class="em-only_endmatter-idx2">clonality of, 41, 308</p>
			<p class="em-only_endmatter-idx2">Fab fragment of, 41</p>
			<p class="em-only_endmatter-idx2">homing of, 38</p>
			<p class="em-only_endmatter-idx2">infiltration of, 41–42</p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 179</p>
			<p class="em-only_endmatter-idx2">in posterior segment, 57</p>
			<p class="em-only_endmatter-idx2">priming of, 30</p>
			<p class="em-only_endmatter-idx2">in resting state, 37</p>
			<p class="em-only_endmatter-idx2">tissue infiltration of, 41–42</p>
			<p class="em-only_endmatter-idx2">tuberculosis response by, 28</p>
			<p class="em-only_endmatter-idx1">B lymphocytes. <span class="endmatter-idx1_italic">See</span> B cells</p>
			<p class="em-only_endmatter-idx1">Babesiosis, 230</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Bacillus</span> spp.</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">B. cereus,</span> hemolysin BL toxin derived from, 9</p>
			<p class="em-only_endmatter-idx2">endogenous endophthalmitis caused by, 296</p>
			<p class="em-only_endmatter-idx1">Bacterial endophthalmitis, endogenous, 296–297</p>
			<p class="em-only_endmatter-idx1">Bacterial uveitis</p>
			<p class="em-only_endmatter-idx2">bartonellosis as cause of. <span class="endmatter-idx2_italic">See</span> Bartonellosis</p>
			<p class="em-only_endmatter-idx2">leptospirosis as cause of, 232–233</p>
			<p class="em-only_endmatter-idx2">Lyme disease as cause of. <span class="endmatter-idx2_italic">See</span> Lyme disease</p>
			<p class="em-only_endmatter-idx2">nocardiosis as cause of, 233</p>
			<p class="em-only_endmatter-idx2">polymerase chain reaction for, 90</p>
			<p class="em-only_endmatter-idx2">syphilis as cause of. <span class="endmatter-idx2_italic">See</span> Syphilis</p>
			<p class="em-only_endmatter-idx2">tuberculosis as cause of, 234–240, 235–238<span class="endmatter-idx2_italic">f. See also</span> Tuberculosis</p>
			<p class="em-only_endmatter-idx2">Whipple disease as cause of, 243–245, 244<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Band keratopathy</p>
			<p class="em-only_endmatter-idx2">calcific, 143<span class="endmatter-idx2_italic">f,</span> 315</p>
			<p class="em-only_endmatter-idx2">in chronic uveitis, 78</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Bartonella henselae,</span> 240–243</p>
			<p class="em-only_endmatter-idx1">Bartonellosis</p>
			<p class="em-only_endmatter-idx2">cat-&#173;scratch disease, 240–243, 242<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">diagnosis of, 243</p>
			<p class="em-only_endmatter-idx2">neuroretinitis associated with, 241, 242<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular involvement in, 241, 242<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">treatment of, 243</p>
			<p class="em-only_endmatter-idx1">Basophils</p>
			<p class="em-only_endmatter-idx2">characteristics of, 2–3</p>
			<p class="em-only_endmatter-idx2">histamine in, 19</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Baylisascaris procyonis,</span> 286</p>
			<p class="em-only_endmatter-idx1">BCG vaccine, tuberculosis skin testing and, 238</p>
			<p class="em-only_endmatter-idx1">Beh<span class="endmatter-idx1_accent">ç</span>et disease</p>
			<p class="em-only_endmatter-idx2">anterior uveitis in, 214</p>
			<p class="em-only_endmatter-idx2">biologic agents for, 218</p>
			<p class="em-only_endmatter-idx2">characteristics of, 211</p>
			<p class="em-only_endmatter-idx2">corticosteroids for, 216–217</p>
			<p class="em-only_endmatter-idx2">definition of, 211</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 212, 212<span class="endmatter-idx2_italic">t,</span> 215–216</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 216</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 216, 217<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">genital ulcers associated with, 213</p>
			<p class="em-only_endmatter-idx2">histologic findings in, 215, 216<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">HLA associations with, 215</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">immunomodulatory therapy for, 216–218</p>
			<p class="em-only_endmatter-idx2">neurologic involvement in, 213–214</p>
			<p class="em-only_endmatter-idx2">nonocular systemic manifestations of, 213–214</p>
			<p class="em-only_endmatter-idx2">ocular manifestations of, 214–215, 214–215<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">optic nerve involvement in, 215</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 216, <br />217<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">oral aphthae associated with, 213, 213<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 215</p>
			<p class="em-only_endmatter-idx2">posterior segment manifestations of, 214–215, 215<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">prevalence of, 212</p>
			<p class="em-only_endmatter-idx2">prognosis for, 218</p>
			<p class="em-only_endmatter-idx2">skin lesions associated with, 213</p>
			<p class="em-only_endmatter-idx2">systemic vasculitis associated with, 213</p>
			<p class="em-only_endmatter-idx2">treatment of, 216–218</p>
			<p class="em-only_endmatter-idx1">Berlin nodules, 80</p>
			<p class="em-only_endmatter-idx1">Beta chemokines, 23<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bilateral diffuse uveal melanocytic proliferation, 311</p>
			<p class="em-only_endmatter-idx1">Biopsy</p>
			<p class="em-only_endmatter-idx2">chorioret&#173;i&#173;nal, in uveitis evaluations, 91</p>
			<p class="em-only_endmatter-idx2">scleral, 91</p>
			<p class="em-only_endmatter-idx2">vitreous</p>
			<p class="em-only_endmatter-idx3">indications for, 91–92</p>
			<p class="em-only_endmatter-idx3">technique for, 92</p>
			<p class="em-only_endmatter-idx1">Birdshot chorioretinopathy (BSCR)</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">course of, 168–169</p>
			<p class="em-only_endmatter-idx2">definition of, 34, 165</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 168</p>
			<p class="em-only_endmatter-idx2">electroretinogram evaluations, 168</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 165–166, 166–167<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence findings in, 163<span class="endmatter-idx2_italic">t,</span> 166, 167<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">HLA-&#173;A29 and, 34, 64–65, 65<span class="endmatter-idx2_italic">t,</span> 165</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 166, 167<span class="endmatter-idx2_italic">f,</span> 179</p>
			<p class="em-only_endmatter-idx2">manifestations of, 165–168, 166–168<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 164<span class="endmatter-idx2_italic">t,</span> 168, 168<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior uveitis in, 165–169, 166–168<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium findings in, 166</p>
			<p class="em-only_endmatter-idx2">T helper cell-17&#160;in, 34</p>
			<p class="em-only_endmatter-idx2">treatment of, 169</p>
			<p class="em-only_endmatter-idx1">Blau syndrome, 197</p>
			<p class="em-only_endmatter-idx1">Blindness, uveitis as cause of, 68</p>
			<p class="em-only_endmatter-idx1">Blood dendritic cells, 4</p>
			<p class="em-only_endmatter-idx1">Blood-&#173;derived macrophages, 3</p>
			<p class="em-only_endmatter-idx1">Blood–&#173;ocular barrier</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus passage across, 258</p>
			<p class="em-only_endmatter-idx2">description of, 56–57</p>
			<p class="em-only_endmatter-idx1">Blurred vision</p>
			<p class="em-only_endmatter-idx2">in intermediate uveitis, 76</p>
			<p class="em-only_endmatter-idx2">in posterior uveitis, 76</p>
			<p class="em-only_endmatter-idx1">Bone loss, corticosteroid-&#173;induced, 103</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Borrelia burgdorferi,</span> 227, 230</p>
			<p class="em-only_endmatter-idx1">Bradyzoites, 277</p>
			<p class="em-only_endmatter-idx1">Branch ret&#173;i&#173;nal artery occlusions, 160</p>
			<p class="em-only_endmatter-idx1">B-&#173;scan ultrasonography, for posterior scleritis, 124</p>
			<p class="em-only_endmatter-idx1">Busacca nodules</p>
			<p class="em-only_endmatter-idx2">in anterior uveitis, 78, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in sarcoidosis, 196</p>
			<p class="endmatter-idx-alpha">Calcific band keratopathy, in juvenile idiopathic arthritis-&#173;related anterior uveitis, 143<span class="endmatter-idx-alpha_italic">f,</span> 315</p>
			<p class="em-only_endmatter-idx1">Cancer-&#173;associated retinopathy, 192–193</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Candida</span> spp.</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">C. albicans,</span> 298</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">C. glabrata,</span> 298</p>
			<p class="em-only_endmatter-idx2">chorioretinitis caused by, 299, 300<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">diagnosis of, 299</p>
			<p class="em-only_endmatter-idx2">endogenous fungal endophthalmitis caused by, 297–301, 298<span class="endmatter-idx2_italic">f,</span> 301<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">histologic features of, 299, 300<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Candidemia, 298</p>
			<p class="em-only_endmatter-idx1">Candidiasis, ocular, 299–300</p>
			<p class="em-only_endmatter-idx1">Candle wax drippings, 196, 197<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Can-&#173;opener capsulotomy, 317</p>
			<p class="em-only_endmatter-idx1">Carbonic anhydrase inhibitors, for uveitis, 113</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">CARD15,</span> 198</p>
			<p class="em-only_endmatter-idx1">Cataract(s)</p>
			<p class="em-only_endmatter-idx2">in pars planitis, 151</p>
			<p class="em-only_endmatter-idx2">in uveitis, 315–319</p>
			<p class="em-only_endmatter-idx1">Cataract surgery</p>
			<p class="em-only_endmatter-idx2">inflammation control &#173;after, 138</p>
			<p class="em-only_endmatter-idx2">necrotizing scleritis &#173;after, 121</p>
			<p class="em-only_endmatter-idx2">in uveitic eyes, 315–316</p>
			<p class="em-only_endmatter-idx1">Cat-&#173;scratch disease, 240–243, 242<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cat-&#173;scratch fever, 240</p>
			<p class="em-only_endmatter-idx1">CD8</p>
			<p class="em-only_endmatter-idx2">in adaptive immune response, 30</p>
			<p class="em-only_endmatter-idx2">cytotoxic T cell expression of, 36, 44</p>
			<p class="em-only_endmatter-idx1">CD4, in adaptive immune response, 30</p>
			<p class="em-only_endmatter-idx1">CD95 receptor, 46</p>
			<p class="em-only_endmatter-idx1">CD4<span class="endmatter-idx1_symbol">+</span> T cells</p>
			<p class="em-only_endmatter-idx2">in AIDS, 329</p>
			<p class="em-only_endmatter-idx2">development of, 43<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in immune pro&#173;cessing, 30–31</p>
			<p class="em-only_endmatter-idx2">in sympathetic ophthalmia, 45</p>
			<p class="em-only_endmatter-idx2">in tubulointerstitial nephritis and uveitis syndrome, 135</p>
			<p class="em-only_endmatter-idx1">CD8<span class="endmatter-idx1_symbol">+</span> T cells</p>
			<p class="em-only_endmatter-idx2">cytotoxicity mechanisms of, 47<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">major histocompatibility class I molecules and, 30</p>
			<p class="em-only_endmatter-idx2">in sympathetic ophthalmia, 45</p>
			<p class="em-only_endmatter-idx1">Cefotaxime, for Lyme disease, 231<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ceftriaxone, for Lyme disease, 231<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cefuroxime axetil, for Lyme disease, 231<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cell adhesion molecules (CAMs)</p>
			<p class="em-only_endmatter-idx2">description of, 10</p>
			<p class="em-only_endmatter-idx2">types of, 11</p>
			<p class="em-only_endmatter-idx1">Cell-&#173;adhesion molecules, 38</p>
			<p class="em-only_endmatter-idx1">Cell-&#173;mediated immunity, mast cells in, 3</p>
			<p class="em-only_endmatter-idx1">Central dysacusia, 205</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral vasculitis, 170</p>
			<p class="em-only_endmatter-idx1">Cerebrospinal fluid, for syphilis testing, 225</p>
			<p class="em-only_endmatter-idx1">Certolizumab, 110</p>
			<p class="em-only_endmatter-idx1">Chemokines</p>
			<p class="em-only_endmatter-idx2">alpha, 23<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">beta, 23<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 21</p>
			<p class="em-only_endmatter-idx1">Chemotactic &#173;factors</p>
			<p class="em-only_endmatter-idx2">definition of, 12</p>
			<p class="em-only_endmatter-idx2">in neutrophil transmigration, 12</p>
			<p class="em-only_endmatter-idx1">Chemotaxis, 2</p>
			<p class="em-only_endmatter-idx1">Chickenpox, 249–250</p>
			<p class="em-only_endmatter-idx1">Chikungunya fever, 270<span class="endmatter-idx1_italic">f,</span> 270–271</p>
			<p class="em-only_endmatter-idx1">&#173;Children</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis in, 257–258</p>
			<p class="em-only_endmatter-idx2">intraocular lens in, 317</p>
			<p class="em-only_endmatter-idx2">uveitis in, 322</p>
			<p class="em-only_endmatter-idx2">vision rehabilitation in, 327</p>
			<p class="em-only_endmatter-idx1">Chlorambucil, for uveitis, 110</p>
			<p class="em-only_endmatter-idx1">Choriocapillaris</p>
			<p class="em-only_endmatter-idx2">immune responses of, 57–59</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 57</p>
			<p class="em-only_endmatter-idx2">immunoregulatory systems of, 59</p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal biopsy, 91</p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal lesions, 273, 274<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal scars, 135<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal spots, 266<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chorioretinitis</p>
			<p class="em-only_endmatter-idx2">acute syphilitic, 222, 222<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Candida,</span> 299, 300<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Ebola virus survivor, 274<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior placoid, 222, 223<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">relentless placoid, 173<span class="endmatter-idx2_italic">f,</span> 173–174</p>
			<p class="em-only_endmatter-idx2">with vitritis, 72–73<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">without vitritis, 73<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Choroid</p>
			<p class="em-only_endmatter-idx2">immune responses of, 57–59</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t,</span> 57–58</p>
			<p class="em-only_endmatter-idx2">immunoregulatory systems of, 59</p>
			<p class="em-only_endmatter-idx2">mast cells in, 58</p>
			<p class="em-only_endmatter-idx2">tuberculosis involvement of, 236–237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidal neovascularization (CNV)</p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 180<span class="endmatter-idx2_italic">f,</span> 181</p>
			<p class="em-only_endmatter-idx2">ocular histoplasmosis syndrome-&#173;associated, 276</p>
			<p class="em-only_endmatter-idx2">prevalence of, 327</p>
			<p class="em-only_endmatter-idx2">in punctate inner choroiditis, 182</p>
			<p class="em-only_endmatter-idx2">serpiginous choroiditis and, 175</p>
			<p class="em-only_endmatter-idx2">treatment of, 327</p>
			<p class="em-only_endmatter-idx2">in uveitis, 326–327</p>
			<p class="em-only_endmatter-idx1">Choroidal scars, 276</p>
			<p class="em-only_endmatter-idx1">Choroidal tubercles, 236, 237<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroiditis</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Cryptococcus neoformans,</span> 335</p>
			<p class="em-only_endmatter-idx2">macular, 276<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">multifocal. <span class="endmatter-idx2_italic">See</span> Multifocal choroiditis; Multifocal choroiditis and panuveitis syndrome</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Pneumocystis jirovecii,</span> 334, 334<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">punctate inner. <span class="endmatter-idx2_italic">See</span> Punctate inner choroiditis</p>
			<p class="em-only_endmatter-idx2">serpiginous. <span class="endmatter-idx2_italic">See</span> Serpiginous choroiditis</p>
			<p class="em-only_endmatter-idx2">serpiginous-&#173;like, 177, 236, 237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chronic anterior uveitis. <span class="endmatter-idx1_italic">See</span> Anterior uveitis, chronic</p>
			<p class="em-only_endmatter-idx1">Chronic Arthus reaction, 42</p>
			<p class="em-only_endmatter-idx1">Chronic cyclitis. <span class="endmatter-idx1_italic">See</span> Pars planitis</p>
			<p class="em-only_endmatter-idx1">Chronic fungal postoperative endophthalmitis, 294–295</p>
			<p class="em-only_endmatter-idx1">Chronic inflammation, local antibody production in, 42</p>
			<p class="em-only_endmatter-idx1">Chronic peripheral rhegmatogenous ret&#173;i&#173;nal detachment, 313</p>
			<p class="em-only_endmatter-idx1">Chronic uveitis</p>
			<p class="em-only_endmatter-idx2">calcific band keratopathy associated with, 315</p>
			<p class="em-only_endmatter-idx2">definition of, 75–76</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 72<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">systemic corticosteroids for, 102–103</p>
			<p class="em-only_endmatter-idx1">Chronic Uveitis Evaluation of the Intravitreal Dexamethasone Implant study, 99<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Churg-&#173;Strauss syndrome, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ciliary body, fenestrated capillaries in, 56</p>
			<p class="em-only_endmatter-idx1">Circinate balanitis, 133</p>
			<p class="em-only_endmatter-idx1">Circumcorneal conjunctival hyperemia, 232</p>
			<p class="em-only_endmatter-idx1">Class I-&#173;dependent antigen-&#173;presenting cells, 31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Class II-&#173;dependent antigen-&#173;presenting cells, 30, 32<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Classic pathway activation, of complement, 17, 18<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Clindamycin, for ocular toxoplasmosis, 283</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Coccidioides immitis,</span> 303</p>
			<p class="em-only_endmatter-idx1">Coccidioidomycosis, 303–304</p>
			<p class="em-only_endmatter-idx1">Cogan syndrome, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Collagen vascular diseases</p>
			<p class="em-only_endmatter-idx2">polyarteritis nodosa, 156–158</p>
			<p class="em-only_endmatter-idx2">systemic lupus erythematosus. <span class="endmatter-idx2_italic">See</span> Systemic lupus erythematosus</p>
			<p class="em-only_endmatter-idx1">Collagenase, in inflammation, 25</p>
			<p class="em-only_endmatter-idx1">Color photography, in uveitis evaluations, 89</p>
			<p class="em-only_endmatter-idx1">Complement</p>
			<p class="em-only_endmatter-idx2">activation pathways for, 17, 18<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">functions of, 17</p>
			<p class="em-only_endmatter-idx2">in inflammation, 17–19</p>
			<p class="em-only_endmatter-idx2">in uveitis-&#173;glaucoma-&#173;hyphema syndrome, 10</p>
			<p class="em-only_endmatter-idx1">Complement receptors, 12</p>
			<p class="em-only_endmatter-idx1">Congenital Epstein-&#173;Barr virus infection, 259</p>
			<p class="em-only_endmatter-idx1">Congenital rubella syndrome, 260–261, 261<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Congenital syphilis, 220, 226</p>
			<p class="em-only_endmatter-idx1">Congenital toxoplasmosis, 278–279, 279<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Congenital Zika syndrome, 271</p>
			<p class="em-only_endmatter-idx1">Conjunctiva</p>
			<p class="em-only_endmatter-idx2">circumcorneal hyperemia of, 232</p>
			<p class="em-only_endmatter-idx2">effector cells in, 53</p>
			<p class="em-only_endmatter-idx2">eosinophils in, 2</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t,</span> 53</p>
			<p class="em-only_endmatter-idx2">immunoregulatory systems of, 53</p>
			<p class="em-only_endmatter-idx2">mast cells in, 3</p>
			<p class="em-only_endmatter-idx2">mucosa-&#173;associated lymphoid tissue of, 53</p>
			<p class="em-only_endmatter-idx2">sarcoidosis involvement of, 195, 195<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Conjunctivitis</p>
			<p class="em-only_endmatter-idx2">in HIV patients, 336</p>
			<p class="em-only_endmatter-idx2">in reactive arthritis syndrome, 133</p>
			<p class="em-only_endmatter-idx2">rubella as cause of, 262</p>
			<p class="em-only_endmatter-idx2">solitary granulomatous, 336</p>
			<p class="em-only_endmatter-idx1">Connective tissue mast cells, 2–3</p>
			<p class="em-only_endmatter-idx1">Cornea</p>
			<p class="em-only_endmatter-idx2">edema of, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">effector cells in, 54</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t,</span> 54<span class="endmatter-idx2_italic">f,</span> 54–55</p>
			<p class="em-only_endmatter-idx2">immunoregulatory systems of, 54–55</p>
			<p class="em-only_endmatter-idx2">Khodadoust line of endothelial rejection, 54, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">plasma-&#173;derived proteins in, 54</p>
			<p class="em-only_endmatter-idx2">sarcoidosis involvement of, 196</p>
			<p class="em-only_endmatter-idx1">Corneal allograft rejection, 55</p>
			<p class="em-only_endmatter-idx1">Corneal melting syndromes, 25</p>
			<p class="em-only_endmatter-idx1">Corticosteroids. <span class="endmatter-idx1_italic">See also specific drug</span></p>
			<p class="em-only_endmatter-idx2">adverse effects of, 94, 103, 143, 150</p>
			<p class="em-only_endmatter-idx2">for autoimmune retinopathy, 193</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 216–217</p>
			<p class="em-only_endmatter-idx2">for cataracts, 316</p>
			<p class="em-only_endmatter-idx2">for diffuse unilateral subacute neuroretinitis-&#173;related inflammation, 290</p>
			<p class="em-only_endmatter-idx2">for herpes simplex virus, 251</p>
			<p class="em-only_endmatter-idx2">for &#173;human T-&#173;lymphocytic virus type 1, 269</p>
			<p class="em-only_endmatter-idx2">for iridocyclitis, 127</p>
			<p class="em-only_endmatter-idx2">for Lyme disease-&#173;related anterior segment inflammation, 230</p>
			<p class="em-only_endmatter-idx2">for multifocal choroiditis and panuveitis syndrome, 181</p>
			<p class="em-only_endmatter-idx2">ocular hypertension caused by, 319, 321</p>
			<p class="em-only_endmatter-idx2">for ocular toxoplasmosis, 283</p>
			<p class="em-only_endmatter-idx2">for pars planitis, 149–150</p>
			<p class="em-only_endmatter-idx2">posterior sub-&#173;Tenon injection of, 95–96, 96<span class="endmatter-idx2_italic">f,</span> 324</p>
			<p class="em-only_endmatter-idx2">for relentless placoid chorioretinitis, 173–174</p>
			<p class="em-only_endmatter-idx2">for sarcoidosis, 199</p>
			<p class="em-only_endmatter-idx2">for scleritis, 126</p>
			<p class="em-only_endmatter-idx2">for sympathetic ophthalmia, 203</p>
			<p class="em-only_endmatter-idx2">for syphilitic uveitis-&#173;related inflammation, 227</p>
			<p class="em-only_endmatter-idx2">topical</p>
			<p class="em-only_endmatter-idx3">for iridocyclitis, 127</p>
			<p class="em-only_endmatter-idx3">for uveitis, 94–95, 130</p>
			<p class="em-only_endmatter-idx2">for uveitis</p>
			<p class="em-only_endmatter-idx3">adverse effects of, 94, 103, 143, 150</p>
			<p class="em-only_endmatter-idx3">in &#173;children, 143</p>
			<p class="em-only_endmatter-idx3">dose and duration of, 94, 102</p>
			<p class="em-only_endmatter-idx3">intermediate, 149–150</p>
			<p class="em-only_endmatter-idx3">intravitreal, 97–98, 102</p>
			<p class="em-only_endmatter-idx3">local, 95</p>
			<p class="em-only_endmatter-idx3">nonsteroidal anti-&#173;inflammatory drugs and, 103</p>
			<p class="em-only_endmatter-idx3">osteoporosis prevention strategies, 103</p>
			<p class="em-only_endmatter-idx3">periocular, 95–96, 96–97<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">phacoantigenic, 137</p>
			<p class="em-only_endmatter-idx3">sustained-&#173;release, 95</p>
			<p class="em-only_endmatter-idx3">systemic, 102–103, 150</p>
			<p class="em-only_endmatter-idx3">tapering of, 94</p>
			<p class="em-only_endmatter-idx3">topical, 94–95</p>
			<p class="em-only_endmatter-idx2">for visceral toxocariasis, 286</p>
			<p class="em-only_endmatter-idx1">Cortisol deficiency, corticosteroid-&#173;induced, 94</p>
			<p class="em-only_endmatter-idx1">Cotton-&#173;wool spots, 154, 155<span class="endmatter-idx1_italic">f,</span> 258, 299, 329, 330<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">COX-1. <span class="endmatter-idx1_italic">See</span> Cyclooxygenase</p>
			<p class="em-only_endmatter-idx1">COX-2. <span class="endmatter-idx1_italic">See</span> Cyclooxygenase</p>
			<p class="em-only_endmatter-idx1">Cryotherapy, for intermediate uveitis, 150</p>
			<p class="em-only_endmatter-idx1">Cryptococcosis, 301–302</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Cryptococcus neoformans</span> choroiditis, 335</p>
			<p class="em-only_endmatter-idx1">C-&#173;type lectin receptors, 46</p>
			<p class="em-only_endmatter-idx1">Curvilinear capsulorrhexis, 317</p>
			<p class="em-only_endmatter-idx1">Cyclodestructive procedures, 322</p>
			<p class="em-only_endmatter-idx1">Cyclooxygenase (COX)</p>
			<p class="em-only_endmatter-idx2">COX-1, 19</p>
			<p class="em-only_endmatter-idx2">COX-2, 19</p>
			<p class="em-only_endmatter-idx1">Cyclooxygenase (COX) pathway, in arachidonic acid oxidation, 19</p>
			<p class="em-only_endmatter-idx1">Cyclophosphamide, for uveitis, 109–110, 158, 160</p>
			<p class="em-only_endmatter-idx1">Cycloplegics, for uveitis, 113, 131</p>
			<p class="em-only_endmatter-idx1">Cyclosporine</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 217</p>
			<p class="em-only_endmatter-idx2">for uveitis, 108</p>
			<p class="em-only_endmatter-idx1">Cysticercosis, 287–288, 287–288<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Cysticercus cellulosae,</span> 287</p>
			<p class="em-only_endmatter-idx1">Cytokines</p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 34</p>
			<p class="em-only_endmatter-idx2">definition of, 21</p>
			<p class="em-only_endmatter-idx2">growth &#173;factors, 21, 24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in inflammation, 21, 22–24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">intercellular signaling of, 21</p>
			<p class="em-only_endmatter-idx2">interferons, 21, 24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">interleukins, 21, 22–23<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">lipopolysaccharide effects on, 7</p>
			<p class="em-only_endmatter-idx2">mast cell-&#173;derived, 49</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium synthesis of, 58</p>
			<p class="em-only_endmatter-idx2">types of, 21, 22–24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cytomegalovirus</p>
			<p class="em-only_endmatter-idx2">anterior uveitis caused by, 250–251</p>
			<p class="em-only_endmatter-idx2">Posner-&#173;Schlossman syndrome caused by, 135</p>
			<p class="em-only_endmatter-idx2">retinitis caused by</p>
			<p class="em-only_endmatter-idx3">characteristics of, 256–259</p>
			<p class="em-only_endmatter-idx3">in &#173;children, 257–258</p>
			<p class="em-only_endmatter-idx3">in HIV/AIDS patients, 258, 330–331</p>
			<p class="em-only_endmatter-idx3">imaging of, 257<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal detachments secondary to, 326, 331</p>
			<p class="em-only_endmatter-idx3">treatment of, 258–259</p>
			<p class="em-only_endmatter-idx1">Cytoplasmic antinuclear antibody testing, 160</p>
			<p class="em-only_endmatter-idx1">Cytotoxic T cells</p>
			<p class="em-only_endmatter-idx2">apoptosis inducement by, 46</p>
			<p class="em-only_endmatter-idx2">assassination by, 46</p>
			<p class="em-only_endmatter-idx2">autoimmunity and, 44</p>
			<p class="em-only_endmatter-idx2">CD8 expression by, 36, 44</p>
			<p class="em-only_endmatter-idx2">cytotoxicity mechanisms of, 46, 47<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 44, 46</p>
			<p class="em-only_endmatter-idx2">precursor, 46</p>
			<p class="em-only_endmatter-idx2">suicide induction by, 46</p>
			<p class="em-only_endmatter-idx1">Cytotoxicity</p>
			<p class="em-only_endmatter-idx2">antibody-&#173;dependent cellular, 47–48</p>
			<p class="em-only_endmatter-idx2">CD8<span class="endmatter-idx2_symbol">+</span> T cell, 47<span class="endmatter-idx2_italic">f</span></p>
			<p class="endmatter-idx-alpha">Daclizumab, for multiple sclerosis, 152</p>
			<p class="em-only_endmatter-idx1">Dacryocystitis, 158</p>
			<p class="em-only_endmatter-idx1">Dalen-&#173;Fuchs nodules, 200, 202</p>
			<p class="em-only_endmatter-idx1">Delayed hypersensitivity</p>
			<p class="em-only_endmatter-idx2">definition of, 42</p>
			<p class="em-only_endmatter-idx2">granulomatous form of, 44</p>
			<p class="em-only_endmatter-idx2">in scleritis, 116</p>
			<p class="em-only_endmatter-idx2">subtypes of, 42</p>
			<p class="em-only_endmatter-idx2">T helper cell-17&#160;in, 44</p>
			<p class="em-only_endmatter-idx2">tuberculin form of, 28</p>
			<p class="em-only_endmatter-idx1">Delayed hypersensitivity T cells</p>
			<p class="em-only_endmatter-idx2">description of, 36, 42–44</p>
			<p class="em-only_endmatter-idx2">inflammatory diseases mediated by, 44<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in sympathetic ophthalmia, 45–46</p>
			<p class="em-only_endmatter-idx2">T helper-&#173;cell 2, 43</p>
			<p class="em-only_endmatter-idx2">in toxocara granuloma, 45</p>
			<p class="em-only_endmatter-idx1">Dendritic cells</p>
			<p class="em-only_endmatter-idx2">characteristics of, 4–5</p>
			<p class="em-only_endmatter-idx2">major histocompatibility class II molecule expression by, 30</p>
			<p class="em-only_endmatter-idx2">pattern recognition receptors used by, 4</p>
			<p class="em-only_endmatter-idx2">primed macrophages and, 14</p>
			<p class="em-only_endmatter-idx1">Dengue fever, 269<span class="endmatter-idx1_italic">f,</span> 269–270</p>
			<p class="em-only_endmatter-idx1">Dexamethasone</p>
			<p class="em-only_endmatter-idx2">intravitreal implant of, 97, 150</p>
			<p class="em-only_endmatter-idx2">pellet formulation of, for uveitis, 97–98</p>
			<p class="em-only_endmatter-idx1">Diffuse anterior scleritis, 116, 118</p>
			<p class="em-only_endmatter-idx1">Diffuse unilateral subacute neuroretinitis (DUNS), 289–290<span class="endmatter-idx1_italic">f,</span> 289–291</p>
			<p class="em-only_endmatter-idx1">Difluprednate, for uveitis, 94</p>
			<p class="em-only_endmatter-idx1">Disease-&#173;modifying antirheumatic drugs (DMARDs), 103. <span class="endmatter-idx1_italic">See also</span> Immunomodulatory therapy</p>
			<p class="em-only_endmatter-idx1">Doxycycline</p>
			<p class="em-only_endmatter-idx2">for bartonellosis, 243</p>
			<p class="em-only_endmatter-idx2">for cat-&#173;scratch disease, 243</p>
			<p class="em-only_endmatter-idx2">for Lyme disease, 231<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Drug-&#173;induced uveitis, 139–140<span class="endmatter-idx1_italic">f,</span> 139–141</p>
			<p class="em-only_endmatter-idx1">Duodenal biopsy, for Whipple disease, 244</p>
			<p class="endmatter-idx-alpha">Eales disease, 237, 238<span class="endmatter-idx-alpha_italic">f,</span> 326</p>
			<p class="em-only_endmatter-idx1">Ebola virus, 272–273, 273<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Edema</p>
			<p class="em-only_endmatter-idx2">corneal, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular. <span class="endmatter-idx2_italic">See</span> Macular edema</p>
			<p class="em-only_endmatter-idx2">optic disc, in bartonellosis, 241</p>
			<p class="em-only_endmatter-idx1">Effector blockade, 57</p>
			<p class="em-only_endmatter-idx1">Effector lymphocytes, 36</p>
			<p class="em-only_endmatter-idx1">Eicosanoids</p>
			<p class="em-only_endmatter-idx2">in inflammation, 19–20, 20<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior diffusion of, 19–20</p>
			<p class="em-only_endmatter-idx2">schematic diagram of, 20<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Electroretinography</p>
			<p class="em-only_endmatter-idx2">birdshot chorioretinopathy evaluations, 168</p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa evaluations, 312</p>
			<p class="em-only_endmatter-idx2">uveitis evaluations, 90</p>
			<p class="em-only_endmatter-idx1">Elschnig spots, 157</p>
			<p class="em-only_endmatter-idx1">Endocrine signaling, of cytokines, 21</p>
			<p class="em-only_endmatter-idx1">Endophthalmitis</p>
			<p class="em-only_endmatter-idx2">acute postoperative, 293–294</p>
			<p class="em-only_endmatter-idx2">bacterial toxin induction in, 9</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Candida,</span> 297–301, 298<span class="endmatter-idx2_italic">f,</span> 301<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">chronic postoperative</p>
			<p class="em-only_endmatter-idx3">bacterial &#173;causes of, 294</p>
			<p class="em-only_endmatter-idx3">clinical findings of, 294, 294<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">diagnosis of, 295</p>
			<p class="em-only_endmatter-idx3">fungal &#173;causes of, 294–295</p>
			<p class="em-only_endmatter-idx3">Nd:YAG capsulotomy triggering of, 294</p>
			<p class="em-only_endmatter-idx3">overview of, 293–294</p>
			<p class="em-only_endmatter-idx3"><span class="endmatter-idx3_italic">Propionibacterium acnes</span> as cause of, 294, 294<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">treatment of, 295</p>
			<p class="em-only_endmatter-idx2">definition of, 293</p>
			<p class="em-only_endmatter-idx2">endogenous</p>
			<p class="em-only_endmatter-idx3">bacterial, 296–297</p>
			<p class="em-only_endmatter-idx3">fungal, 297–304, 298<span class="endmatter-idx3_italic">f,</span> 300<span class="endmatter-idx3_italic">f,</span> 302<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fungal</p>
			<p class="em-only_endmatter-idx3"><span class="endmatter-idx3_italic">Aspergillus</span> as cause of, 302–303</p>
			<p class="em-only_endmatter-idx3"><span class="endmatter-idx3_italic">Candida,</span> 297–301, 298<span class="endmatter-idx3_italic">f,</span> 301<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">coccidioidomycosis as cause of, 303–304</p>
			<p class="em-only_endmatter-idx3">cryptococcosis as cause of, 301–302</p>
			<p class="em-only_endmatter-idx3">endogenous, 297–304, 298<span class="endmatter-idx3_italic">f,</span> 300<span class="endmatter-idx3_italic">f,</span> 302<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">manifestations of, 297</p>
			<p class="em-only_endmatter-idx3">“string of pearls” in, 298<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">hypopyon of, 6</p>
			<p class="em-only_endmatter-idx2">infectious, acute anterior uveitis associated with, <br />137</p>
			<p class="em-only_endmatter-idx2">innate immune response in, 5</p>
			<p class="em-only_endmatter-idx1">Endoplasmic reticulum aminopeptidase (ERAP), <br />65</p>
			<p class="em-only_endmatter-idx1">Endothelial cells, activation of, 10, 12</p>
			<p class="em-only_endmatter-idx1">Endothelial graft rejection</p>
			<p class="em-only_endmatter-idx2">epithelial edema with, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">Khodadoust line, 54, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">stromal edema with, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Endotoxin. <span class="endmatter-idx1_italic">See also</span> Lipopolysaccharide</p>
			<p class="em-only_endmatter-idx2">in innate immune response activation, 7</p>
			<p class="em-only_endmatter-idx2">uveitis induced by, 8, 62</p>
			<p class="em-only_endmatter-idx1">Enhanced depth imaging optical coherence tomography</p>
			<p class="em-only_endmatter-idx2">in posterior scleritis, 124</p>
			<p class="em-only_endmatter-idx2">in uveitis, 85, 88<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Enteropathic arthritis, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Enthesitis-&#173;related arthritis (ERA), 142</p>
			<p class="em-only_endmatter-idx1">Enzyme-&#173;linked immunosorbent assay (ELISA)</p>
			<p class="em-only_endmatter-idx2">for leptospirosis, 232</p>
			<p class="em-only_endmatter-idx2">for syphilis, 225</p>
			<p class="em-only_endmatter-idx1">Eosinophils</p>
			<p class="em-only_endmatter-idx2">characteristics of, 2</p>
			<p class="em-only_endmatter-idx2">granule products of, 2</p>
			<p class="em-only_endmatter-idx1">Epiret&#173;i&#173;nal membranes, 325</p>
			<p class="em-only_endmatter-idx1">Episcleritis</p>
			<p class="em-only_endmatter-idx2">nonsteroidal anti-&#173;inflammatory drugs for, 113</p>
			<p class="em-only_endmatter-idx2">scleritis versus, 117</p>
			<p class="em-only_endmatter-idx1">Epithelioid cells, macrophage activation into, 4</p>
			<p class="em-only_endmatter-idx1">Epitope(s)</p>
			<p class="em-only_endmatter-idx2">in adaptive immune response, 27, 30</p>
			<p class="em-only_endmatter-idx2">antigenic, 27, 41</p>
			<p class="em-only_endmatter-idx2">definition of, 27</p>
			<p class="em-only_endmatter-idx2">idiotopes versus, 41</p>
			<p class="em-only_endmatter-idx1">Epstein-&#173;Barr virus, 259–260</p>
			<p class="em-only_endmatter-idx1">Equine recurrent uveitis, 62</p>
			<p class="em-only_endmatter-idx1">Erythema chronicum migrans, 227–228, 228<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">E-&#173;Selectin, 11–12</p>
			<p class="em-only_endmatter-idx1">Etanercept, for sarcoidosis, 199</p>
			<p class="em-only_endmatter-idx1">Ethylenediaminetetraacetic acid, 315</p>
			<p class="em-only_endmatter-idx1">Exciting eye, 199–200</p>
			<p class="em-only_endmatter-idx1">Exotoxins</p>
			<p class="em-only_endmatter-idx2">definition of, 9</p>
			<p class="em-only_endmatter-idx2">innate immune response triggered by, 9</p>
			<p class="em-only_endmatter-idx1">Experimental autoimmune uveoretinitis (EAU), 61–62</p>
			<p class="endmatter-idx-alpha">Fab fragment, of B cells, 41</p>
			<p class="em-only_endmatter-idx1">Famciclovir, for herpes simplex virus, 251</p>
			<p class="em-only_endmatter-idx1">Fas ligand</p>
			<p class="em-only_endmatter-idx2">apoptosis induced by, 57</p>
			<p class="em-only_endmatter-idx2">in effector blockade, 57</p>
			<p class="em-only_endmatter-idx1">Fc receptors</p>
			<p class="em-only_endmatter-idx2">antibody, 12</p>
			<p class="em-only_endmatter-idx2">description of, 3</p>
			<p class="em-only_endmatter-idx2">mast-&#173;cell, 19</p>
			<p class="em-only_endmatter-idx2">types of, 47</p>
			<p class="em-only_endmatter-idx1">Fibrin</p>
			<p class="em-only_endmatter-idx2">dissolution of, 18</p>
			<p class="em-only_endmatter-idx2">in inflammation, 18–19</p>
			<p class="em-only_endmatter-idx2">in uveitis-&#173;glaucoma-&#173;hyphema syndrome, 10</p>
			<p class="em-only_endmatter-idx1">Fibrinogen, 18</p>
			<p class="em-only_endmatter-idx1">Fingolimod, for multiple sclerosis, 152</p>
			<p class="em-only_endmatter-idx1">Floaters, in intermediate uveitis, 76</p>
			<p class="em-only_endmatter-idx1">Fluconazole, for coccidioidomycosis, 304</p>
			<p class="em-only_endmatter-idx1">Fluocinolone acetonide implant</p>
			<p class="em-only_endmatter-idx2">for birdshot chorioretinopathy, 169</p>
			<p class="em-only_endmatter-idx2">for multifocal choroiditis and panuveitis syndrome, 181</p>
			<p class="em-only_endmatter-idx2">for sympathetic ophthalmia, 203</p>
			<p class="em-only_endmatter-idx2">for uveitis</p>
			<p class="em-only_endmatter-idx3">description of, 97–98</p>
			<p class="em-only_endmatter-idx3">macular edema caused by, 324</p>
			<p class="em-only_endmatter-idx1">Fluorescein angiography (FA)</p>
			<p class="em-only_endmatter-idx2">in acute posterior multifocal placoid pigment epitheliopathy, 163<span class="endmatter-idx2_italic">t,</span> 170, 171<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in acute ret&#173;i&#173;nal pigment epitheliitis, 189, 189<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in acute zonal occult outer retinopathy, 163<span class="endmatter-idx2_italic">t,</span> 191</p>
			<p class="em-only_endmatter-idx2">in Beh<span class="endmatter-idx2_accent">ç</span>et disease, 216, 217<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 163<span class="endmatter-idx2_italic">t,</span> 165–166, 166–167<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Dengue fever, 269</p>
			<p class="em-only_endmatter-idx2">in granulomatous necrotizing scleritis, 120<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in intermediate uveitis, 148</p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 163<span class="endmatter-idx2_italic">t,</span> 179, 179<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in multiple evanescent white dot syndrome, 163<span class="endmatter-idx2_italic">t,</span> 185, 186<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in ocular ischemic syndrome, 312</p>
			<p class="em-only_endmatter-idx2">in pars planitis, 148</p>
			<p class="em-only_endmatter-idx2">in primary vitreoret&#173;i&#173;nal lymphoma, 307</p>
			<p class="em-only_endmatter-idx2">in punctate inner choroiditis, 163<span class="endmatter-idx2_italic">t,</span> 182, 183<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in serpiginous choroiditis, 163<span class="endmatter-idx2_italic">t,</span> 175<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in subret&#173;i&#173;nal fibrosis and uveitis syndrome, 163<span class="endmatter-idx2_italic">t,</span> 184</p>
			<p class="em-only_endmatter-idx2">in sympathetic ophthalmia, 200, 201<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in tubercular uveitis, 236, 237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in uveitis, 88, 89<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Vogt-&#173;Koyanagi-&#173;Harada syndrome, 208–209, 209<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in West Nile virus, 265, 266<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fluo&#173;rescent treponemal antibody absorption assay (FTS-&#173;ABS), 224–225</p>
			<p class="em-only_endmatter-idx1">Foreign bodies, intraocular, 313</p>
			<p class="em-only_endmatter-idx1">Foscarnet</p>
			<p class="em-only_endmatter-idx2">for cytomegalovirus, 258</p>
			<p class="em-only_endmatter-idx2">for herpes simplex virus, 254</p>
			<p class="em-only_endmatter-idx1">“Frosted-&#173;branch” angiitis, 256, 257<span class="endmatter-idx1_italic">f,</span> 306</p>
			<p class="em-only_endmatter-idx1">Fuchs heterochromic uveitis</p>
			<p class="em-only_endmatter-idx2">Goldmann-&#173;Witmer coefficient for, 41–42</p>
			<p class="em-only_endmatter-idx2">keratic precipitates in, 250</p>
			<p class="em-only_endmatter-idx2">medical management of, 93</p>
			<p class="em-only_endmatter-idx1">Fuchs uveitis syndrome, 145–146, 146<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fundus autofluorescence</p>
			<p class="em-only_endmatter-idx2">in acute posterior multifocal placoid pigment epitheliopathy, 163<span class="endmatter-idx2_italic">t,</span> 171, 172<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in acute ret&#173;i&#173;nal pigment epitheliitis, 189</p>
			<p class="em-only_endmatter-idx2">in acute zonal occult outer retinopathy, 163<span class="endmatter-idx2_italic">t,</span> 191, 192<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 163<span class="endmatter-idx2_italic">t,</span> 166, 167<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 163<span class="endmatter-idx2_italic">t,</span> 179, 180<span class="endmatter-idx2_italic">f</span> 186–187<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in multiple evanescent white dot syndrome, <br />163<span class="endmatter-idx2_italic">t,</span> 186<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in punctate inner choroiditis, 163<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in serpiginous choroiditis, 163<span class="endmatter-idx2_italic">t,</span> 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in subret&#173;i&#173;nal fibrosis and uveitis syndrome, 163<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in uveitis evaluations, 89</p>
			<p class="em-only_endmatter-idx1">Fungal endophthalmitis, endogenous</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Aspergillus</span> as cause of, 302–303</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Candida,</span> 297–301, 298<span class="endmatter-idx2_italic">f,</span> 301<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">coccidioidomycosis as cause of, 303–304</p>
			<p class="em-only_endmatter-idx2">cryptococcosis as cause of, 301–302</p>
			<p class="em-only_endmatter-idx2">endogenous, 297–304, 298<span class="endmatter-idx2_italic">f,</span> 300<span class="endmatter-idx2_italic">f,</span> 302<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 297</p>
			<p class="em-only_endmatter-idx2">“string of pearls” in, 298<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fungal uveitis</p>
			<p class="em-only_endmatter-idx2">ocular histoplasmosis syndrome, 274–277, 275–276<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">polymerase chain reaction for, 90</p>
			<p class="endmatter-idx-alpha">Ganciclovir</p>
			<p class="em-only_endmatter-idx2">for cytomegalovirus, 258</p>
			<p class="em-only_endmatter-idx2">for herpes simplex virus, 254</p>
			<p class="em-only_endmatter-idx1">GATA3 transcription &#173;factor, 32</p>
			<p class="em-only_endmatter-idx1">Gene therapy, ret&#173;i&#173;nal, 58</p>
			<p class="em-only_endmatter-idx1">Genotyping, 63</p>
			<p class="em-only_endmatter-idx1">&#173;Giant cell arteritis, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">&#173;Giant cells, macrophage activation into, 4</p>
			<p class="em-only_endmatter-idx1">Glaucoma</p>
			<p class="em-only_endmatter-idx2">angle-&#173;closure, secondary, 320</p>
			<p class="em-only_endmatter-idx2">corticosteroid-&#173;induced, 321</p>
			<p class="em-only_endmatter-idx2">open-&#173;angle, secondary, 320–321</p>
			<p class="em-only_endmatter-idx2">in pars planitis, 151</p>
			<p class="em-only_endmatter-idx2">phacolytic, 13, 137</p>
			<p class="em-only_endmatter-idx2">uveitic, 319</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 85</p>
			<p class="em-only_endmatter-idx1">Glaucoma filtering surgery, 321</p>
			<p class="em-only_endmatter-idx1">Glaucomatocyclitic crisis, acute anterior uveitis in, 135–136</p>
			<p class="em-only_endmatter-idx1">Goldmann-&#173;Witmer (GW) coefficient</p>
			<p class="em-only_endmatter-idx2">calculation of, 41–42</p>
			<p class="em-only_endmatter-idx2">description of, 253–254</p>
			<p class="em-only_endmatter-idx2">for Fuchs heterochromic uveitis, 41–42</p>
			<p class="em-only_endmatter-idx2">polymerase chain reaction and, 91</p>
			<p class="em-only_endmatter-idx2">for toxoplasmosis, 91</p>
			<p class="em-only_endmatter-idx1">Golimumab, 110</p>
			<p class="em-only_endmatter-idx1">Gomori methenamine silver stain, 300<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Goniotomy, 322</p>
			<p class="em-only_endmatter-idx1">Granular cytomegalovirus retinitis, 257<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Granuloma</p>
			<p class="em-only_endmatter-idx2">iris, 302<span class="endmatter-idx2_italic">f,</span> 304</p>
			<p class="em-only_endmatter-idx2">toxocara, 45</p>
			<p class="em-only_endmatter-idx1">Granulomatosis with polyangiitis (GPA)</p>
			<p class="em-only_endmatter-idx2">definition of, 158</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 159–160</p>
			<p class="em-only_endmatter-idx2">laboratory investigations for, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 158–159, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">necrotizing scleritis in, 120<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular involvement in, 159</p>
			<p class="em-only_endmatter-idx2">treatment of, 160</p>
			<p class="em-only_endmatter-idx2">vision loss in, 159</p>
			<p class="em-only_endmatter-idx1">Granulomatous necrotizing scleritis, 120<span class="endmatter-idx1_italic">f,</span> 120–121</p>
			<p class="em-only_endmatter-idx1">Growth &#173;factors</p>
			<p class="em-only_endmatter-idx2">definition of, 21</p>
			<p class="em-only_endmatter-idx2">types of, 24<span class="endmatter-idx2_italic">t</span></p>
			<p class="endmatter-idx-alpha">Haplotype, 63</p>
			<p class="em-only_endmatter-idx1">Haze (vitreous), in intermediate uveitis, 81<span class="endmatter-idx1_italic">f,</span> <br />81–82, 82<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Heerfordt syndrome, 195</p>
			<p class="em-only_endmatter-idx1">Helper T cells</p>
			<p class="em-only_endmatter-idx2">accessory molecules expressed by, 31</p>
			<p class="em-only_endmatter-idx2">in adaptive immune response, 30, 32<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">antigen receptor on, 30</p>
			<p class="em-only_endmatter-idx2">classification of, 32</p>
			<p class="em-only_endmatter-idx2">differentiation of, 32–35</p>
			<p class="em-only_endmatter-idx2">priming of, 31</p>
			<p class="em-only_endmatter-idx2">subsets of, 32</p>
			<p class="em-only_endmatter-idx2">Th1, 32–33</p>
			<p class="em-only_endmatter-idx2">Th2, 32</p>
			<p class="em-only_endmatter-idx2">Th17, 33–34</p>
			<p class="em-only_endmatter-idx1">Hemorrhage, intraret&#173;i&#173;nal, 157<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Herpes simplex virus (HSV)</p>
			<p class="em-only_endmatter-idx2">anterior uveitis associated with, 249–252</p>
			<p class="em-only_endmatter-idx2">infectious scleritis caused by, 124</p>
			<p class="em-only_endmatter-idx2">keratitis associated with, 336</p>
			<p class="em-only_endmatter-idx2">ocular hypertension associated with, 250–251</p>
			<p class="em-only_endmatter-idx1">Herpes zoster, 250, 336</p>
			<p class="em-only_endmatter-idx1">Herpes zoster ophthalmicus, 250</p>
			<p class="em-only_endmatter-idx1">Herpetic choroiditis, 177</p>
			<p class="em-only_endmatter-idx1">Herpetic encephalitis, 253</p>
			<p class="em-only_endmatter-idx1">Herpetic retinitis</p>
			<p class="em-only_endmatter-idx2">necrotizing, 332, 332<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">nonnecrotizing, 252–256</p>
			<p class="em-only_endmatter-idx1">Heterochromia, in Fuchs uveitis syndrome, 145, 146<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Histamine</p>
			<p class="em-only_endmatter-idx2">in basophils, 19</p>
			<p class="em-only_endmatter-idx2">in connective tissue mast cells, 3</p>
			<p class="em-only_endmatter-idx2">in mast cells, 19</p>
			<p class="em-only_endmatter-idx2">in mucosal mast cells, 3</p>
			<p class="em-only_endmatter-idx1">Histo spots, 275, 275<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Histoplasma capsulatum,</span> 274</p>
			<p class="em-only_endmatter-idx1">HIV. <span class="endmatter-idx1_italic">See also</span> AIDS</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis in, 258</p>
			<p class="em-only_endmatter-idx2">herpes zoster and, 336</p>
			<p class="em-only_endmatter-idx2">ocular toxoplasmosis in, 283–284, 284<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ophthalmic manifestations of, 329–335, 330<span class="endmatter-idx2_italic">f,</span> 332<span class="endmatter-idx2_italic">f,</span> 334<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinopathy associated with, 329, 330<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">syphilis and, 219–220, 333–334</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;A29</p>
			<p class="em-only_endmatter-idx2">birdshot chorioretinopathy and, 34, 64–65, 65<span class="endmatter-idx2_italic">t,</span> 165</p>
			<p class="em-only_endmatter-idx2">prevalence of, 64</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;B12, 215</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;B27</p>
			<p class="em-only_endmatter-idx2">characteristics of, 131</p>
			<p class="em-only_endmatter-idx2">diseases associated with</p>
			<p class="em-only_endmatter-idx3">ankylosing spondylitis, 130<span class="endmatter-idx3_italic">f,</span> 131–132</p>
			<p class="em-only_endmatter-idx3">clinical pre&#173;sen&#173;ta&#173;tion of, 130, 130<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">inflammatory bowel syndrome, 133</p>
			<p class="em-only_endmatter-idx3">pattern of, 130</p>
			<p class="em-only_endmatter-idx3">psoriatic arthritis, 133, 134<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">reactive arthritis syndrome, 132–133, 133<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">uveitis and, 64, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">HLA-&#173;B51, 215</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;D, 63</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;DM, 63</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;DR4</p>
			<p class="em-only_endmatter-idx2">Lyme disease and, 228</p>
			<p class="em-only_endmatter-idx2">Vogt-&#173;Koyanagi-&#173;Harada syndrome and, 204</p>
			<p class="em-only_endmatter-idx1">Homing, 38</p>
			<p class="em-only_endmatter-idx1">&#173;Human granulocytic anaplasmosis, 230</p>
			<p class="em-only_endmatter-idx1">&#173;Human granulocytic ehrlichiosis, 230</p>
			<p class="em-only_endmatter-idx1">&#173;Human herpesvirus 8, 335</p>
			<p class="em-only_endmatter-idx1">&#173;Human immunodeficiency virus. <span class="endmatter-idx1_italic">See</span>&#160;HIV</p>
			<p class="em-only_endmatter-idx1">&#173;Human leukocyte antigens. <span class="endmatter-idx1_italic">See also specific HLA</span></p>
			<p class="em-only_endmatter-idx2">allelic variation, 63–64</p>
			<p class="em-only_endmatter-idx2">disease associations with, 64–66, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">function of, 63</p>
			<p class="em-only_endmatter-idx2">genotyping of, 63</p>
			<p class="em-only_endmatter-idx2">haplotype of</p>
			<p class="em-only_endmatter-idx3">definition of, 63</p>
			<p class="em-only_endmatter-idx3">disease associations with, 64–66, 65<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx1">&#173;Human T-&#173;lymphocytic virus type 1 (HTLV-1)</p>
			<p class="em-only_endmatter-idx2">description of, 267–269, 268<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">keratopathy associated with, 268</p>
			<p class="em-only_endmatter-idx1">Hutchinson sign, 250</p>
			<p class="em-only_endmatter-idx1">Hutchinson triad, 220</p>
			<p class="em-only_endmatter-idx1">Hyalocytes, 56</p>
			<p class="em-only_endmatter-idx1">Hydrogen peroxide, 16</p>
			<p class="em-only_endmatter-idx1">Hydroxyl radical, 16</p>
			<p class="em-only_endmatter-idx1">Hyperemia, in scleritis, 117, 117<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hypersensitivity</p>
			<p class="em-only_endmatter-idx2">delayed</p>
			<p class="em-only_endmatter-idx3">definition of, 42</p>
			<p class="em-only_endmatter-idx3">granulomatous form of, 44</p>
			<p class="em-only_endmatter-idx3">subtypes of, 42</p>
			<p class="em-only_endmatter-idx3">T cells</p>
			<p class="em-only_endmatter-idx4">description of, 36, 42–44</p>
			<p class="em-only_endmatter-idx4">inflammatory diseases mediated by, 44<span class="endmatter-idx4_italic">t</span></p>
			<p class="em-only_endmatter-idx4">in sympathetic ophthalmia, 45–46</p>
			<p class="em-only_endmatter-idx4">T helper-&#173;cell 2, 43</p>
			<p class="em-only_endmatter-idx4">in toxocara granuloma, 45</p>
			<p class="em-only_endmatter-idx3">T helper cell-17&#160;in, 44</p>
			<p class="em-only_endmatter-idx3">tuberculin form of, 28</p>
			<p class="em-only_endmatter-idx2">immediate, 48–49</p>
			<p class="em-only_endmatter-idx1">Hypopyon</p>
			<p class="em-only_endmatter-idx2">in acute anterior uveitis, 130, 131<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in <span class="endmatter-idx2_italic">Aspergillus</span> endophthalmitis, 302</p>
			<p class="em-only_endmatter-idx2">in Beh<span class="endmatter-idx2_accent">ç</span>et disease, 214, 214<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">endophthalmitis, 6</p>
			<p class="em-only_endmatter-idx2">lens-&#173;associated uveitis, 6</p>
			<p class="em-only_endmatter-idx2">in leukemia, 310</p>
			<p class="em-only_endmatter-idx1">Hypotony, 323</p>
			<p class="endmatter-idx-alpha">Idiopathic stellate maculopathy, 241</p>
			<p class="em-only_endmatter-idx1">Idiotopes, 41</p>
			<p class="em-only_endmatter-idx1">Immediate hypersensitivity, 48–49</p>
			<p class="em-only_endmatter-idx1">Immune checkpoint inhibitors, Vogt-&#173;Koyanagi-&#173;Harada syndrome caused by, 140<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Immune privilege</p>
			<p class="em-only_endmatter-idx2">in cornea, 54</p>
			<p class="em-only_endmatter-idx2">definition of, 51</p>
			<p class="em-only_endmatter-idx1">Immune pro&#173;cessing</p>
			<p class="em-only_endmatter-idx2">antigen in, 30, 33<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">CD4<span class="endmatter-idx2_symbol">+</span> T cells in, 30–31</p>
			<p class="em-only_endmatter-idx1">Immune recovery uveitis (IRU), 331</p>
			<p class="em-only_endmatter-idx1">Immune response(s)</p>
			<p class="em-only_endmatter-idx2">adaptive. <span class="endmatter-idx2_italic">See</span> Adaptive immune response/adaptive immunity</p>
			<p class="em-only_endmatter-idx2">of anterior chamber, 55–57</p>
			<p class="em-only_endmatter-idx2">of anterior uvea, 55–57</p>
			<p class="em-only_endmatter-idx2">of choriocapillaris, 57–59</p>
			<p class="em-only_endmatter-idx2">of choroid, 57–59</p>
			<p class="em-only_endmatter-idx2">of conjunctiva, 53</p>
			<p class="em-only_endmatter-idx2">of cornea, 54<span class="endmatter-idx2_italic">f,</span> 54–55</p>
			<p class="em-only_endmatter-idx2">definition of, 1, 6</p>
			<p class="em-only_endmatter-idx2">inflammation versus, 6</p>
			<p class="em-only_endmatter-idx2">innate. <span class="endmatter-idx2_italic">See</span> Innate immune response/innate immune system</p>
			<p class="em-only_endmatter-idx2">mediator systems that amplify</p>
			<p class="em-only_endmatter-idx3">complement, 17–19</p>
			<p class="em-only_endmatter-idx3">eicosanoids, 19–20, 20<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">fibrin, 18–19</p>
			<p class="em-only_endmatter-idx3">histamine, 18</p>
			<p class="em-only_endmatter-idx3">overview of, 17</p>
			<p class="em-only_endmatter-idx3">plasma-&#173;derived enzyme systems, 17–19</p>
			<p class="em-only_endmatter-idx3">plasminogen, 18</p>
			<p class="em-only_endmatter-idx3">platelet-&#173;activating &#173;factors, 20–21</p>
			<p class="em-only_endmatter-idx2">neutrophils in, 2</p>
			<p class="em-only_endmatter-idx2">primary, 37–38</p>
			<p class="em-only_endmatter-idx2">regional immunity and, 51, 52<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">of ret&#173;ina, 57–59</p>
			<p class="em-only_endmatter-idx2">of ret&#173;i&#173;nal pigment epithelium, 57–59</p>
			<p class="em-only_endmatter-idx2">secondary, 37–38</p>
			<p class="em-only_endmatter-idx2">of vitreous, 55–57</p>
			<p class="em-only_endmatter-idx1">Immune response arc</p>
			<p class="em-only_endmatter-idx2">mucosa-&#173;associated lymphoid tissue, 53</p>
			<p class="em-only_endmatter-idx2">phases of, 28–37, 29<span class="endmatter-idx2_italic">f,</span> 31–33<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx3">afferent, 29<span class="endmatter-idx3_italic">f,</span> 29–30</p>
			<p class="em-only_endmatter-idx3">effector, 36–37</p>
			<p class="em-only_endmatter-idx3">pro&#173;cessing, 30–35, 33<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">regional immunity and, 51, 52<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Immune system</p>
			<p class="em-only_endmatter-idx2">components of, 2–5</p>
			<p class="em-only_endmatter-idx2">leukocytes of. <span class="endmatter-idx2_italic">See</span> Leukocytes</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin(s). <span class="endmatter-idx1_italic">See also</span> Antibodies</p>
			<p class="em-only_endmatter-idx2">classes of, 39</p>
			<p class="em-only_endmatter-idx2">description of, 11</p>
			<p class="em-only_endmatter-idx2">functional properties of, 39, 41</p>
			<p class="em-only_endmatter-idx2">isotypes of, 39, 40<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">plasma cell production of, 37</p>
			<p class="em-only_endmatter-idx2">structural features of, 39, 39<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Immunoglobulin&#160;A</p>
			<p class="em-only_endmatter-idx2">in conjunctiva, 53</p>
			<p class="em-only_endmatter-idx2">molecular size of, 39</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin A1, 41</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin A2, 41</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin&#160;E</p>
			<p class="em-only_endmatter-idx2">inflammatory reactions mediated by</p>
			<p class="em-only_endmatter-idx3">Fc receptors for, 3</p>
			<p class="em-only_endmatter-idx3">mast cells in, 3</p>
			<p class="em-only_endmatter-idx2">mast-&#173;cell degranulation mediated by, 48–49</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin G4, 41</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin&#160;M</p>
			<p class="em-only_endmatter-idx2">description of, 35</p>
			<p class="em-only_endmatter-idx2">molecular size of, 39</p>
			<p class="em-only_endmatter-idx2">primary immune response production of, 37</p>
			<p class="em-only_endmatter-idx1">Immunologic microenvironment</p>
			<p class="em-only_endmatter-idx2">of anterior chamber, 55–56</p>
			<p class="em-only_endmatter-idx2">of anterior uvea, 55–56</p>
			<p class="em-only_endmatter-idx2">of choriocapillaris, 57–58</p>
			<p class="em-only_endmatter-idx2">of choroid, 57–58</p>
			<p class="em-only_endmatter-idx2">of conjunctiva, 52<span class="endmatter-idx2_italic">t,</span> 53</p>
			<p class="em-only_endmatter-idx2">of cornea, 54<span class="endmatter-idx2_italic">f,</span> 54–55</p>
			<p class="em-only_endmatter-idx2">of ret&#173;ina, 57–58</p>
			<p class="em-only_endmatter-idx2">of ret&#173;i&#173;nal pigment epithelium, 52<span class="endmatter-idx2_italic">t,</span> 57–58</p>
			<p class="em-only_endmatter-idx2">of vitreous, 52<span class="endmatter-idx2_italic">t,</span> 55–56, 56</p>
			<p class="em-only_endmatter-idx1">Immunomodulatory therapy (IMT)</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 216–218</p>
			<p class="em-only_endmatter-idx2">for birdshot chorioretinopathy, 169</p>
			<p class="em-only_endmatter-idx2">for sarcoidosis, 199</p>
			<p class="em-only_endmatter-idx2">for scleritis, 126</p>
			<p class="em-only_endmatter-idx2">for uveitis</p>
			<p class="em-only_endmatter-idx3">abatacept, 112</p>
			<p class="em-only_endmatter-idx3">adalimumab, 110–111</p>
			<p class="em-only_endmatter-idx3">alkylating agents, 105, 109–110</p>
			<p class="em-only_endmatter-idx3">antimetabolites, 106–108</p>
			<p class="em-only_endmatter-idx3">azathioprine, 106–107</p>
			<p class="em-only_endmatter-idx3">biologic agents, 104, 110–113</p>
			<p class="em-only_endmatter-idx3">chlorambucil, 110</p>
			<p class="em-only_endmatter-idx3">complications of, 105</p>
			<p class="em-only_endmatter-idx3">cyclophosphamide, 109–110</p>
			<p class="em-only_endmatter-idx3">cyclosporine, 108</p>
			<p class="em-only_endmatter-idx3">description of, 103</p>
			<p class="em-only_endmatter-idx3">evaluations before initiating, 104–105</p>
			<p class="em-only_endmatter-idx3">indications for, 104</p>
			<p class="em-only_endmatter-idx3">infliximab, 111–112</p>
			<p class="em-only_endmatter-idx3">interferon alfa-2a/2b, 112</p>
			<p class="em-only_endmatter-idx3">methotrexate, 107</p>
			<p class="em-only_endmatter-idx3">monitoring during, 105</p>
			<p class="em-only_endmatter-idx3">mycophenolate mofetil, 107</p>
			<p class="em-only_endmatter-idx3">nonbiologic agents, 104, 106–110</p>
			<p class="em-only_endmatter-idx3">onset of action, 105</p>
			<p class="em-only_endmatter-idx3">pregnancy contraindications for, 105</p>
			<p class="em-only_endmatter-idx3">in psoriatic arthritis, 133</p>
			<p class="em-only_endmatter-idx3">rituximab, 112</p>
			<p class="em-only_endmatter-idx3">tacrolimus, 108</p>
			<p class="em-only_endmatter-idx3">T-&#173;cell inhibitors, 108–1109</p>
			<p class="em-only_endmatter-idx3">tumor necrosis &#173;factor inhibitors, 105, 110–112, 130–131</p>
			<p class="em-only_endmatter-idx1">Immunoregulatory systems</p>
			<p class="em-only_endmatter-idx2">of anterior chamber, 56–57</p>
			<p class="em-only_endmatter-idx2">of anterior uvea, 56–57</p>
			<p class="em-only_endmatter-idx2">of choriocapillaris, 59</p>
			<p class="em-only_endmatter-idx2">of choroid, 59</p>
			<p class="em-only_endmatter-idx2">of conjunctiva, 53</p>
			<p class="em-only_endmatter-idx2">of cornea, 54–55</p>
			<p class="em-only_endmatter-idx2">of ret&#173;ina, 59</p>
			<p class="em-only_endmatter-idx2">of ret&#173;i&#173;nal pigment epithelium, 59</p>
			<p class="em-only_endmatter-idx2">of vitreous, 56–57</p>
			<p class="em-only_endmatter-idx1">Indocyanine green angiography (IGA)</p>
			<p class="em-only_endmatter-idx2">in acute posterior multifocal placoid pigment epitheliopathy, 163<span class="endmatter-idx2_italic">t,</span> 170–171, 171<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in acute zonal occult outer retinopathy, 163<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 163<span class="endmatter-idx2_italic">t,</span> 166, 167<span class="endmatter-idx2_italic">f,</span> 179</p>
			<p class="em-only_endmatter-idx2">in granulomatous necrotizing scleritis, 120<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 163<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in multiple evanescent white dot syndrome, 163<span class="endmatter-idx2_italic">t,</span> 188<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in punctate inner choroiditis, 163<span class="endmatter-idx2_italic">t,</span> 182, 183<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in serpiginous choroiditis, 163<span class="endmatter-idx2_italic">t,</span> 175</p>
			<p class="em-only_endmatter-idx2">in subret&#173;i&#173;nal fibrosis and uveitis syndrome, 163<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in sympathetic ophthalmia, 201, 202<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in tubercular uveitis, 236, 237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in uveitis, 89</p>
			<p class="em-only_endmatter-idx2">in Vogt-&#173;Koyanagi-&#173;Harada syndrome, 209</p>
			<p class="em-only_endmatter-idx1">Inducible nitric oxide synthetase (iNOS), 16</p>
			<p class="em-only_endmatter-idx1">Inducible T regulatory cells, 34</p>
			<p class="em-only_endmatter-idx1">Infectious endophthalmitis, acute anterior uveitis associated with, 137</p>
			<p class="em-only_endmatter-idx1">Infectious scleritis</p>
			<p class="em-only_endmatter-idx2">actinomycetes as cause of, 119<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 124</p>
			<p class="em-only_endmatter-idx2">description of, 116</p>
			<p class="em-only_endmatter-idx2">microbiological examination for, 125</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 123–124</p>
			<p class="em-only_endmatter-idx2">treatment of, 127</p>
			<p class="em-only_endmatter-idx2">vision loss risks, 128</p>
			<p class="em-only_endmatter-idx1">Infectious uveitis</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis, 252, 253<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">adenovirus as cause of, 274</p>
			<p class="em-only_endmatter-idx2">bartonellosis as cause of. <span class="endmatter-idx2_italic">See</span> Bartonellosis</p>
			<p class="em-only_endmatter-idx2">Chikungunya fever as cause of, 270–271</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus as cause of, 250–251, 256–259, <br />257<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">Dengue fever as cause of, 269<span class="endmatter-idx2_italic">f,</span> 269–270</p>
			<p class="em-only_endmatter-idx2">Ebola virus as cause of, 272–273, 273<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">Epstein-&#173;Barr virus as cause of, 259–260</p>
			<p class="em-only_endmatter-idx2">herpes simplex virus as cause of, 249–252, 250–251<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">&#173;human T-&#173;lymphocytic virus type 1 as cause of, 267–269, 268<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">immunologic uveitis versus, 313</p>
			<p class="em-only_endmatter-idx2">leptospirosis as cause of, 232–233</p>
			<p class="em-only_endmatter-idx2">Lyme disease as cause of. <span class="endmatter-idx2_italic">See</span> Lyme disease</p>
			<p class="em-only_endmatter-idx2">lymphocytic choriomeningitis virus as cause <br />of, 263</p>
			<p class="em-only_endmatter-idx2">measles as cause of, 263–265</p>
			<p class="em-only_endmatter-idx2">mumps as cause of, 263</p>
			<p class="em-only_endmatter-idx2">nocardiosis as cause of, 233</p>
			<p class="em-only_endmatter-idx2">periocular injection contraindications in, 96</p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis, 252–256, 255<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment associated <br />with, 326</p>
			<p class="em-only_endmatter-idx2">Rift Valley fever as cause of, 267, 267<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">rubella as cause of, 260–263</p>
			<p class="em-only_endmatter-idx2">subacute sclerosing panencephalitis as cause of, 264–265</p>
			<p class="em-only_endmatter-idx2">syphilis as cause of. <span class="endmatter-idx2_italic">See</span> Syphilis</p>
			<p class="em-only_endmatter-idx2">tuberculosis as cause of, 234–240, 235–238<span class="endmatter-idx2_italic">f. See also</span> Tuberculosis</p>
			<p class="em-only_endmatter-idx2">West Nile virus as cause of, 265–266</p>
			<p class="em-only_endmatter-idx2">Whipple disease as cause of, 243–245, 244<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">Zika fever as cause of, 271–272, 272<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inferior transseptal injection, of periocular corticosteroids, 96, 97<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inflammation</p>
			<p class="em-only_endmatter-idx2">cytokines in, 21, 22–24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">eicosanoids in, 19–20, 20<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">immune response versus, 6</p>
			<p class="em-only_endmatter-idx2">leukotrienes in, 20</p>
			<p class="em-only_endmatter-idx2">pathologic findings associated with, 6</p>
			<p class="em-only_endmatter-idx1">Inflammatory bowel disease, acute anterior uveitis <br />in, 133</p>
			<p class="em-only_endmatter-idx1">Inflammatory cells, in anterior uveitis, 77, 79<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inflammatory chorioretinopathies</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy. <span class="endmatter-idx2_italic">See</span> Acute posterior multifocal placoid pigment epitheliopathy</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal pigment epitheliitis, 162–164<span class="endmatter-idx2_italic">f,</span> 189<span class="endmatter-idx2_italic">f,</span> 189–190</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy. <span class="endmatter-idx2_italic">See</span> Acute zonal occult outer retinopathy</p>
			<p class="em-only_endmatter-idx2">birdshot chorioretinopathy. <span class="endmatter-idx2_italic">See</span> Birdshot chorioretinopathy</p>
			<p class="em-only_endmatter-idx2">definition of, 161</p>
			<p class="em-only_endmatter-idx2">multifocal choroiditis and panuveitis syndrome. <span class="endmatter-idx2_italic">See</span> Multifocal choroiditis and panuveitis syndrome</p>
			<p class="em-only_endmatter-idx2">multiple evanescent white dot syndrome. <span class="endmatter-idx2_italic">See</span> Multiple evanescent white dot syndrome</p>
			<p class="em-only_endmatter-idx2">punctate inner choroiditis. <span class="endmatter-idx2_italic">See</span> Punctate inner choroiditis</p>
			<p class="em-only_endmatter-idx2">serpiginous choroiditis. <span class="endmatter-idx2_italic">See</span> Serpiginous choroiditis</p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal fibrosis and uveitis syndrome. <span class="endmatter-idx2_italic">See</span> Subret&#173;i&#173;nal fibrosis and uveitis syndrome</p>
			<p class="em-only_endmatter-idx1">Inflammatory dendritic cells, 4</p>
			<p class="em-only_endmatter-idx1">Inflammatory response</p>
			<p class="em-only_endmatter-idx2">clinical manifestations of, 6</p>
			<p class="em-only_endmatter-idx2">definition of, 6</p>
			<p class="em-only_endmatter-idx2">lipopolysaccharide-&#173;induced, 8–9</p>
			<p class="em-only_endmatter-idx1">Infliximab</p>
			<p class="em-only_endmatter-idx2">anti-&#173;idiotypic antibodies’ effect on, 41</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 216</p>
			<p class="em-only_endmatter-idx2">sarcoidosis-&#173;associated uveitis treated with, 199</p>
			<p class="em-only_endmatter-idx2">for uveitis, 111–112</p>
			<p class="em-only_endmatter-idx1">Innate immune response/innate immune system</p>
			<p class="em-only_endmatter-idx2">adaptive immune response versus, 27</p>
			<p class="em-only_endmatter-idx2">conjunctiva and, 53</p>
			<p class="em-only_endmatter-idx2">definition of, 1</p>
			<p class="em-only_endmatter-idx2">macrophage activation by, 14</p>
			<p class="em-only_endmatter-idx2">overview of, 5</p>
			<p class="em-only_endmatter-idx2">subclinical presence of, 6</p>
			<p class="em-only_endmatter-idx2">summary of, 7<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">triggers of</p>
			<p class="em-only_endmatter-idx3">bacterial-&#173;derived molecules, 7<span class="endmatter-idx3_italic">t,</span> 7–9</p>
			<p class="em-only_endmatter-idx3">exotoxins, 9</p>
			<p class="em-only_endmatter-idx3">lipopolysaccharide, 7–8</p>
			<p class="em-only_endmatter-idx3">overview of, 6–7, 7<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Integrins, 11</p>
			<p class="em-only_endmatter-idx1">Intercellular adhesion molecule-1 (ICAM-1), 11</p>
			<p class="em-only_endmatter-idx1">Intercellular signaling, of cytokines, 21</p>
			<p class="em-only_endmatter-idx1">Interferon(s)</p>
			<p class="em-only_endmatter-idx2">definition of, 21</p>
			<p class="em-only_endmatter-idx2">types of, 24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interferon-&#173;<span class="endmatter-idx1_greek">α</span>, 24<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interferon alfa-2a/2b</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 218</p>
			<p class="em-only_endmatter-idx2">for uveitis, 112</p>
			<p class="em-only_endmatter-idx1">Interferon-&#173;gamma</p>
			<p class="em-only_endmatter-idx2">characteristics of, 24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">macrophage activation by, 42</p>
			<p class="em-only_endmatter-idx2">T helper cell-1 production of, 35</p>
			<p class="em-only_endmatter-idx1">Interferon-&#173;gamma release assays, tuberculosis testing using, 29</p>
			<p class="em-only_endmatter-idx1">Interleukin(s)</p>
			<p class="em-only_endmatter-idx2">definition of, 21</p>
			<p class="em-only_endmatter-idx2">types of, 22–23<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interleukin-1<span class="endmatter-idx1_accent">ß</span>, 22<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interleukin-2</p>
			<p class="em-only_endmatter-idx2">characteristics of, 22<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">T cell synthesis and release of, 31</p>
			<p class="em-only_endmatter-idx1">Interleukin-4</p>
			<p class="em-only_endmatter-idx2">in B-&#173;cell activation, 35, 43</p>
			<p class="em-only_endmatter-idx2">characteristics of, 22<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interleukin-5</p>
			<p class="em-only_endmatter-idx2">characteristics of, 22<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">eosinophils and, 2</p>
			<p class="em-only_endmatter-idx1">Interleukin-6</p>
			<p class="em-only_endmatter-idx2">characteristics of, 22<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in inflammatory uveitis, 308</p>
			<p class="em-only_endmatter-idx1">Interleukin-8, 23<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interleukin-10</p>
			<p class="em-only_endmatter-idx2">in intraocular lymphoma, 308</p>
			<p class="em-only_endmatter-idx2">in T regulatory cell effector function, 35</p>
			<p class="em-only_endmatter-idx1">Interleukin-12</p>
			<p class="em-only_endmatter-idx2">antigen-&#173;presenting cell production of, 35</p>
			<p class="em-only_endmatter-idx2">characteristics of, 23<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interleukin-17A, 23<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Intermediate uveitis</p>
			<p class="em-only_endmatter-idx2">characteristics of, 70</p>
			<p class="em-only_endmatter-idx2">chronic, 82</p>
			<p class="em-only_endmatter-idx2">conditions associated with, 147</p>
			<p class="em-only_endmatter-idx2">evaluation of, 72<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">floaters in, 76</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in &#173;human T-&#173;lymphocytic virus type 1, 268</p>
			<p class="em-only_endmatter-idx2">immune recovery and, 259</p>
			<p class="em-only_endmatter-idx2">in Lyme disease, 229</p>
			<p class="em-only_endmatter-idx2">in multiple sclerosis, 151–152</p>
			<p class="em-only_endmatter-idx2">pars planitis. <span class="endmatter-idx2_italic">See</span> Pars planitis</p>
			<p class="em-only_endmatter-idx2">peripheral vascular sheathing in, 75</p>
			<p class="em-only_endmatter-idx2">signs of, 81–82, 81–82<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">snowball opacities in, 82, 147, 148<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">snowbanks in, 82, 147</p>
			<p class="em-only_endmatter-idx2">symptoms of, 76, 77<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vitreous cells in, 81–82, 82<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vitreous haze in, 81<span class="endmatter-idx2_italic">f,</span> 81–82</p>
			<p class="em-only_endmatter-idx1">International Study Group for Beh<span class="endmatter-idx1_accent">ç</span>et disease, <br />212, 212<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interphotoreceptor retinoid-&#173;binding protein-&#173;specific T-&#173;cell receptor transgenic mice, 62</p>
			<p class="em-only_endmatter-idx1">Interstitial keratitis, 220, 221<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Intraepithelial lymphocytes, 5</p>
			<p class="em-only_endmatter-idx1">Intraocular foreign bodies, 313</p>
			<p class="em-only_endmatter-idx1">Intraocular lens (IOLs)</p>
			<p class="em-only_endmatter-idx2">anterior chamber</p>
			<p class="em-only_endmatter-idx3">anterior uveitis caused by, 138, 138<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">fixed-&#173;haptic, 138<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">biocompatibility of, 138</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 317</p>
			<p class="em-only_endmatter-idx2">in juvenile idiopathic arthritis-&#173;associated uveitis cataracts, 317</p>
			<p class="em-only_endmatter-idx2">phacoemulsification with, 317</p>
			<p class="em-only_endmatter-idx2">retained fragments of, 90</p>
			<p class="em-only_endmatter-idx2">uveitis associated with, 137–139, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">uveitis-&#173;glaucoma-&#173;hyphema syndrome associated with, 10, 137</p>
			<p class="em-only_endmatter-idx1">Intraocular pressure. <span class="endmatter-idx1_italic">See also</span> Ocular hypertension</p>
			<p class="em-only_endmatter-idx2">in anterior uveitis, 80–81, 319</p>
			<p class="em-only_endmatter-idx2">increased</p>
			<p class="em-only_endmatter-idx3">difluprednate as cause of, 94</p>
			<p class="em-only_endmatter-idx3">periocular corticosteroids as cause of, 96</p>
			<p class="em-only_endmatter-idx1">Intraret&#173;i&#173;nal hemorrhage, 157<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Intravenous immunoglobulin, for uveitis, 113</p>
			<p class="em-only_endmatter-idx1">Intravitreal corticosteroids, for uveitis, 97–98, 102</p>
			<p class="em-only_endmatter-idx1">Intravitreal cysts, 288<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Iridocyclitis</p>
			<p class="em-only_endmatter-idx2">corticosteroids for, 127</p>
			<p class="em-only_endmatter-idx2">definition of, 70</p>
			<p class="em-only_endmatter-idx1">Iridolenticular diaphragm, 123</p>
			<p class="em-only_endmatter-idx1">Iris bomb<span class="endmatter-idx1_accent">é</span>, 81, 130, 196</p>
			<p class="em-only_endmatter-idx1">Iris chafing, 137</p>
			<p class="em-only_endmatter-idx1">Iris granulomas, 302<span class="endmatter-idx1_italic">f,</span> 304</p>
			<p class="em-only_endmatter-idx1">Iris heterochromia, in Ebola virus, 273<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Iris nodules</p>
			<p class="em-only_endmatter-idx2">in anterior uveitis, 77–78, 80, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in ocular tuberculosis, 235<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Iris stromal atrophy, 251<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Iritis, 70</p>
			<p class="em-only_endmatter-idx1">Isoniazid, for tuberculosis, 239–240</p>
			<p class="em-only_endmatter-idx1">Ivermectin, for onchocerciasis, 292</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Ixodes pacificus,</span> 227</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Ixodes scapularis,</span> 227</p>
			<p class="endmatter-idx-alpha">Jarisch-&#173;Herxheimer reaction, 226, 230</p>
			<p class="em-only_endmatter-idx1">Juvenile idiopathic arthritis (JIA)</p>
			<p class="em-only_endmatter-idx2">calcific band keratopathy in, 143<span class="endmatter-idx2_italic">f,</span> 315</p>
			<p class="em-only_endmatter-idx2">chronic anterior uveitis in</p>
			<p class="em-only_endmatter-idx3">description of, 76, 141–145</p>
			<p class="em-only_endmatter-idx3">methotrexate for, 107</p>
			<p class="em-only_endmatter-idx2">classification of, 141–142</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 142</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular involvement in, 141–142, 143<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">oligoarticular, 142</p>
			<p class="em-only_endmatter-idx2">polyarticular, 141–142</p>
			<p class="em-only_endmatter-idx2">prognosis for, 142</p>
			<p class="em-only_endmatter-idx2">treatment of, 142–145</p>
			<p class="em-only_endmatter-idx1">Juvenile xanthogranuloma, 311</p>
			<p class="endmatter-idx-alpha">Kaposi sarcoma, 335, 335<span class="endmatter-idx-alpha_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Keratic precipitates</p>
			<p class="em-only_endmatter-idx2">in anterior uveitis, 77–78, 79<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Fuchs heterochromic uveitis, 250</p>
			<p class="em-only_endmatter-idx2">in Fuchs uveitis syndrome, 146<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">mutton-&#173;fat, 78, 79<span class="endmatter-idx2_italic">f,</span> 196</p>
			<p class="em-only_endmatter-idx2">in sarcoidosis, 196, 196<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Vogt-&#173;Koyanagi-&#173;Harada syndrome, 205, 207</p>
			<p class="em-only_endmatter-idx1">Keratitis</p>
			<p class="em-only_endmatter-idx2">herpes simplex, 336</p>
			<p class="em-only_endmatter-idx2">in Lyme disease, 229</p>
			<p class="em-only_endmatter-idx2">punctate epithelial, 336<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Keratoderma blennorrhagicum, 133, 134<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Keratouveitis, 70, 220, 249</p>
			<p class="em-only_endmatter-idx1">Khodadoust line of endothelial rejection, 54, 54<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Killer cells, 48</p>
			<p class="em-only_endmatter-idx1">Killer immunoglobulin-&#173;like receptors, 46</p>
			<p class="em-only_endmatter-idx1">Koeppe nodules</p>
			<p class="em-only_endmatter-idx2">in anterior uveitis, 78</p>
			<p class="em-only_endmatter-idx2">in sarcoidosis, 196, 196<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Krill disease. <span class="endmatter-idx1_italic">See</span> Acute ret&#173;i&#173;nal pigment epitheliitis</p>
			<p class="em-only_endmatter-idx1">Kupffer cells, 3</p>
			<p class="em-only_endmatter-idx1">Kyrielesis arteriolitis, 280</p>
			<p class="endmatter-idx-alpha">Lacrimal gland, sarcoidosis involvement of, 195</p>
			<p class="em-only_endmatter-idx1">Langerhans cells</p>
			<p class="em-only_endmatter-idx2">characteristics of, 4–5</p>
			<p class="em-only_endmatter-idx2">functions of, 4–5</p>
			<p class="em-only_endmatter-idx1">&#173;Laser photocoagulation, for intermediate uveitis, 150</p>
			<p class="em-only_endmatter-idx1">Leber congenital amaurosis, 58</p>
			<p class="em-only_endmatter-idx1">Leber idiopathic stellate maculopathy, 241</p>
			<p class="em-only_endmatter-idx1">Lens-&#173;associated uveitis</p>
			<p class="em-only_endmatter-idx2">hypopyon in, 6</p>
			<p class="em-only_endmatter-idx2">types of, 136<span class="endmatter-idx2_italic">f,</span> 136–137</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Leptospira interrogans,</span> 232</p>
			<p class="em-only_endmatter-idx1">Leptospirosis, 232–233</p>
			<p class="em-only_endmatter-idx1">Leukemia, neoplastic masquerade syndromes secondary to, 310</p>
			<p class="em-only_endmatter-idx1">Leukocytes</p>
			<p class="em-only_endmatter-idx2">basophils, 2–3</p>
			<p class="em-only_endmatter-idx2">classification of, 2</p>
			<p class="em-only_endmatter-idx2">cytokine effects on, 25</p>
			<p class="em-only_endmatter-idx2">dendritic cells, 4–5</p>
			<p class="em-only_endmatter-idx2">eosinophils, 2</p>
			<p class="em-only_endmatter-idx2">Fc receptor expression by, 47</p>
			<p class="em-only_endmatter-idx2">Langerhans cells, 4–5</p>
			<p class="em-only_endmatter-idx2">lymphocytes, 5</p>
			<p class="em-only_endmatter-idx2">macrophages, 3–4</p>
			<p class="em-only_endmatter-idx2">mast cells, 2–3</p>
			<p class="em-only_endmatter-idx2">monocytes, 3–4</p>
			<p class="em-only_endmatter-idx2">neutrophils, 2</p>
			<p class="em-only_endmatter-idx2">oxygen metabolism by, 16</p>
			<p class="em-only_endmatter-idx2">platelet-&#173;activating &#173;factor activation of, 21</p>
			<p class="em-only_endmatter-idx1">Leukocytoclastic vasculitis, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Leukotrienes, in inflammation, 20</p>
			<p class="em-only_endmatter-idx1">Linkage disequilibrium, 64</p>
			<p class="em-only_endmatter-idx1">Lipofuscin, 89</p>
			<p class="em-only_endmatter-idx1">Lipopolysaccharide (LPS)</p>
			<p class="em-only_endmatter-idx2">animal models of, 8</p>
			<p class="em-only_endmatter-idx2">components of, 7</p>
			<p class="em-only_endmatter-idx2">gut release of, 8</p>
			<p class="em-only_endmatter-idx2">inflammatory response induced by injection of, 8–9</p>
			<p class="em-only_endmatter-idx2">in innate immune response activation, 7–8</p>
			<p class="em-only_endmatter-idx2">in neutrophil activation, 12</p>
			<p class="em-only_endmatter-idx2">ocular effects induced by, 8</p>
			<p class="em-only_endmatter-idx1">Lipoxin, 20</p>
			<p class="em-only_endmatter-idx1">5-&#173;Lipoxygenase</p>
			<p class="em-only_endmatter-idx2">in arachidonic acid oxidation, 19</p>
			<p class="em-only_endmatter-idx2">derivatives of, 20</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Loa loa,</span> 292</p>
			<p class="em-only_endmatter-idx1">L<span class="endmatter-idx1_accent">ö</span>fgren syndrome, 195</p>
			<p class="em-only_endmatter-idx1">L-&#173;Selectin, 11–12</p>
			<p class="em-only_endmatter-idx1">Lupus choroidopathy, 154, 155<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lupus retinopathy, 154, 155<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lyme disease</p>
			<p class="em-only_endmatter-idx2">antibiotics for, 230, 231<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">clinical features of, 227–229, 228<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">corticosteroids for, 230</p>
			<p class="em-only_endmatter-idx2">definition of, 227</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 230</p>
			<p class="em-only_endmatter-idx2">epidemiology of, 227</p>
			<p class="em-only_endmatter-idx2">erythema chronicum migrans associated with, 227–228, 228<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">HLA-&#173;DR4 and, 228</p>
			<p class="em-only_endmatter-idx2">keratitis in, 229</p>
			<p class="em-only_endmatter-idx2">neuro-&#173;ophthalmic manifestations of, 229</p>
			<p class="em-only_endmatter-idx2">ocular involvement in, 229, 229<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">stage 1, 227–228, 228<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">stage 2, 228</p>
			<p class="em-only_endmatter-idx2">stage 3, 228–229</p>
			<p class="em-only_endmatter-idx2">treatment of, 230, 231<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vitritis in, 229, 229<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lymphatics, 30</p>
			<p class="em-only_endmatter-idx1">Lymphocytes</p>
			<p class="em-only_endmatter-idx2">activation of, 30</p>
			<p class="em-only_endmatter-idx2">B.&#160;<span class="endmatter-idx2_italic">See</span> B cells</p>
			<p class="em-only_endmatter-idx2">characteristics of, 5</p>
			<p class="em-only_endmatter-idx2">effector, 36</p>
			<p class="em-only_endmatter-idx2">homing of, 38</p>
			<p class="em-only_endmatter-idx2">sensitization of, 30</p>
			<p class="em-only_endmatter-idx2">surface markers of, 5</p>
			<p class="em-only_endmatter-idx2">T.&#160;<span class="endmatter-idx2_italic">See</span> T cells</p>
			<p class="em-only_endmatter-idx1">Lymphocytic choriomeningitis virus (LCMV), 263</p>
			<p class="em-only_endmatter-idx1">Lymphoma</p>
			<p class="em-only_endmatter-idx2">primary central ner&#173;vous system, 305, 306<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal</p>
			<p class="em-only_endmatter-idx3">age of onset, 305</p>
			<p class="em-only_endmatter-idx3">clinical features and findings of, 306–307, 306–307<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">diagnostic testing for, 307–308</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography findings in, 307</p>
			<p class="em-only_endmatter-idx3">histology of, 308, 309<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">incidence of, 305</p>
			<p class="em-only_endmatter-idx1">Lysosomes</p>
			<p class="em-only_endmatter-idx2">in eosinophils, 2</p>
			<p class="em-only_endmatter-idx2">in neutrophils, 2</p>
			<p class="endmatter-idx-alpha">Macrolides, for Lyme disease, 231<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Macrophage(s)</p>
			<p class="em-only_endmatter-idx2">activation of, 13–16, 15<span class="endmatter-idx2_italic">f,</span> 21</p>
			<p class="em-only_endmatter-idx2">as antigen-&#173;presenting cells, 14</p>
			<p class="em-only_endmatter-idx2">characteristics of, 3–4</p>
			<p class="em-only_endmatter-idx2">epithelioid cell activation of, 4</p>
			<p class="em-only_endmatter-idx2">functions of, 3</p>
			<p class="em-only_endmatter-idx2">&#173;giant cell activation of, 4</p>
			<p class="em-only_endmatter-idx2">interferon-&#173;gamma activation of, 42</p>
			<p class="em-only_endmatter-idx2">major histocompatibility class II molecule expression by, 30</p>
			<p class="em-only_endmatter-idx2">mediators synthesized by, 15</p>
			<p class="em-only_endmatter-idx2">primed, 14, 15<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">recruitment of, 13–16</p>
			<p class="em-only_endmatter-idx2">reparative, 16</p>
			<p class="em-only_endmatter-idx2">resting, 13, 15<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">scavenging, 13</p>
			<p class="em-only_endmatter-idx2">stimulated, 14–16, 15<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">tuberculosis response by, 28</p>
			<p class="em-only_endmatter-idx1">Macrophage chemotactic protein-1, characteristics <br />of, 23<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Macrophage-&#173;activating &#173;factor, 42</p>
			<p class="em-only_endmatter-idx1">Macular choroiditis, 276<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Macular edema</p>
			<p class="em-only_endmatter-idx2">in intermediate uveitis, 70</p>
			<p class="em-only_endmatter-idx2">nonsteroidal anti-&#173;inflammatory drugs for, 113</p>
			<p class="em-only_endmatter-idx2">in pars planitis, 147</p>
			<p class="em-only_endmatter-idx2">in tubulointerstitial nephritis and uveitis syndrome, 134</p>
			<p class="em-only_endmatter-idx2">uveitic</p>
			<p class="em-only_endmatter-idx3">description of, 19</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography of, 88, 89<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 85, 88<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">in phacoemulsification, 318</p>
			<p class="em-only_endmatter-idx3">postoperative, 318</p>
			<p class="em-only_endmatter-idx3">smoking as risk &#173;factor for, 323</p>
			<p class="em-only_endmatter-idx3">treatment of, 324</p>
			<p class="em-only_endmatter-idx1">Macular hole, 325</p>
			<p class="em-only_endmatter-idx1">Major histocompatibility class I molecules</p>
			<p class="em-only_endmatter-idx2">CD8<span class="endmatter-idx2_symbol">+</span> T cells and, 30</p>
			<p class="em-only_endmatter-idx2">definition of, 63</p>
			<p class="em-only_endmatter-idx1">Major histocompatibility class II molecules</p>
			<p class="em-only_endmatter-idx2">cellular expression of, 30</p>
			<p class="em-only_endmatter-idx2">definition of, 63</p>
			<p class="em-only_endmatter-idx2">expression of, 4</p>
			<p class="em-only_endmatter-idx2">Langerhans cell expression of, 5</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium expression of, 57</p>
			<p class="em-only_endmatter-idx1">Mannose-&#173;binding lectin pathway, 17, 18<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Masquerade syndromes, 84</p>
			<p class="em-only_endmatter-idx2">chronic peripheral rhegmatogenous ret&#173;i&#173;nal detachment, 313</p>
			<p class="em-only_endmatter-idx2">intraocular foreign bodies, 313</p>
			<p class="em-only_endmatter-idx2">juvenile xanthogranuloma, 311</p>
			<p class="em-only_endmatter-idx2">leukemia as cause of, 310</p>
			<p class="em-only_endmatter-idx2">metastatic tumors as, 311</p>
			<p class="em-only_endmatter-idx2">neoplastic, 305–311</p>
			<p class="em-only_endmatter-idx2">nonneoplastic, 312–313</p>
			<p class="em-only_endmatter-idx2">ocular ischemic syndrome, 312</p>
			<p class="em-only_endmatter-idx2">pigment dispersion syndrome, 313</p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal lymphoma. <span class="endmatter-idx2_italic">See</span> Primary vitreoret&#173;i&#173;nal lymphoma</p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa, 312</p>
			<p class="em-only_endmatter-idx2">retinoblastoma, 310–311</p>
			<p class="em-only_endmatter-idx2">systemic lymphoma as cause of, 309</p>
			<p class="em-only_endmatter-idx2">uveal lymphoid proliferations, 310</p>
			<p class="em-only_endmatter-idx2">uveal melanoma, 310</p>
			<p class="em-only_endmatter-idx1">Mast cells</p>
			<p class="em-only_endmatter-idx2">acute immunoglobulin E-&#173;mediated degranulation of, 48–49</p>
			<p class="em-only_endmatter-idx2">characteristics of, 2–3</p>
			<p class="em-only_endmatter-idx2">in choroid, 58</p>
			<p class="em-only_endmatter-idx2">in conjunctival substantia propria, 3, 53</p>
			<p class="em-only_endmatter-idx2">connective tissue, 2–3</p>
			<p class="em-only_endmatter-idx2">cytokines derived from, 49</p>
			<p class="em-only_endmatter-idx2">histamine in, 19</p>
			<p class="em-only_endmatter-idx2">mucosal, 2–3</p>
			<p class="em-only_endmatter-idx1">Measles, 263–265</p>
			<p class="em-only_endmatter-idx1">Mediators</p>
			<p class="em-only_endmatter-idx2">reactive nitrogen products, 16</p>
			<p class="em-only_endmatter-idx2">reactive oxygen intermediates, 16</p>
			<p class="em-only_endmatter-idx1">Melanoma</p>
			<p class="em-only_endmatter-idx2">metastatic, 311</p>
			<p class="em-only_endmatter-idx2">uveal, 310</p>
			<p class="em-only_endmatter-idx1">Melanoma-&#173;associated retinopathy, 192–193</p>
			<p class="em-only_endmatter-idx1">Memory cells, 37</p>
			<p class="em-only_endmatter-idx1">6-&#173;Mercaptopurine, 106</p>
			<p class="em-only_endmatter-idx1">Metamorphopsia, 275</p>
			<p class="em-only_endmatter-idx1">Metastatic melanoma, 311</p>
			<p class="em-only_endmatter-idx1">Metastatic tumors, 311</p>
			<p class="em-only_endmatter-idx1">Methotrexate, for uveitis</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 107</p>
			<p class="em-only_endmatter-idx2">dosing of, 107</p>
			<p class="em-only_endmatter-idx2">treatment studies involving, 100<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Methylprednisolone</p>
			<p class="em-only_endmatter-idx2">for scleritis, 126–127</p>
			<p class="em-only_endmatter-idx2">for uveitis, 95, 96<span class="endmatter-idx2_italic">f,</span> 102–103</p>
			<p class="em-only_endmatter-idx1">Micafungin, for <span class="endmatter-idx1_italic">Candida</span> fungal postoperative endophthalmitis, 301</p>
			<p class="em-only_endmatter-idx1">Microglia, 3</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_accent">ß</span>2-&#173;Microglobulin, 31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Microhemagglutination assay for <span class="endmatter-idx1_italic">T. pallidum</span> antibodies, 224</p>
			<p class="em-only_endmatter-idx1">Microscopic polyangiitis (MPA), 125<span class="endmatter-idx1_italic">t,</span> 158</p>
			<p class="em-only_endmatter-idx1">Migratory dendritic cells, 4</p>
			<p class="em-only_endmatter-idx1">Miliary disease, 234</p>
			<p class="em-only_endmatter-idx1">Mitomycin&#160;C, 321</p>
			<p class="em-only_endmatter-idx1">Molluscum contagiosum, 336</p>
			<p class="em-only_endmatter-idx1">Monoclonal antibodies</p>
			<p class="em-only_endmatter-idx2">description of, 41</p>
			<p class="em-only_endmatter-idx2">recombinant, 41</p>
			<p class="em-only_endmatter-idx1">Monocytes</p>
			<p class="em-only_endmatter-idx2">as antigen-&#173;presenting cells, 3</p>
			<p class="em-only_endmatter-idx2">characteristics of, 3–4</p>
			<p class="em-only_endmatter-idx2">lipopolysaccharide effects on, 7</p>
			<p class="em-only_endmatter-idx1">Mononeuritis multiplex, 158</p>
			<p class="em-only_endmatter-idx1">Moxifloxacin, 139</p>
			<p class="em-only_endmatter-idx1">Mucosa-&#173;associated lymphoid tissue (MALT), 53</p>
			<p class="em-only_endmatter-idx1">Mucosal mast cells, 2–3</p>
			<p class="em-only_endmatter-idx1">Multicenter Uveitis Ste&#173;roid Treatment Trial, 98, 99<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Multidrug-&#173;resistant tuberculosis (MDRTB), 239</p>
			<p class="em-only_endmatter-idx1">Multifocal chorioretinitis</p>
			<p class="em-only_endmatter-idx2">in West Nile virus, 265</p>
			<p class="em-only_endmatter-idx2">in Whipple disease, 244, 244<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Multifocal choroiditis</p>
			<p class="em-only_endmatter-idx2">in AIDS patients, 334</p>
			<p class="em-only_endmatter-idx2">peripheral, 229</p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">tubercular, 236<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Multifocal choroiditis and panuveitis syndrome (MCP)</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t,</span> 177–178</p>
			<p class="em-only_endmatter-idx2">definition of, 178</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 181</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 179, 179<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence findings in, 163<span class="endmatter-idx2_italic">t,</span> 179, 180<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">lesions in, 178, 178<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 178–180<span class="endmatter-idx2_italic">f,</span> 178–181</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 164<span class="endmatter-idx2_italic">t,</span> 179, 180<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">prognosis for, 181</p>
			<p class="em-only_endmatter-idx2">treatment of, 181</p>
			<p class="em-only_endmatter-idx1">Multifocal serpiginous choroiditis, 177</p>
			<p class="em-only_endmatter-idx1">Multiple evanescent white dot syndrome (MEWDS)</p>
			<p class="em-only_endmatter-idx2">acute macular neuroretinopathy and, 189</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">definition of, 185</p>
			<p class="em-only_endmatter-idx2">description of, 161</p>
			<p class="em-only_endmatter-idx2">diseases associated with, 189</p>
			<p class="em-only_endmatter-idx2">early receptor potential amplitudes in, 187</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 185, 186–187<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence findings in, 163<span class="endmatter-idx2_italic">t,</span> 186–187<span class="endmatter-idx2_italic">f,</span> 187</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 188<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 185–188, 185–188<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">medical management of, 93</p>
			<p class="em-only_endmatter-idx2">prognosis for, 188</p>
			<p class="em-only_endmatter-idx1">Multiple sclerosis</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">intermediate uveitis associated with, 151–152</p>
			<p class="em-only_endmatter-idx1">Mumps, 263</p>
			<p class="em-only_endmatter-idx1">Murine models</p>
			<p class="em-only_endmatter-idx2">autoimmune regulator–&#173;deficient mice, 62</p>
			<p class="em-only_endmatter-idx2">interphotoreceptor retinoid-&#173;binding protein-&#173;specific T-&#173;cell receptor transgenic mice, 62</p>
			<p class="em-only_endmatter-idx1">Mutton-&#173;fat keratic precipitates, 78, 79<span class="endmatter-idx1_italic">f,</span> 196</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Mycobacteria tuberculosis. See also</span> Tuberculosis</p>
			<p class="em-only_endmatter-idx2">description of, 234</p>
			<p class="em-only_endmatter-idx2">interferon-&#173;gamma release assays for, 29</p>
			<p class="em-only_endmatter-idx2">nucleic acid amplification techniques for, 239</p>
			<p class="em-only_endmatter-idx2">serpiginous-&#173;like choroiditis caused by, 177</p>
			<p class="em-only_endmatter-idx1">Mycophenolate mofetil, for uveitis, 107</p>
			<p class="em-only_endmatter-idx1">Mydriatics, for uveitis, 113</p>
			<p class="em-only_endmatter-idx1">Myeloperoxidase, 158, 160</p>
			<p class="endmatter-idx-alpha">National Institutes of Health vitreous haze grading system, 82</p>
			<p class="em-only_endmatter-idx1">Natu&#173;ral killer (NK) cells, 5, 46</p>
			<p class="em-only_endmatter-idx1">Naturally occurring T regulatory cells, 34</p>
			<p class="em-only_endmatter-idx1">Nd:YAG capsulotomy</p>
			<p class="em-only_endmatter-idx2">chronic postoperative endophthalmitis triggered <br />by, 294</p>
			<p class="em-only_endmatter-idx2">uveitis and, 318</p>
			<p class="em-only_endmatter-idx1">Necrotizing herpetic retinitis, 332, 332<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Necrotizing retinopathies</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis, 252, 253–254<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cytomegalovirus-&#173;related anterior uveitis, 250–251</p>
			<p class="em-only_endmatter-idx2">definition of, 252</p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis, 252–256</p>
			<p class="em-only_endmatter-idx1">Necrotizing scleritis</p>
			<p class="em-only_endmatter-idx2">anterior, 118<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 118<span class="endmatter-idx2_italic">f,</span> 119–122</p>
			<p class="em-only_endmatter-idx2">delayed hypersensitivity response in, 116</p>
			<p class="em-only_endmatter-idx2">description of, 115</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 124</p>
			<p class="em-only_endmatter-idx2">granulomatous, 120<span class="endmatter-idx2_italic">f,</span> 120–121</p>
			<p class="em-only_endmatter-idx2">with inflammation, 120–121, 120–121<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 124</p>
			<p class="em-only_endmatter-idx2">mortality rates for, 119</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 116</p>
			<p class="em-only_endmatter-idx2">postsurgical, 121, 121<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">vaso-&#173;occlusive, 120, 121<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">vision loss risks, 128</p>
			<p class="em-only_endmatter-idx2">without inflammation, 121–122, 122<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Neovascularization</p>
			<p class="em-only_endmatter-idx2">choroidal. <span class="endmatter-idx2_italic">See</span> Choroidal neovascularization</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal, in uveitis, 326–327</p>
			<p class="em-only_endmatter-idx1">Neuropeptides, 24<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Neuroretinitis</p>
			<p class="em-only_endmatter-idx2">bartonellosis as cause of, 241, 242<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 242<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">diffuse unilateral subacute, 289–290<span class="endmatter-idx2_italic">f,</span> 289–291</p>
			<p class="em-only_endmatter-idx2">syphilis versus, 223</p>
			<p class="em-only_endmatter-idx1">Neurosyphilis, 226</p>
			<p class="em-only_endmatter-idx1">Neutrophil(s)</p>
			<p class="em-only_endmatter-idx2">activation of, 10, 11<span class="endmatter-idx2_italic">f,</span> 12</p>
			<p class="em-only_endmatter-idx2">adhesion of, 11<span class="endmatter-idx2_italic">f,</span> 12</p>
			<p class="em-only_endmatter-idx2">characteristics of, 2</p>
			<p class="em-only_endmatter-idx2">granule products of, 25</p>
			<p class="em-only_endmatter-idx2">in innate immune response, 10–12</p>
			<p class="em-only_endmatter-idx2">lipopolysaccharide effects on, 7</p>
			<p class="em-only_endmatter-idx2">recruitment and activation of, 10–12, 11<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">resting, 10</p>
			<p class="em-only_endmatter-idx2">transmigration of, 11<span class="endmatter-idx2_italic">f,</span> 12</p>
			<p class="em-only_endmatter-idx1">Neutrophil rolling, 10, 11<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nitric oxide, 16</p>
			<p class="em-only_endmatter-idx1">Nitric oxide synthetase (NOS), 16</p>
			<p class="em-only_endmatter-idx1">Nivolumab, Vogt-&#173;Koyanagi-&#173;Harada syndrome caused by, 140<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Nocardia asteroides,</span> 233, 313</p>
			<p class="em-only_endmatter-idx1">Nocardiosis, 233</p>
			<p class="em-only_endmatter-idx1">Nodular anterior scleritis, 116, 118–119, 119<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nonnecrotizing herpetic retinitis, 252–256</p>
			<p class="em-only_endmatter-idx1">Nonnecrotizing herpetic retinopathy, 252</p>
			<p class="em-only_endmatter-idx1">Nonsteroidal anti-&#173;inflammatory drugs (NSAIDs)</p>
			<p class="em-only_endmatter-idx2">ankylosing spondylitis treated with, 132</p>
			<p class="em-only_endmatter-idx2">corticosteroids and, concomitant use of, 103</p>
			<p class="em-only_endmatter-idx2">macular edema treated with, 324</p>
			<p class="em-only_endmatter-idx2">scleritis treated with, 126</p>
			<p class="em-only_endmatter-idx2">uveitis treated with, 113, 317</p>
			<p class="em-only_endmatter-idx1">Nonulcerative stromal interstitial keratitis, 220, 221<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nozik technique, for uveitis, 95–96, 97<span class="endmatter-idx1_italic">f</span></p>
			<p class="endmatter-idx-alpha">Ocular adnexal Kaposi sarcoma, 335, 335<span class="endmatter-idx-alpha_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ocular histoplasmosis syndrome (OHS), 274–277, 275–276<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ocular hypertension. <span class="endmatter-idx1_italic">See also</span> Intraocular pressure</p>
			<p class="em-only_endmatter-idx2">corticosteroid-&#173;induced, 319, 321</p>
			<p class="em-only_endmatter-idx2">herpes simplex virus and, 250–251</p>
			<p class="em-only_endmatter-idx2">uveitic, 319</p>
			<p class="em-only_endmatter-idx1">Ocular immune privilege</p>
			<p class="em-only_endmatter-idx2">antigens, 56</p>
			<p class="em-only_endmatter-idx2">definition of, 51</p>
			<p class="em-only_endmatter-idx2">regulators involved in, 57</p>
			<p class="em-only_endmatter-idx1">Ocular ischemic syndrome, 312</p>
			<p class="em-only_endmatter-idx1">Ocular nocardiosis, 233</p>
			<p class="em-only_endmatter-idx1">Oligoarthritis, 143<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Onchocerca volvulus,</span> 291</p>
			<p class="em-only_endmatter-idx1">Onchocerciasis, 291<span class="endmatter-idx1_italic">f,</span> 291–292</p>
			<p class="em-only_endmatter-idx1">Open-&#173;angle glaucoma, secondary, 320–321</p>
			<p class="em-only_endmatter-idx1">Opportunistic infections</p>
			<p class="em-only_endmatter-idx2">in AIDS patients, 330</p>
			<p class="em-only_endmatter-idx2">during cyclophosphamide treatment, 109</p>
			<p class="em-only_endmatter-idx1">Optic disc edema, in bartonellosis, 241</p>
			<p class="em-only_endmatter-idx1">Optic nerve</p>
			<p class="em-only_endmatter-idx2">atrophy of, 271, 272<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">Beh<span class="endmatter-idx2_accent">ç</span>et disease involvement of, 215</p>
			<p class="em-only_endmatter-idx1">Optic neuritis, 223</p>
			<p class="em-only_endmatter-idx1">Optical coherence tomographic angiography (OCTA), in uveitis, 87</p>
			<p class="em-only_endmatter-idx1">Optical coherence tomography (OCT)</p>
			<p class="em-only_endmatter-idx2">in acute posterior multifocal placoid pigment epitheliopathy, 164<span class="endmatter-idx2_italic">t,</span> 171, 172<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in acute ret&#173;i&#173;nal pigment epitheliitis, 189</p>
			<p class="em-only_endmatter-idx2">in acute zonal occult outer retinopathy, 164<span class="endmatter-idx2_italic">t,</span> 191, 191<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anterior segment</p>
			<p class="em-only_endmatter-idx3">indications for, 85</p>
			<p class="em-only_endmatter-idx3">in uveitis evaluations, 85</p>
			<p class="em-only_endmatter-idx2">in Beh<span class="endmatter-idx2_accent">ç</span>et disease, 216, 217<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 164<span class="endmatter-idx2_italic">t,</span> 168, 168<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Dengue fever, 269, 269<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">enhanced depth imaging</p>
			<p class="em-only_endmatter-idx3">in posterior scleritis, 124</p>
			<p class="em-only_endmatter-idx3">in uveitis, 85, 88<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in macular edema, uveitic, 85, 88<span class="endmatter-idx2_italic">f,</span> 323</p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 164<span class="endmatter-idx2_italic">t,</span> 179, 180<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in multiple evanescent white dot syndrome, 164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in posterior scleritis, 123<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in punctate inner choroiditis, 164<span class="endmatter-idx2_italic">t,</span> 182, 183<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in serpiginous choroiditis, 164<span class="endmatter-idx2_italic">t,</span> 175, 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain, for posterior scleritis, 124–125</p>
			<p class="em-only_endmatter-idx2">in subret&#173;i&#173;nal fibrosis and uveitis syndrome, 164<span class="endmatter-idx2_italic">t,</span> 184</p>
			<p class="em-only_endmatter-idx2">sympathetic ophthalmia findings in, 201–202, 202<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">uveitis evaluations, 85, 88<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Vogt-&#173;Koyanagi-&#173;Harada syndrome, 209, 210<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Orbital cellulitis, 158</p>
			<p class="em-only_endmatter-idx1">Orbital pseudotumor, 158</p>
			<p class="em-only_endmatter-idx1">Osteoporosis, corticosteroid-&#173;induced, 103</p>
			<p class="em-only_endmatter-idx1">Oxygen, leukocyte metabolism of, 16</p>
			<p class="endmatter-idx-alpha">Panuveitis</p>
			<p class="em-only_endmatter-idx2">characteristics of, 75</p>
			<p class="em-only_endmatter-idx2">definition of, 194</p>
			<p class="em-only_endmatter-idx2">in Ebola virus, 273<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">evaluation of, 71<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment associated with, 326</p>
			<p class="em-only_endmatter-idx2">in sarcoidosis, 194–199</p>
			<p class="em-only_endmatter-idx2">in sympathetic ophthalmia, 199–203</p>
			<p class="em-only_endmatter-idx2">in Vogt-&#173;Koyanagi-&#173;Harada syndrome. <span class="endmatter-idx2_italic">See</span> Vogt-&#173;Koyanagi-&#173;Harada (VKH) syndrome</p>
			<p class="em-only_endmatter-idx1">Paracentesis, anterior chamber</p>
			<p class="em-only_endmatter-idx2">in bacterial endogenous endophthalmitis, 297</p>
			<p class="em-only_endmatter-idx2">technique for, 92</p>
			<p class="em-only_endmatter-idx2">in uveitis, 90–92</p>
			<p class="em-only_endmatter-idx1">Paracrine signaling, of cytokines, 21</p>
			<p class="em-only_endmatter-idx1">Paratope, 35</p>
			<p class="em-only_endmatter-idx1">Parinaud oculoglandular syndrome, 241</p>
			<p class="em-only_endmatter-idx1">Pars plana vitrectomy</p>
			<p class="em-only_endmatter-idx2">chronic postoperative endophthalmitis treated with, 295</p>
			<p class="em-only_endmatter-idx2">description of, 150</p>
			<p class="em-only_endmatter-idx2">sympathetic ophthalmia &#173;after, 199–200</p>
			<p class="em-only_endmatter-idx2">uveitis macular edema treated with, 324</p>
			<p class="em-only_endmatter-idx1">Pars planitis</p>
			<p class="em-only_endmatter-idx2">ancillary tests for, 148–149</p>
			<p class="em-only_endmatter-idx2">cataracts in, 151</p>
			<p class="em-only_endmatter-idx2">clinical characteristics of, 147–148</p>
			<p class="em-only_endmatter-idx2">complications of, 151</p>
			<p class="em-only_endmatter-idx2">corticosteroids for, 149–150</p>
			<p class="em-only_endmatter-idx2">description of, 70</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 148</p>
			<p class="em-only_endmatter-idx2">glaucoma in, 151</p>
			<p class="em-only_endmatter-idx2">histologic findings in, 148–149</p>
			<p class="em-only_endmatter-idx2">macular edema in, 147</p>
			<p class="em-only_endmatter-idx2">medical management of, 93</p>
			<p class="em-only_endmatter-idx2">prognosis for, 149</p>
			<p class="em-only_endmatter-idx2">treatment of, 149–150</p>
			<p class="em-only_endmatter-idx1">Pathogen-&#173;associated molecular patterns (PAMPs), 5</p>
			<p class="em-only_endmatter-idx1">Pattern recognition receptors (PRRs)</p>
			<p class="em-only_endmatter-idx2">dendritic cells’ use of, 4</p>
			<p class="em-only_endmatter-idx2">description of, 5</p>
			<p class="em-only_endmatter-idx2">toll-&#173;like receptors as, 58</p>
			<p class="em-only_endmatter-idx1">Pediatric uveitis, 322</p>
			<p class="em-only_endmatter-idx1">Penetrating keratoplasty</p>
			<p class="em-only_endmatter-idx2">rejection of, 55</p>
			<p class="em-only_endmatter-idx2">success rate for, 55</p>
			<p class="em-only_endmatter-idx1">Penicillin&#160;G</p>
			<p class="em-only_endmatter-idx2">for leptospirosis, 233</p>
			<p class="em-only_endmatter-idx2">for Lyme disease, 231<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">for syphilis, 225–226, 226<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Perimetry, in uveitis evaluations, 90</p>
			<p class="em-only_endmatter-idx1">Perinuclear antinuclear antibody testing, 160</p>
			<p class="em-only_endmatter-idx1">Periocular corticosteroids, for uveitis, 95–96, 96–97<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripapillary choroiditis, 201<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripheral granuloma, <span class="endmatter-idx1_italic">Toxocara,</span> 286<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripheral iridectomy, 320</p>
			<p class="em-only_endmatter-idx1">Peripheral iridotomy, 320</p>
			<p class="em-only_endmatter-idx1">Peripheral multifocal choroiditis, 229</p>
			<p class="em-only_endmatter-idx1">Peripheral necrotizing retinochoroiditis, 222</p>
			<p class="em-only_endmatter-idx1">Peripheral retinitis, 253<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripheral ulcerative keratitis, 157</p>
			<p class="em-only_endmatter-idx1">Peripheral uveitis. <span class="endmatter-idx1_italic">See</span> Pars planitis</p>
			<p class="em-only_endmatter-idx1">Peripheral vascular sheathing, in intermediate uveitis, 75</p>
			<p class="em-only_endmatter-idx1">Periphlebitis</p>
			<p class="em-only_endmatter-idx2">description of, 237</p>
			<p class="em-only_endmatter-idx2">in multiple sclerosis, 152</p>
			<p class="em-only_endmatter-idx1">Phacoanaphylactic uveitis. <span class="endmatter-idx1_italic">See</span> Phacoantigenic uveitis</p>
			<p class="em-only_endmatter-idx1">Phacoantigenic uveitis, 136–137</p>
			<p class="em-only_endmatter-idx1">Phacolytic glaucoma, 13</p>
			<p class="em-only_endmatter-idx1">Phacolytic uveitis, 136<span class="endmatter-idx1_italic">f,</span> 136–137</p>
			<p class="em-only_endmatter-idx1">Phagocytosis</p>
			<p class="em-only_endmatter-idx2">antigen-&#173;presenting cells in, 30, 32<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 12</p>
			<p class="em-only_endmatter-idx2">mechanisms of, 16</p>
			<p class="em-only_endmatter-idx2">reactive oxygen intermediates in, 16</p>
			<p class="em-only_endmatter-idx1">Phagosomes, 12</p>
			<p class="em-only_endmatter-idx1">Phospholipase A2</p>
			<p class="em-only_endmatter-idx2">arachidonic acid from, 19</p>
			<p class="em-only_endmatter-idx2">functions of, 21</p>
			<p class="em-only_endmatter-idx1">Phospholipids, arachidonic acid from, 19</p>
			<p class="em-only_endmatter-idx1">Pigment dispersion syndrome, 313</p>
			<p class="em-only_endmatter-idx1">Pigmentary retinopathy, 261, 261<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Plasma cells, 37, 41</p>
			<p class="em-only_endmatter-idx1">Plasma-&#173;derived proteins, in cornea, 54</p>
			<p class="em-only_endmatter-idx1">Plasminogen, 18</p>
			<p class="em-only_endmatter-idx1">Platelet degranulation, 8</p>
			<p class="em-only_endmatter-idx1">Platelet-&#173;activating &#173;factors (PAF), in inflammation, 12, 20<span class="endmatter-idx1_italic">f,</span> 20–21</p>
			<p class="em-only_endmatter-idx1">Platelet-&#173;derived growth &#173;factors, 24<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Pneumocystis jirovecii</span> choroiditis, 334, 334<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Polarization, 14</p>
			<p class="em-only_endmatter-idx1">Polyarteritis nodosa (PAN), 125<span class="endmatter-idx1_italic">t,</span> 156–158, 157<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Polyarthritis, 143<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Polymerase chain reaction (PCR)</p>
			<p class="em-only_endmatter-idx2">for chronic postoperative endophthalmitis, 295</p>
			<p class="em-only_endmatter-idx2">disadvantages of, 90</p>
			<p class="em-only_endmatter-idx2">Goldmann-&#173;Witmer coefficient and, 91</p>
			<p class="em-only_endmatter-idx2">syphilis diagnosis using, 225</p>
			<p class="em-only_endmatter-idx2">for <span class="endmatter-idx2_italic">Tropheryma whipplei,</span> 245</p>
			<p class="em-only_endmatter-idx2">in uveitis, 90–91</p>
			<p class="em-only_endmatter-idx1">Polymorphonuclear leukocytes (PMNs), 2</p>
			<p class="em-only_endmatter-idx1">Population-&#173;wide immunity, 63</p>
			<p class="em-only_endmatter-idx1">Posner-&#173;Schlossman syndrome, 135, 320</p>
			<p class="em-only_endmatter-idx1">Post-&#173;Ebola virus disease syndrome, 273</p>
			<p class="em-only_endmatter-idx1">Posterior placoid chorioretinitis, 222, 223<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior scleritis</p>
			<p class="em-only_endmatter-idx2">B-&#173;scan ultrasonography for, 124</p>
			<p class="em-only_endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 123</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 123<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography of, 124–125</p>
			<p class="em-only_endmatter-idx2">subtype of, 116<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vision loss risks, 128</p>
			<p class="em-only_endmatter-idx1">Posterior segment</p>
			<p class="em-only_endmatter-idx2">B cells in, 57</p>
			<p class="em-only_endmatter-idx2">Beh<span class="endmatter-idx2_accent">ç</span>et disease manifestations of, 214–215, 215<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">inflammation of, 83. <span class="endmatter-idx2_italic">See also</span> Posterior uveitis</p>
			<p class="em-only_endmatter-idx2">sarcoidosis involvement of, 196–197</p>
			<p class="em-only_endmatter-idx2">sympathetic ophthalmia findings in, 200, 201<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">syphilis findings in, 221<span class="endmatter-idx2_italic">f,</span> 221–222</p>
			<p class="em-only_endmatter-idx2">T cells in, 57</p>
			<p class="em-only_endmatter-idx2">toxoplasmosis involvement of, 279</p>
			<p class="em-only_endmatter-idx1">Posterior sub-&#173;Tenon injection, of periocular corticosteroids, 95–96, 96<span class="endmatter-idx1_italic">f,</span> 324</p>
			<p class="em-only_endmatter-idx1">Posterior synechiae, in anterior uveitis, 77, 80<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior synechiolysis, 131<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior uveitis</p>
			<p class="em-only_endmatter-idx2">in acute posterior multifocal placoid pigment epitheliopathy, 169–174, 170–173<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in acute ret&#173;i&#173;nal pigment epitheliitis, 189<span class="endmatter-idx2_italic">f,</span> 189–190</p>
			<p class="em-only_endmatter-idx2">in acute zonal occult outer retinopathy, 162–164<span class="endmatter-idx2_italic">t</span> 190–192, 192<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in autoimmune retinopathy, 192–193</p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 165–169, 166–168<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 70, 75</p>
			<p class="em-only_endmatter-idx2">definition of, 70, 153</p>
			<p class="em-only_endmatter-idx2">evaluation of, 72–74<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">fluocinolone acetonide implant for, 97–98</p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence of, 89</p>
			<p class="em-only_endmatter-idx2">idiopathic, 256</p>
			<p class="em-only_endmatter-idx2">in inflammatory chorioretinopathies of unknown etiology. <span class="endmatter-idx2_italic">See</span> Inflammatory chorioretinopathies</p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 179–181, 180<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in polyarteritis nodosa, 156–158, 157<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in punctate inner choroiditis, 181–184, 182–183<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">signs of, 83</p>
			<p class="em-only_endmatter-idx2">in subret&#173;i&#173;nal fibrosis and uveitis syndrome, 184–185</p>
			<p class="em-only_endmatter-idx2">in Susac syndrome, 160<span class="endmatter-idx2_italic">f,</span> 160–161</p>
			<p class="em-only_endmatter-idx2">symptoms of, 76, 77<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">syphilitic, 224<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus. <span class="endmatter-idx2_italic">See</span> Systemic lupus erythematosus</p>
			<p class="em-only_endmatter-idx2">toxoplasmosis as cause of, 277</p>
			<p class="em-only_endmatter-idx1">Postsurgical necrotizing scleritis, 121, 121<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Prednisone</p>
			<p class="em-only_endmatter-idx2">for Beh<span class="endmatter-idx2_accent">ç</span>et disease, 217</p>
			<p class="em-only_endmatter-idx2">for uveitis, 102–103</p>
			<p class="em-only_endmatter-idx1">Pregnancy, congenital toxoplasmosis in, 277–278, 283</p>
			<p class="em-only_endmatter-idx1">Primary central ner&#173;vous system lymphoma, 305, 306<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Primary immune response, 37–38</p>
			<p class="em-only_endmatter-idx1">Primary syphilis, 221</p>
			<p class="em-only_endmatter-idx1">Primary vitreoret&#173;i&#173;nal lymphoma</p>
			<p class="em-only_endmatter-idx2">age of onset, 305</p>
			<p class="em-only_endmatter-idx2">clinical features and findings of, 306–307, 306–307<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">diagnostic testing for, 307–308</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 307</p>
			<p class="em-only_endmatter-idx2">histology of, 308, 309<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">incidence of, 305</p>
			<p class="em-only_endmatter-idx1">Primed macrophages, 14, 15<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Progressive outer ret&#173;i&#173;nal necrosis (PORN), 252–256, 255<span class="endmatter-idx1_italic">f,</span> 332</p>
			<p class="em-only_endmatter-idx1">Proliferative vitreoretinopathy (PVR), 56, 326</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Propionibacterium acnes,</span> chronic postoperative endophthalmitis caused by, 294, 294<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Prostaglandin analogues, for uveitic glaucoma, 321</p>
			<p class="em-only_endmatter-idx1">Prostaglandins</p>
			<p class="em-only_endmatter-idx2">D2, connective tissue mast cell synthesis of, 3</p>
			<p class="em-only_endmatter-idx2">in uveitic macular edema, 19</p>
			<p class="em-only_endmatter-idx1">Protozoal uveitis</p>
			<p class="em-only_endmatter-idx2">cysticercosis, 287–288, 287–288<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">diffuse unilateral subacute neuroretinitis, 289–290<span class="endmatter-idx2_italic">f,</span> 289–291</p>
			<p class="em-only_endmatter-idx2">ocular toxoplasmosis. <span class="endmatter-idx2_italic">See</span> Toxoplasmosis, ocular</p>
			<p class="em-only_endmatter-idx2">onchocerciasis, 291<span class="endmatter-idx2_italic">f,</span> 291–292</p>
			<p class="em-only_endmatter-idx2">toxocariasis, 285–286, 285–287<span class="endmatter-idx2_italic">f</span> 286<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">P-&#173;Selectin, 11–12</p>
			<p class="em-only_endmatter-idx1">Pseudophakic bullous keratopathy, chronic anterior uveitis in, 138<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Psoriatic arthritis</p>
			<p class="em-only_endmatter-idx2">acute anterior uveitis in, 133</p>
			<p class="em-only_endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 133, 134<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Punctate epithelial keratitis, 336<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Punctate inner choroiditis (PIC)</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization in, 182</p>
			<p class="em-only_endmatter-idx2">definition of, 181</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 182, 183<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 182, 183<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 181–182, 182<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 164<span class="endmatter-idx2_italic">t,</span> <br />182, 183<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Punctate keratitis, in reactive arthritis syndrome, 133</p>
			<p class="em-only_endmatter-idx1">Punctate outer ret&#173;i&#173;nal toxoplasmosis (PORT), 281, 281<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Purified protein derivative (PPD), 28, 238</p>
			<p class="em-only_endmatter-idx1">Pyrimethamine, for ocular toxoplasmosis, 283</p>
			<p class="endmatter-idx-alpha">Rapid plasma reagin, 224</p>
			<p class="em-only_endmatter-idx1">Reactive arthritis syndrome</p>
			<p class="em-only_endmatter-idx2">acute anterior uveitis in, 132–133</p>
			<p class="em-only_endmatter-idx2">diagnostic criteria for, 132–133, 133<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t,</span> 132</p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Reactive nitrogen products, 16</p>
			<p class="em-only_endmatter-idx1">Reactive oxygen intermediates, in phagocytosis, 16</p>
			<p class="em-only_endmatter-idx1">Recurrent uveitis, 76</p>
			<p class="em-only_endmatter-idx1">Regional immunity, 51, 52<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Reiter syndrome. <span class="endmatter-idx1_italic">See</span> Reactive arthritis syndrome</p>
			<p class="em-only_endmatter-idx1">Relapsing polychondritis, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Relative risk, 64</p>
			<p class="em-only_endmatter-idx1">Relentless placoid chorioretinitis, 173<span class="endmatter-idx1_italic">f,</span> 173–174</p>
			<p class="em-only_endmatter-idx1">Reparative macrophages, 16</p>
			<p class="em-only_endmatter-idx1">Resting macrophages, 13, 15<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Resting neutrophils, 10</p>
			<p class="em-only_endmatter-idx1">Ret&#173;ina</p>
			<p class="em-only_endmatter-idx2">acute necrosis of, 252, 253–254<span class="endmatter-idx2_italic">f,</span> 332</p>
			<p class="em-only_endmatter-idx2">immune responses of, 57–59</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 57–58</p>
			<p class="em-only_endmatter-idx2">immunoregulatory systems of, 59</p>
			<p class="em-only_endmatter-idx2">metastasis to, 311</p>
			<p class="em-only_endmatter-idx2">microglia in, 57</p>
			<p class="em-only_endmatter-idx2">neovascularization of, in uveitis, 326–327</p>
			<p class="em-only_endmatter-idx2">tuberculosis involvement of, 237–238</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal detachment</p>
			<p class="em-only_endmatter-idx2">in cytomegalovirus retinitis, 326, 331</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous</p>
			<p class="em-only_endmatter-idx3">chronic peripheral, 313</p>
			<p class="em-only_endmatter-idx3">risk &#173;factors for, 151</p>
			<p class="em-only_endmatter-idx3">uveitis as cause of, 326</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal gene therapy, 58</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal necrosis, 281<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal pigment epithelium</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy involvement of, 171</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy involvement in, 190, 190<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">birdshot chorioretinopathy findings in, 166</p>
			<p class="em-only_endmatter-idx2">cytokine synthesis by, 58</p>
			<p class="em-only_endmatter-idx2">immune responses of, 57–59</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t,</span> 57–58</p>
			<p class="em-only_endmatter-idx2">immunoregulatory systems of, 59</p>
			<p class="em-only_endmatter-idx2">lipofuscin from, 89</p>
			<p class="em-only_endmatter-idx2">major histocompatibility class II molecule expression by, 57</p>
			<p class="em-only_endmatter-idx2">ocular histoplasmosis syndrome findings in, 275</p>
			<p class="em-only_endmatter-idx2">peripapillary changes in, 190<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal lymphoma findings in, 307</p>
			<p class="em-only_endmatter-idx2">rubella as cause of, 262</p>
			<p class="em-only_endmatter-idx2">serpiginous choroiditis findings in, 175</p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal fibrosis in, 178</p>
			<p class="em-only_endmatter-idx2">toll-&#173;like receptor expression by, 57</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal vascular occlusive disease, in systemic lupus erythematosus, 154, 155<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal vasculitis</p>
			<p class="em-only_endmatter-idx2">characteristics of, 75</p>
			<p class="em-only_endmatter-idx2">diseases associated with, 75<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in posterior uveitis, 74<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vasculopathy versus, 75</p>
			<p class="em-only_endmatter-idx1">Retinitis</p>
			<p class="em-only_endmatter-idx2">Chikungunya fever, 270, 270<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cytomegalovirus</p>
			<p class="em-only_endmatter-idx3">characteristics of, 256–259</p>
			<p class="em-only_endmatter-idx3">in &#173;children, 257–258</p>
			<p class="em-only_endmatter-idx3">in HIV/AIDS patients, 258, 330–331</p>
			<p class="em-only_endmatter-idx3">imaging of, 257<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal detachments secondary to, 326, 331</p>
			<p class="em-only_endmatter-idx3">treatment of, 258–259</p>
			<p class="em-only_endmatter-idx2">Epstein-&#173;Barr virus, 259–260, 260<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">nonnecrotizing herpetic, 252–256</p>
			<p class="em-only_endmatter-idx2">syphilitic, 222, 224<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinitis pigmentosa, 192, 312</p>
			<p class="em-only_endmatter-idx1">Retinoblastoma, 310–311</p>
			<p class="em-only_endmatter-idx1">Retinochoroidal scar, 280, 280<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinochoroiditis, toxoplasmosis, 280<span class="endmatter-idx1_italic">f,</span> 280–282, 299, 332<span class="endmatter-idx1_italic">f,</span> 332–333</p>
			<p class="em-only_endmatter-idx1">Retinochoroidopathies, 88</p>
			<p class="em-only_endmatter-idx1">Retinoic acid-&#173;inducible gene-&#173;I-&#173;like (RIG-&#173;I-&#173;like) receptors, 5</p>
			<p class="em-only_endmatter-idx1">Retinopathy</p>
			<p class="em-only_endmatter-idx2">autoimmune, 192–193</p>
			<p class="em-only_endmatter-idx2">cancer-&#173;associated, 192–193</p>
			<p class="em-only_endmatter-idx2">HIV-&#173;associated, 329, 330<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">measles, 264</p>
			<p class="em-only_endmatter-idx2">melanoma-&#173;associated, 192–193</p>
			<p class="em-only_endmatter-idx1">Rhegmatogenous ret&#173;i&#173;nal detachment</p>
			<p class="em-only_endmatter-idx2">chronic peripheral, 313</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 151</p>
			<p class="em-only_endmatter-idx2">uveitis as cause of, 326</p>
			<p class="em-only_endmatter-idx1">Rheumatoid arthritis, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rifabutin, 139</p>
			<p class="em-only_endmatter-idx1">Rifampin, for bartonellosis, 243</p>
			<p class="em-only_endmatter-idx1">Rift Valley fever, 267, 267<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Rituximab, for uveitis, 112</p>
			<p class="em-only_endmatter-idx1">River blindness. <span class="endmatter-idx1_italic">See</span> Onchocerciasis</p>
			<p class="em-only_endmatter-idx1">Roth spots, 296</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">RPE65</span> mutation-&#173;associated ret&#173;i&#173;nal dystrophy, 58</p>
			<p class="em-only_endmatter-idx1">Rubella, 260–263</p>
			<p class="em-only_endmatter-idx1">Rubeola. <span class="endmatter-idx1_italic">See</span> Measles</p>
			<p class="endmatter-idx-alpha">Sabin’s tetrad, 279</p>
			<p class="em-only_endmatter-idx1">Sacroiliitis, in reactive arthritis syndrome, 132</p>
			<p class="em-only_endmatter-idx1">S-&#173;antigen, in experimental autoimmune uveoretinitis, 61</p>
			<p class="em-only_endmatter-idx1">Sarcoidosis</p>
			<p class="em-only_endmatter-idx2">angiotensin-&#173;converting enzyme levels in, 198</p>
			<p class="em-only_endmatter-idx2">anterior uveitis in, 195–196</p>
			<p class="em-only_endmatter-idx2">biomicroscopic findings in, 196, 196<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">chest radiograph findings in, 198</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 194–195</p>
			<p class="em-only_endmatter-idx2">conjunctival involvement by, 195, 195<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">corneal involvement in, 196</p>
			<p class="em-only_endmatter-idx2">definition of, 194</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 197–198</p>
			<p class="em-only_endmatter-idx2">early-&#173;onset, 194, 197</p>
			<p class="em-only_endmatter-idx2">epidemiology of, 194</p>
			<p class="em-only_endmatter-idx2">etiology of, 195</p>
			<p class="em-only_endmatter-idx2">granulomas associated with, 195, 195<span class="endmatter-idx2_italic">f,</span> 197<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">histologic findings, 194, 194<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">imaging of, 198</p>
			<p class="em-only_endmatter-idx2">laboratory tests for, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 195–197, 195–197<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">panuveitis in, 194–199</p>
			<p class="em-only_endmatter-idx2">posterior segment involvement in, 196–197</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vascular sheathing in, 197, 198<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">treatment of, 199</p>
			<p class="em-only_endmatter-idx1">Sarcoidosis-&#173;associated uveitis, 148</p>
			<p class="em-only_endmatter-idx1">Scavenging macrophages, 13</p>
			<p class="em-only_endmatter-idx1">Schwartz syndrome, 313</p>
			<p class="em-only_endmatter-idx1">Sclera</p>
			<p class="em-only_endmatter-idx2">biopsy of, indications for, 91</p>
			<p class="em-only_endmatter-idx2">edema, hyperemia in, 117</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">inflammation of. <span class="endmatter-idx2_italic">See</span> Scleritis</p>
			<p class="em-only_endmatter-idx2">thinning of, in infectious uveitis, 96</p>
			<p class="em-only_endmatter-idx1">Scleral grafting, for scleritis, 127, 128<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Scleritis</p>
			<p class="em-only_endmatter-idx2">anterior</p>
			<p class="em-only_endmatter-idx3">diffuse, 116, 118</p>
			<p class="em-only_endmatter-idx3">nodular, 116, 118–119, 119<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">subtype of, 116<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">classification of, 115–116, 116<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 117–123<span class="endmatter-idx2_italic">f,</span> 117–124</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 124–126, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">epidemiology of, 117</p>
			<p class="em-only_endmatter-idx2">episcleritis versus, 117</p>
			<p class="em-only_endmatter-idx2">hyperemia in, 117, 117<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">immunomodulatory therapy for, 126</p>
			<p class="em-only_endmatter-idx2">incidence of, 117</p>
			<p class="em-only_endmatter-idx2">infectious</p>
			<p class="em-only_endmatter-idx3">actinomycetes as cause of, 119<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">clinical pre&#173;sen&#173;ta&#173;tion of, 124</p>
			<p class="em-only_endmatter-idx3">description of, 116</p>
			<p class="em-only_endmatter-idx3">microbiological examination for, 125</p>
			<p class="em-only_endmatter-idx3">pathophysiology of, 123–124</p>
			<p class="em-only_endmatter-idx3">treatment of, 127</p>
			<p class="em-only_endmatter-idx3">vision loss risks, 128</p>
			<p class="em-only_endmatter-idx2">manifestations of, 115</p>
			<p class="em-only_endmatter-idx2">methylprednisolone for, 126–127</p>
			<p class="em-only_endmatter-idx2">necrotizing</p>
			<p class="em-only_endmatter-idx3">anterior, 118<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">clinical pre&#173;sen&#173;ta&#173;tion of, 118<span class="endmatter-idx3_italic">f,</span> 119–122</p>
			<p class="em-only_endmatter-idx3">delayed hypersensitivity response in, 116</p>
			<p class="em-only_endmatter-idx3">description of, 115</p>
			<p class="em-only_endmatter-idx3">diagnosis of, 124</p>
			<p class="em-only_endmatter-idx3">granulomatous, 120<span class="endmatter-idx3_italic">f,</span> 120–121</p>
			<p class="em-only_endmatter-idx3">with inflammation, 120–121, 120–121<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">laboratory tests for, 124</p>
			<p class="em-only_endmatter-idx3">mortality rates for, 119</p>
			<p class="em-only_endmatter-idx3">pathophysiology of, 116</p>
			<p class="em-only_endmatter-idx3">postsurgical, 121, 121<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">vaso-&#173;occlusive, 120, 121<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">vision loss risks, 128</p>
			<p class="em-only_endmatter-idx3">without inflammation, 121–122, 122<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">nodular anterior, 116, 118–119, 119<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">noninfectious, 116</p>
			<p class="em-only_endmatter-idx2">nonsteroidal anti-&#173;inflammatory drugs for, 126</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 116</p>
			<p class="em-only_endmatter-idx2">posterior</p>
			<p class="em-only_endmatter-idx3">B-&#173;scan ultrasonography for, 124</p>
			<p class="em-only_endmatter-idx3">clinical pre&#173;sen&#173;ta&#173;tion of, 123</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 123<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">spectral-&#173;domain optical coherence tomography of, 124–125</p>
			<p class="em-only_endmatter-idx3">subtype of, 116<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">vision loss risks, 128</p>
			<p class="em-only_endmatter-idx2">prognosis for, 127–128</p>
			<p class="em-only_endmatter-idx2">scleral grafting for, 127, 128<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">surgical treatment of, 127</p>
			<p class="em-only_endmatter-idx2">systemic diseases associated with, 115</p>
			<p class="em-only_endmatter-idx2">topical therapy for, 126</p>
			<p class="em-only_endmatter-idx2">treatment of, 126–127</p>
			<p class="em-only_endmatter-idx2">vision loss risks, 128</p>
			<p class="em-only_endmatter-idx1">Scleromalacia perforans, 121–122, 122<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sclerouveitis, 70</p>
			<p class="em-only_endmatter-idx1">Secondary immune response, 37–38</p>
			<p class="em-only_endmatter-idx1">Secondary syphilis, 221</p>
			<p class="em-only_endmatter-idx1">Selectins</p>
			<p class="em-only_endmatter-idx2">description of, 11</p>
			<p class="em-only_endmatter-idx2">E-&#173;, 11–12</p>
			<p class="em-only_endmatter-idx2">L-&#173;, 11–12</p>
			<p class="em-only_endmatter-idx2">P-&#173;, 11–12</p>
			<p class="em-only_endmatter-idx1">Self-&#173;tolerance, 34</p>
			<p class="em-only_endmatter-idx1">Sentinel T cells, 5</p>
			<p class="em-only_endmatter-idx1">Sentinel vessels, 125</p>
			<p class="em-only_endmatter-idx1">Sepsis</p>
			<p class="em-only_endmatter-idx2">bacterial, pathophysiologic responses to, 7</p>
			<p class="em-only_endmatter-idx2">lipopolysaccharide in, 7</p>
			<p class="em-only_endmatter-idx1">Seronegative spondyloarthropathies</p>
			<p class="em-only_endmatter-idx2">acute anterior uveitis associated with, 131–134, 133–134<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ankylosing spondylitis. <span class="endmatter-idx2_italic">See</span> Ankylosing spondylitis</p>
			<p class="em-only_endmatter-idx2">definition of, 131</p>
			<p class="em-only_endmatter-idx1">Serous ret&#173;i&#173;nal detachment, tubercular multifocal choroiditis with, 236<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Serpiginous choroiditis</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy versus, 171</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">course of, 175</p>
			<p class="em-only_endmatter-idx2">definition of, 174</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 175<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence in, 163<span class="endmatter-idx2_italic">t,</span> 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">imaging of, 174<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 175</p>
			<p class="em-only_endmatter-idx2">manifestations of, 174–175</p>
			<p class="em-only_endmatter-idx2">multifocal, 177</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 164<span class="endmatter-idx2_italic">t,</span> <br />175, 176<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium findings in, 175</p>
			<p class="em-only_endmatter-idx2">treatment of, 176–177</p>
			<p class="em-only_endmatter-idx1">Serpiginous-&#173;like choroiditis, 177, 236, 237<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Smoking, uveitic macular edema risks associated <br />with, 323</p>
			<p class="em-only_endmatter-idx1">Snowball opacities</p>
			<p class="em-only_endmatter-idx2">in chronic postoperative endophthalmitis, 294</p>
			<p class="em-only_endmatter-idx2">in intermediate uveitis, 82, 147, 148<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Snowbanks, in intermediate uveitis, 82, 147</p>
			<p class="em-only_endmatter-idx1">Spectral-&#173;domain optical coherence tomography</p>
			<p class="em-only_endmatter-idx2">for multiple evanescent white dot syndrome, 188, 188<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">for posterior scleritis, 124–125</p>
			<p class="em-only_endmatter-idx1">Standardization of Uveitis Nomenclature system, 68–69, 69–70<span class="endmatter-idx1_italic">t,</span> 77, 80<span class="endmatter-idx1_italic">t,</span> 147, 153</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Staphylococcus aureus,</span> endogenous endophthalmitis caused by, 296</p>
			<p class="em-only_endmatter-idx1">Still disease, 141</p>
			<p class="em-only_endmatter-idx1">Stimulated macrophages, 14–16, 15<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Stimulatory hypersensitivity, 38</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Streptococcus</span> spp., endogenous endophthalmitis caused by, 296</p>
			<p class="em-only_endmatter-idx1">“String of pearls,” 196, 294, 298<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Stromal interstitial keratitis, 220, 221<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Subacute sclerosing panencephalitis (SSPE), 264–265</p>
			<p class="em-only_endmatter-idx1">Subconjunctival lymphomas, 310</p>
			<p class="em-only_endmatter-idx1">Subepithelial keratitis, in reactive arthritis syndrome, 133</p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal fibrosis and uveitis syndrome</p>
			<p class="em-only_endmatter-idx2">characteristics of, 162–164<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">definition of, 184</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 184</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 163<span class="endmatter-idx2_italic">t,</span> 184</p>
			<p class="em-only_endmatter-idx2">manifestations of, 184, 184<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 164<span class="endmatter-idx2_italic">t,</span> 184</p>
			<p class="em-only_endmatter-idx2">treatment of, 185</p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal space, immunologic microenvironment of, 52<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Substance&#160;P, 24<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Substantia propria, conjunctival, 3, 53</p>
			<p class="em-only_endmatter-idx1">Sub-&#173;Tenon injection, of periocular corticosteroids, 95–96, 96<span class="endmatter-idx1_italic">f,</span> 324</p>
			<p class="em-only_endmatter-idx1">Sugiura sign, 206, 207<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sulfadiazine, for ocular toxoplasmosis, 283</p>
			<p class="em-only_endmatter-idx1">Sunset-&#173;glow fundus, 204, 206, 207<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superoxide anion, 16</p>
			<p class="em-only_endmatter-idx1">Surgery</p>
			<p class="em-only_endmatter-idx2">cataract. <span class="endmatter-idx2_italic">See</span> Cataract surgery</p>
			<p class="em-only_endmatter-idx2">for scleritis, 127</p>
			<p class="em-only_endmatter-idx2">for uveitis, 113</p>
			<p class="em-only_endmatter-idx1">Susac syndrome, 160<span class="endmatter-idx1_italic">f,</span> 160–161</p>
			<p class="em-only_endmatter-idx1">SYCAMORE study, 100<span class="endmatter-idx1_italic">t,</span> 111</p>
			<p class="em-only_endmatter-idx1">Sympathetic ophthalmia (SO)</p>
			<p class="em-only_endmatter-idx2">anterior segment findings in, 200</p>
			<p class="em-only_endmatter-idx2">Dalen-&#173;Fuchs nodules in, 200, 202</p>
			<p class="em-only_endmatter-idx2">description of, 45–46</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 203</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 200, 201<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">histologic features of, 202</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">incidence of, 199–200</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography findings in, 201, 202<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 200–202, 201–202<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular trauma as cause of, 199</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 201–202, 202<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">panuveitis in, 199–203</p>
			<p class="em-only_endmatter-idx2">&#173;after pars plana vitrectomy, 199–200</p>
			<p class="em-only_endmatter-idx2">posterior segment findings in, 200, 201<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">treatment of, 203</p>
			<p class="em-only_endmatter-idx2">Vogt-&#173;Koyanagi-&#173;Harada syndrome versus, 203</p>
			<p class="em-only_endmatter-idx1">Sympathizing eye, 199–200</p>
			<p class="em-only_endmatter-idx1">Synechiae</p>
			<p class="em-only_endmatter-idx2">anterior, 320</p>
			<p class="em-only_endmatter-idx2">posterior, in anterior uveitis, 77, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Syphilis</p>
			<p class="em-only_endmatter-idx2">acquired, 221</p>
			<p class="em-only_endmatter-idx2">anterior segment findings of, 221–222</p>
			<p class="em-only_endmatter-idx2">cerebrospinal fluid testing in, 225</p>
			<p class="em-only_endmatter-idx2">chorioretinitis in, 222–223<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">congenital, 220, 226</p>
			<p class="em-only_endmatter-idx2">definition of, 219</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 224–225</p>
			<p class="em-only_endmatter-idx2">HIV and, 219–220, 333–334</p>
			<p class="em-only_endmatter-idx2">incidence of, 219</p>
			<p class="em-only_endmatter-idx2">neuro-&#173;ophthalmic manifestations of, 223–224</p>
			<p class="em-only_endmatter-idx2">nontreponemal tests for, 224–225</p>
			<p class="em-only_endmatter-idx2">ocular involvement in, 221–224, 222–224<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">penicillin G for, 225–226, 226<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">polymerase chain reaction diagnosis of, 225</p>
			<p class="em-only_endmatter-idx2">posterior segment findings of, 221<span class="endmatter-idx2_italic">f,</span> 221–222</p>
			<p class="em-only_endmatter-idx2">primary, 221</p>
			<p class="em-only_endmatter-idx2">retinitis in, 222, 224<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">secondary, 221</p>
			<p class="em-only_endmatter-idx2">tertiary, 221</p>
			<p class="em-only_endmatter-idx2">testing for, 84–85, 148</p>
			<p class="em-only_endmatter-idx2">transmission of, 219</p>
			<p class="em-only_endmatter-idx2">treatment of, 225–227, 226<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">treponemal tests for, 224–225</p>
			<p class="em-only_endmatter-idx2">uveitis caused by, 84–85, 148, 219–227</p>
			<p class="em-only_endmatter-idx1">Syphilitic choroiditis, 177</p>
			<p class="em-only_endmatter-idx1">Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study (SITE), 100<span class="endmatter-idx1_italic">t,</span> 105, 150</p>
			<p class="em-only_endmatter-idx1">Systemic lupus erythematosus (SLE)</p>
			<p class="em-only_endmatter-idx2">antinuclear antibody testing in, 156</p>
			<p class="em-only_endmatter-idx2">autoantibodies associated with, 154</p>
			<p class="em-only_endmatter-idx2">definition of, 153</p>
			<p class="em-only_endmatter-idx2">description of, 125<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">lupus choroidopathy in, 154, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">lupus retinopathy in, 154, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">manifestations of, 154–156</p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 153–154</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vascular occlusive disease in, 154, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">treatment of, 156</p>
			<p class="em-only_endmatter-idx1">Systemic sarcoidosis. <span class="endmatter-idx1_italic">See</span> Sarcoidosis</p>
			<p class="endmatter-idx-alpha">T cells</p>
			<p class="em-only_endmatter-idx2">in anterior uvea, 56</p>
			<p class="em-only_endmatter-idx2">in B cell activation, 35</p>
			<p class="em-only_endmatter-idx2">CD4<span class="endmatter-idx2_symbol">+</span>. <span class="endmatter-idx2_italic">See</span> CD4<span class="endmatter-idx2_symbol">+</span> T cells</p>
			<p class="em-only_endmatter-idx2">CD8<span class="endmatter-idx2_symbol">+</span>. <span class="endmatter-idx2_italic">See</span> CD8<span class="endmatter-idx2_symbol">+</span> T cells</p>
			<p class="em-only_endmatter-idx2">clonal expansion of, 37</p>
			<p class="em-only_endmatter-idx2">cytotoxic. <span class="endmatter-idx2_italic">See</span> Cytotoxic T cells</p>
			<p class="em-only_endmatter-idx2">delayed hypersensitivity</p>
			<p class="em-only_endmatter-idx3">description of, 36, 42–44</p>
			<p class="em-only_endmatter-idx3">inflammatory diseases mediated by, 44<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">in sympathetic ophthalmia, 45–46</p>
			<p class="em-only_endmatter-idx3">T helper-&#173;cell 2, 43</p>
			<p class="em-only_endmatter-idx3">in toxocara granuloma, 45</p>
			<p class="em-only_endmatter-idx2">description of, 21</p>
			<p class="em-only_endmatter-idx2">gamma-&#173;delta, 5</p>
			<p class="em-only_endmatter-idx2">helper. <span class="endmatter-idx2_italic">See</span> Helper T cells</p>
			<p class="em-only_endmatter-idx2">homing of, 38</p>
			<p class="em-only_endmatter-idx2">inhibitors of, for uveitis, 108–1109</p>
			<p class="em-only_endmatter-idx2">interleukin-2 synthesis and release by, 31</p>
			<p class="em-only_endmatter-idx2">in multifocal choroiditis and panuveitis syndrome, 179</p>
			<p class="em-only_endmatter-idx2">in posterior segment, 57</p>
			<p class="em-only_endmatter-idx2">priming of, 30</p>
			<p class="em-only_endmatter-idx2">in resting state, 37</p>
			<p class="em-only_endmatter-idx2">sentinel, 5</p>
			<p class="em-only_endmatter-idx2">subsets of, 34–35, 42</p>
			<p class="em-only_endmatter-idx2">tuberculosis response by, 28</p>
			<p class="em-only_endmatter-idx1">T helper cell-1</p>
			<p class="em-only_endmatter-idx2">in conjunctiva, 53</p>
			<p class="em-only_endmatter-idx2">delayed hypersensitivity mechanisms mediated by, 42, 44<span class="endmatter-idx2_italic">t,</span> 53</p>
			<p class="em-only_endmatter-idx2">interferon-&#173;gamma produced by, 35</p>
			<p class="em-only_endmatter-idx2">macrophage activation by, 42</p>
			<p class="em-only_endmatter-idx1">T helper cell-2</p>
			<p class="em-only_endmatter-idx2">in conjunctiva, 53</p>
			<p class="em-only_endmatter-idx2">cytokines secreted by, 43</p>
			<p class="em-only_endmatter-idx1">T helper cell-17</p>
			<p class="em-only_endmatter-idx2">in birdshot chorioretinopathy, 34</p>
			<p class="em-only_endmatter-idx2">in delayed hypersensitivity, 44</p>
			<p class="em-only_endmatter-idx2">interleukins produced by, 34</p>
			<p class="em-only_endmatter-idx1">T lymphocytes. <span class="endmatter-idx1_italic">See</span> T cells</p>
			<p class="em-only_endmatter-idx1">T regulatory cells</p>
			<p class="em-only_endmatter-idx2">adaptive, 34</p>
			<p class="em-only_endmatter-idx2">in CD4<span class="endmatter-idx2_symbol">+</span> T cell development, 43<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 33</p>
			<p class="em-only_endmatter-idx2">immune responses suppressed by, 35</p>
			<p class="em-only_endmatter-idx2">inducible, 34</p>
			<p class="em-only_endmatter-idx2">naturally occurring, 34</p>
			<p class="em-only_endmatter-idx2">in peripheral tolerance to self-&#173;antigens, 35</p>
			<p class="em-only_endmatter-idx1">Taches de bougie, 196</p>
			<p class="em-only_endmatter-idx1">Tachyzoites, 277</p>
			<p class="em-only_endmatter-idx1">Tacrolimus, for uveitis, 108</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Taenia solium,</span> 287</p>
			<p class="em-only_endmatter-idx1">Takayasu arteritis, 125<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">T-&#173;cell antigen receptor, in &#173;human leukocyte antigen–&#173;disease association, 66</p>
			<p class="em-only_endmatter-idx1">Tertiary syphilis, 221</p>
			<p class="em-only_endmatter-idx1">Thiabendazole, for diffuse unilateral subacute neuroretinitis, 290</p>
			<p class="em-only_endmatter-idx1">Thiopurine-&#173;S-&#173;methyltransferase (TPMT), 106</p>
			<p class="em-only_endmatter-idx1">Thrombin, 18</p>
			<p class="em-only_endmatter-idx1">Tissue dendritic cells, 4</p>
			<p class="em-only_endmatter-idx1">Tissue plasminogen activator, 18</p>
			<p class="em-only_endmatter-idx1">Toll-&#173;like receptors (TLRs)</p>
			<p class="em-only_endmatter-idx2">dendritic cells’ use of, 4</p>
			<p class="em-only_endmatter-idx2">&#173;family of, 5</p>
			<p class="em-only_endmatter-idx2">lipopolysaccharide, 7</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium expression of, 58</p>
			<p class="em-only_endmatter-idx2">TLR2, 8</p>
			<p class="em-only_endmatter-idx1">TORCH syndrome, 262</p>
			<p class="em-only_endmatter-idx1">Touton &#173;giant cells, 311</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Toxocara canis,</span> 45, 285, 289</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Toxocara cati,</span> 285</p>
			<p class="em-only_endmatter-idx1">Toxocara granuloma, 45</p>
			<p class="em-only_endmatter-idx1">Toxocariasis, 285–286, 285–287<span class="endmatter-idx1_italic">f,</span> 286<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Toxoplasma gondii,</span> 277–279, 278<span class="endmatter-idx1_italic">f,</span> 333</p>
			<p class="em-only_endmatter-idx1">Toxoplasmosis, ocular</p>
			<p class="em-only_endmatter-idx2">in AIDS patients, 333</p>
			<p class="em-only_endmatter-idx2">congenital, 278–279, 279<span class="endmatter-idx2_italic">f,</span> 283</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 282</p>
			<p class="em-only_endmatter-idx2">Goldmann-&#173;Witmer coefficient for, 91</p>
			<p class="em-only_endmatter-idx2">punctate outer ret&#173;i&#173;nal, 281, 281<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">pyrimethamine for, 283</p>
			<p class="em-only_endmatter-idx2">retinochoroidal scar caused by, 280, 280<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinochoroiditis caused by, 280, 280<span class="endmatter-idx2_italic">f,</span> 282, 299, 332<span class="endmatter-idx2_italic">f,</span> 332–333</p>
			<p class="em-only_endmatter-idx2">sulfadiazine for, 283</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">Toxoplasma gondii</span> as cause of, 277–279, 278<span class="endmatter-idx2_italic">f,</span> <br />333</p>
			<p class="em-only_endmatter-idx2">treatment of, 282–284</p>
			<p class="em-only_endmatter-idx1">Tractional ret&#173;i&#173;nal detachment, 237</p>
			<p class="em-only_endmatter-idx1">Transforming growth &#173;factor <span class="endmatter-idx1_accent">ß</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 24<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in T regulatory cell effector function, 35</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Treponema pallidum,</span> 219, 224</p>
			<p class="em-only_endmatter-idx1">Triamcinolone acetonide</p>
			<p class="em-only_endmatter-idx2">for scleritis, 127</p>
			<p class="em-only_endmatter-idx2">for uveitis</p>
			<p class="em-only_endmatter-idx3">inferior transseptal injection of, 96, 97<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">intravitreal injection of, 96<span class="endmatter-idx3_italic">f,</span> 97</p>
			<p class="em-only_endmatter-idx3">posterior sub-&#173;Tenon injection of, 95, 96<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Trimethoprim-&#173;sulfamethoxazole</p>
			<p class="em-only_endmatter-idx2">for ocular toxoplasmosis, 283–284</p>
			<p class="em-only_endmatter-idx2">for <span class="endmatter-idx2_italic">Pneumocystis jirovecii</span> choroiditis, 334</p>
			<p class="em-only_endmatter-idx2">for Whipple disease, 245</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Tropheryma whipplei,</span> 243, 313</p>
			<p class="em-only_endmatter-idx1">Trophozoites, 333</p>
			<p class="em-only_endmatter-idx1">Tuberculin skin test, for tuberculosis, 28, 238</p>
			<p class="em-only_endmatter-idx1">Tuberculoma, 237<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Tuberculosis. <span class="endmatter-idx1_italic">See also Mycobacteria tuberculosis</span></p>
			<p class="em-only_endmatter-idx2">choroidal involvement in, 236–237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">diagnosis of, 238–239</p>
			<p class="em-only_endmatter-idx2">extrapulmonary, 234</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 236, 237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">incidence of, 234</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography findings in, <br />236, 237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">isoniazid for, 239–240</p>
			<p class="em-only_endmatter-idx2">latent, 240</p>
			<p class="em-only_endmatter-idx2">multidrug-&#173;resistant, 239</p>
			<p class="em-only_endmatter-idx2">multifocal choroiditis in, 236, 236<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular involvement in, 235–238, 235–238<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">primary response to, 28</p>
			<p class="em-only_endmatter-idx2">pulmonary, 234</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal involvement in, 237–238</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 234</p>
			<p class="em-only_endmatter-idx2">secondary response to, 28</p>
			<p class="em-only_endmatter-idx2">serpiginous-&#173;like choroiditis associated with, 177, <br />236, 237<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">treatment of, 239–240</p>
			<p class="em-only_endmatter-idx2">tuberculin skin test for, 28, 238</p>
			<p class="em-only_endmatter-idx2">uveitis caused by, 234–240, 235–238<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Tubulointerstitial nephritis and uveitis (TINU) syndrome</p>
			<p class="em-only_endmatter-idx2">acute anterior uveitis in, 134–135, 135<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">CD4<span class="endmatter-idx2_symbol">+</span> T cells in, 135</p>
			<p class="em-only_endmatter-idx2">characteristics of, 134</p>
			<p class="em-only_endmatter-idx2">diagnostic criteria for, 134</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tumor necrosis factor-&#173;<span class="endmatter-idx1_greek">α</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 23<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">immune response suppression by, 25</p>
			<p class="em-only_endmatter-idx2">inhibitors of</p>
			<p class="em-only_endmatter-idx3">for Beh<span class="endmatter-idx3_accent">ç</span>et disease, 217–218</p>
			<p class="em-only_endmatter-idx3">side effects of, 139–140</p>
			<p class="em-only_endmatter-idx3">for uveitis, 105, 110–112, 130–131, 139</p>
			<p class="em-only_endmatter-idx1">Tumor necrosis factor-&#173;<span class="endmatter-idx1_accent">ß</span>, 23<span class="endmatter-idx1_italic">t</span></p>
			<p class="endmatter-idx-alpha">Ultrasonography, in uveitis evaluations, 89–90</p>
			<p class="em-only_endmatter-idx1">Undifferentiated anterior uveitis, 146–147</p>
			<p class="em-only_endmatter-idx1">Undifferentiated uveitis, 84</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Ureaplasma urealyticum,</span> 132</p>
			<p class="em-only_endmatter-idx1">Uvea</p>
			<p class="em-only_endmatter-idx2">anatomy of, 67</p>
			<p class="em-only_endmatter-idx2">anterior. <span class="endmatter-idx2_italic">See</span> Anterior uvea</p>
			<p class="em-only_endmatter-idx1">Uveal lymphoid hyperplasia, 310</p>
			<p class="em-only_endmatter-idx1">Uveal melanocytic proliferation, bilateral diffuse, 311</p>
			<p class="em-only_endmatter-idx1">Uveal melanoma, 310</p>
			<p class="em-only_endmatter-idx1">Uveal tract</p>
			<p class="em-only_endmatter-idx2">connective tissue mast cells in, 3</p>
			<p class="em-only_endmatter-idx2">inflammation of. <span class="endmatter-idx2_italic">See</span> Uveitis</p>
			<p class="em-only_endmatter-idx1">Uveitis</p>
			<p class="em-only_endmatter-idx2">acute</p>
			<p class="em-only_endmatter-idx3">anterior. <span class="endmatter-idx3_italic">See</span> Anterior uveitis, acute</p>
			<p class="em-only_endmatter-idx3">definition of, 75</p>
			<p class="em-only_endmatter-idx3">signs and symptoms of, 71<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ancillary testing for, 84–92, 86–87<span class="endmatter-idx2_italic">t,</span> 88–89<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">animal models of, 61–62</p>
			<p class="em-only_endmatter-idx2">anterior. <span class="endmatter-idx2_italic">See</span> Anterior uveitis</p>
			<p class="em-only_endmatter-idx2">anterior chamber paracentesis for, 90–92</p>
			<p class="em-only_endmatter-idx2">bacterial. <span class="endmatter-idx2_italic">See</span> Bacterial uveitis</p>
			<p class="em-only_endmatter-idx2">blindness caused by, 68</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 322</p>
			<p class="em-only_endmatter-idx2">chronic</p>
			<p class="em-only_endmatter-idx3">calcific band keratopathy associated with, 315</p>
			<p class="em-only_endmatter-idx3">definition of, 75–76</p>
			<p class="em-only_endmatter-idx3">signs and symptoms of, 72<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">systemic corticosteroids for, 102–103</p>
			<p class="em-only_endmatter-idx2">classification of</p>
			<p class="em-only_endmatter-idx3">anatomical, 68–75</p>
			<p class="em-only_endmatter-idx3">clinical features, 75–76</p>
			<p class="em-only_endmatter-idx3">Standardization of Uveitis Nomenclature system, 68–69, 69–70<span class="endmatter-idx3_italic">t,</span> 77, 80<span class="endmatter-idx3_italic">t,</span> 147</p>
			<p class="em-only_endmatter-idx2">clinical features of, 75–76</p>
			<p class="em-only_endmatter-idx2">complications of</p>
			<p class="em-only_endmatter-idx3">calcific band keratopathy, 143<span class="endmatter-idx3_italic">f,</span> 315</p>
			<p class="em-only_endmatter-idx3">cataracts, 315–319</p>
			<p class="em-only_endmatter-idx3">choroidal neovascularization, 326–327</p>
			<p class="em-only_endmatter-idx3">epiret&#173;i&#173;nal membranes, 325</p>
			<p class="em-only_endmatter-idx3">glaucoma, 319–323</p>
			<p class="em-only_endmatter-idx3">hypotony, 323</p>
			<p class="em-only_endmatter-idx3">macular edema. <span class="endmatter-idx3_italic">See</span> Uveitis, macular edema caused by</p>
			<p class="em-only_endmatter-idx3">macular hole, 325</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal neovascularization, 326–327</p>
			<p class="em-only_endmatter-idx3">rhegmatogenous ret&#173;i&#173;nal detachment, 325–326</p>
			<p class="em-only_endmatter-idx3">vitreous opacification, 325–326</p>
			<p class="em-only_endmatter-idx3">vitritis, 325–326</p>
			<p class="em-only_endmatter-idx2">corticosteroids for</p>
			<p class="em-only_endmatter-idx3">adverse effects of, 94, 103, 143, 150</p>
			<p class="em-only_endmatter-idx3">in &#173;children, 143</p>
			<p class="em-only_endmatter-idx3">dose and duration of, 94, 102</p>
			<p class="em-only_endmatter-idx3">intermediate, 149–150</p>
			<p class="em-only_endmatter-idx3">intravitreal, 97–98, 102</p>
			<p class="em-only_endmatter-idx3">local, 95</p>
			<p class="em-only_endmatter-idx3">nonsteroidal anti-&#173;inflammatory drugs and, 103</p>
			<p class="em-only_endmatter-idx3">osteoporosis prevention strategies, 103</p>
			<p class="em-only_endmatter-idx3">periocular, 95–96, 96–97<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">phacoantigenic, 137</p>
			<p class="em-only_endmatter-idx3">sustained-&#173;release, 95</p>
			<p class="em-only_endmatter-idx3">systemic, 102–103, 150</p>
			<p class="em-only_endmatter-idx3">tapering of, 94</p>
			<p class="em-only_endmatter-idx3">topical, 94–95, 130</p>
			<p class="em-only_endmatter-idx2">definition of, 67</p>
			<p class="em-only_endmatter-idx2">descriptors of, 69<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">diagnosis of</p>
			<p class="em-only_endmatter-idx3">ancillary testing in, 84–92, 86–87<span class="endmatter-idx3_italic">t,</span> 88–89<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">cytology, 91–92</p>
			<p class="em-only_endmatter-idx3">fluid and tissue sampling tests, 90–91</p>
			<p class="em-only_endmatter-idx3">history-&#173;taking for, 67, 83–84</p>
			<p class="em-only_endmatter-idx3">imaging for, 67–68, 85–90, 88–89<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">laboratory tests, 86–87<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">patient &#173;factors in, 83<span class="endmatter-idx3_italic">t,</span> 83–84</p>
			<p class="em-only_endmatter-idx3">physical examination in, 67</p>
			<p class="em-only_endmatter-idx3">signs, 77–83</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 84</p>
			<p class="em-only_endmatter-idx2">drug-&#173;induced, 139–140<span class="endmatter-idx2_italic">f,</span> 139–141</p>
			<p class="em-only_endmatter-idx2">endotoxin-&#173;induced, 8, 62</p>
			<p class="em-only_endmatter-idx2">epidemiology of, 68</p>
			<p class="em-only_endmatter-idx2">equine recurrent, 62</p>
			<p class="em-only_endmatter-idx2">evaluation of, 71–74<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">fluid and tissue sampling tests</p>
			<p class="em-only_endmatter-idx3">antibody production, 91</p>
			<p class="em-only_endmatter-idx3">ocular serology, 91</p>
			<p class="em-only_endmatter-idx3">polymerase chain reaction tests, 90–91</p>
			<p class="em-only_endmatter-idx2">in Fuchs uveitis syndrome, 145–146, 146<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">granulomatous, 76</p>
			<p class="em-only_endmatter-idx2">HLA-&#173;B27 association with, 64</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen associations in, 63–66</p>
			<p class="em-only_endmatter-idx2">imaging tests for, 67–68, 85–90, 88–89<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx3">color photography, 89</p>
			<p class="em-only_endmatter-idx3">electroretinography, 90</p>
			<p class="em-only_endmatter-idx3">enhanced depth imaging optical coherence tomography, 85, 88<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">fluorescein angiography, 88, 89<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">fundus autofluorescence, 89</p>
			<p class="em-only_endmatter-idx3">indocyanine green angiography, 89</p>
			<p class="em-only_endmatter-idx3">optical coherence tomographic angiography, 87</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography, 85, 88<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">perimetry, 90</p>
			<p class="em-only_endmatter-idx3">ultrasonography, 89–90</p>
			<p class="em-only_endmatter-idx3">visual field testing, 90</p>
			<p class="em-only_endmatter-idx2">immune recovery, 331</p>
			<p class="em-only_endmatter-idx2">infectious. <span class="endmatter-idx2_italic">See</span> Infectious uveitis</p>
			<p class="em-only_endmatter-idx2">intermediate. <span class="endmatter-idx2_italic">See</span> Intermediate uveitis</p>
			<p class="em-only_endmatter-idx2">intraocular lens-&#173;associated, 137–139, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">lens-&#173;associated</p>
			<p class="em-only_endmatter-idx3">hypopyon in, 6</p>
			<p class="em-only_endmatter-idx3">types of, 136<span class="endmatter-idx3_italic">f,</span> 136–137</p>
			<p class="em-only_endmatter-idx2">macular edema caused by</p>
			<p class="em-only_endmatter-idx3">description of, 19, 323–324</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography of, 88, 89<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 85, 88<span class="endmatter-idx3_italic">f,</span> 323</p>
			<p class="em-only_endmatter-idx3">in phacoemulsification, 318</p>
			<p class="em-only_endmatter-idx3">postoperative, 318</p>
			<p class="em-only_endmatter-idx3">smoking as risk &#173;factor for, 323</p>
			<p class="em-only_endmatter-idx3">treatment of, 324</p>
			<p class="em-only_endmatter-idx2">nongranulomatous, 76</p>
			<p class="em-only_endmatter-idx2">ocular hypertension associated with, 319</p>
			<p class="em-only_endmatter-idx2">pediatric, 322</p>
			<p class="em-only_endmatter-idx2">peripheral. <span class="endmatter-idx2_italic">See</span> Pars planitis</p>
			<p class="em-only_endmatter-idx2">phacoantigenic, 136–137</p>
			<p class="em-only_endmatter-idx2">phacolytic, 136<span class="endmatter-idx2_italic">f,</span> 136–137</p>
			<p class="em-only_endmatter-idx2">posterior. <span class="endmatter-idx2_italic">See</span> Posterior uveitis</p>
			<p class="em-only_endmatter-idx2">prevalence of, 68</p>
			<p class="em-only_endmatter-idx2">recurrent, 76</p>
			<p class="em-only_endmatter-idx2">sarcoidosis-&#173;associated, 148</p>
			<p class="em-only_endmatter-idx2">signs of, 77–83, 78<span class="endmatter-idx2_italic">t,</span> 79–82<span class="endmatter-idx2_italic">f,</span> 80<span class="endmatter-idx2_italic">t,</span> 82<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">Standardization of Uveitis Nomenclature system for, 68–69, 69–70<span class="endmatter-idx2_italic">t,</span> 77, 80<span class="endmatter-idx2_italic">t,</span> 147</p>
			<p class="em-only_endmatter-idx2">symptoms of, 76, 77<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">syndromes masquerading as, 84, 305–311. <span class="endmatter-idx2_italic">See also</span> Masquerade syndromes</p>
			<p class="em-only_endmatter-idx2">syphilis testing in, 84–85, 148</p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">carbonic anhydrase inhibitors, 113</p>
			<p class="em-only_endmatter-idx3">corticosteroids. <span class="endmatter-idx3_italic">See</span> Uveitis, corticosteroids for</p>
			<p class="em-only_endmatter-idx3">cycloplegics, 113</p>
			<p class="em-only_endmatter-idx3">goals for, 93</p>
			<p class="em-only_endmatter-idx3">immunomodulatory therapy. <span class="endmatter-idx3_italic">See</span> Immunomodulatory therapy, for uveitis</p>
			<p class="em-only_endmatter-idx3">intravenous immunoglobulin, 113</p>
			<p class="em-only_endmatter-idx3">mydriatics, 113</p>
			<p class="em-only_endmatter-idx3">nonsteroidal anti-&#173;inflammatory drugs, 113, 317</p>
			<p class="em-only_endmatter-idx3">surgery, 113</p>
			<p class="em-only_endmatter-idx2">undifferentiated, 84</p>
			<p class="em-only_endmatter-idx2">vision rehabilitation in, 327</p>
			<p class="em-only_endmatter-idx1">Uveitis-&#173;glaucoma-&#173;hyphema (UGH) syndrome, 10, 137–138</p>
			<p class="em-only_endmatter-idx1">Uveoretinitis, experimental autoimmune, 61–62</p>
			<p class="endmatter-idx-alpha">Vaccinations, anterior uveitis caused by, 140</p>
			<p class="em-only_endmatter-idx1">Valacyclovir</p>
			<p class="em-only_endmatter-idx2">for cytomegalovirus, 258</p>
			<p class="em-only_endmatter-idx2">for herpes simplex virus, 251, 254</p>
			<p class="em-only_endmatter-idx1">Vancomycin, for chronic postoperative endophthalmitis, 295</p>
			<p class="em-only_endmatter-idx1">Varicella-&#173;zoster sine herpete, 250</p>
			<p class="em-only_endmatter-idx1">Varicella-&#173;zoster virus (VZV)</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis caused by, 254</p>
			<p class="em-only_endmatter-idx2">anterior uveitis associated with, 249–252</p>
			<p class="em-only_endmatter-idx2">infectious scleritis caused by, 124</p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis caused by, 255, 255<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">skin lesions in, 250, 250<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vascular endothelial growth &#173;factor (VEGF) inhibitors, 312, 324</p>
			<p class="em-only_endmatter-idx2">for ocular ischemic syndrome, 312</p>
			<p class="em-only_endmatter-idx2">for uveitic macular edema, 324</p>
			<p class="em-only_endmatter-idx1">Vasculopathy, ret&#173;i&#173;nal vasculitis versus, 75</p>
			<p class="em-only_endmatter-idx1">Vasoactive intestinal peptide, 24<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vaso-&#173;occlusive necrotizing scleritis, 120, 121<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Venereal Disease Research Laboratory (VDRL), 224</p>
			<p class="em-only_endmatter-idx1">Vernal conjunctivitis, mast cells in, 3</p>
			<p class="em-only_endmatter-idx1">Visceral toxocariasis, 285</p>
			<p class="em-only_endmatter-idx1">Viscocanalostomy, 321</p>
			<p class="em-only_endmatter-idx1">Vision loss, scleritis as cause of, 128</p>
			<p class="em-only_endmatter-idx1">Vision rehabilitation, in uveitis, 327</p>
			<p class="em-only_endmatter-idx1">Visual field testing, in uveitis, 90</p>
			<p class="em-only_endmatter-idx1">Vitrectomy, diagnostic, 92, 300</p>
			<p class="em-only_endmatter-idx1">Vitreoret&#173;i&#173;nal lymphoma</p>
			<p class="em-only_endmatter-idx2">cytologic studies for, 91</p>
			<p class="em-only_endmatter-idx2">primary. <span class="endmatter-idx2_italic">See</span> Primary vitreoret&#173;i&#173;nal lymphoma</p>
			<p class="em-only_endmatter-idx1">Vitreous</p>
			<p class="em-only_endmatter-idx2">biopsy of</p>
			<p class="em-only_endmatter-idx3">indications for, 91–92</p>
			<p class="em-only_endmatter-idx3">technique for, 92</p>
			<p class="em-only_endmatter-idx2">collagen type II in, 56</p>
			<p class="em-only_endmatter-idx2">immunologic microenvironment of, 52<span class="endmatter-idx2_italic">t,</span> 56</p>
			<p class="em-only_endmatter-idx2">opacification in, from uveitis, 325–326</p>
			<p class="em-only_endmatter-idx2">polymerase chain reaction testing of, in uveitis evaluations, 90–91</p>
			<p class="em-only_endmatter-idx1">Vitreous cells</p>
			<p class="em-only_endmatter-idx2">grading scheme for, 82, 82<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in intermediate uveitis, 81, 82<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vitreous haze, in intermediate uveitis, 81<span class="endmatter-idx1_italic">f,</span> 81–82, 82<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vitreous hemorrhage, in pars planitis, 151</p>
			<p class="em-only_endmatter-idx1">Vitritis</p>
			<p class="em-only_endmatter-idx2">chorioretinitis with, 72–73<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 148</p>
			<p class="em-only_endmatter-idx2">Lyme disease in, 229, 229<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">uveitis as cause of, 325–326</p>
			<p class="em-only_endmatter-idx1">Vogt-&#173;Koyanagi-&#173;Harada (VKH) syndrome</p>
			<p class="em-only_endmatter-idx2">acute secondary angle-&#173;closure glaucoma associated with, 320</p>
			<p class="em-only_endmatter-idx2">acute uveitic stage of, 205, 205<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">chronic recurrent stage of, 207</p>
			<p class="em-only_endmatter-idx2">convalescent stage of, 205–206</p>
			<p class="em-only_endmatter-idx2">definition of, 204</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 206–210, 208<span class="endmatter-idx2_italic">t,</span> 209–210<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 210</p>
			<p class="em-only_endmatter-idx2">enhanced depth imaging optical coherence tomography in, 85, 88<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 208–209, 209<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">histologic findings of, 204</p>
			<p class="em-only_endmatter-idx2">HLA-&#173;DR4 and, 204</p>
			<p class="em-only_endmatter-idx2">&#173;human leukocyte antigen association with, 65<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">incidence of, 204</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography in, 209</p>
			<p class="em-only_endmatter-idx2">integumentary changes in, 206</p>
			<p class="em-only_endmatter-idx2">lumbar puncture for, 209</p>
			<p class="em-only_endmatter-idx2">manifestations of, 205–207, 205–207<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">nivolumab-&#173;induced, 140<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography findings in, 209, 210<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">prodromal stage of, 205</p>
			<p class="em-only_endmatter-idx2">prognosis for, 211</p>
			<p class="em-only_endmatter-idx2">Sugiura sign in, 206, 207<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sunset-&#173;glow fundus in, 204, 206, 207<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sympathetic ophthalmia versus, 203</p>
			<p class="em-only_endmatter-idx2">treatment of, 211</p>
			<p class="em-only_endmatter-idx2">ultrasonography of, 209</p>
			<p class="em-only_endmatter-idx1">Voretigene neparvovec-&#173;rzy, 58</p>
			<p class="em-only_endmatter-idx1">Voriconazole</p>
			<p class="em-only_endmatter-idx2">for <span class="endmatter-idx2_italic">Candida</span> fungal postoperative endophthalmitis, 300</p>
			<p class="em-only_endmatter-idx2">for coccidioidomycosis, 304</p>
			<p class="endmatter-idx-alpha">Wegener granulomatosis, 158</p>
			<p class="em-only_endmatter-idx1">Weil disease, 232</p>
			<p class="em-only_endmatter-idx1">West Nile virus, 265–266, 266<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Whipple disease, 243–245, 244<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">White blood cells. <span class="endmatter-idx1_italic">See</span> Leukocytes</p>
			<p class="em-only_endmatter-idx1">White dot syndromes</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy versus, 192</p>
			<p class="em-only_endmatter-idx2">definition of, 161</p>
			<p class="em-only_endmatter-idx2">etiology of, 161, 165</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 88</p>
			<p class="em-only_endmatter-idx2">multiple evanescent. <span class="endmatter-idx2_italic">See</span> Multiple evanescent white dot syndrome</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Wolbachia,</span> 292</p>
			<p class="endmatter-idx-alpha">Zika fever, 271–272, 272<span class="endmatter-idx-alpha_italic">f</span></p>
		</div>
		<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
		</div>
	</body>
</html>
